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Recent findings reveal that more than 70% of diabetic individuals are prone to developing some 
form of heart disease during their life span. Population-based studies have shown that the risk 
of heart failure is augmented 2 to 3 fold by diabetes signifying that diabetes itself is an 
independent risk factor for cardiovascular disease. The occurrence of diabetes substantially 
accelerates the development of heart failure in patients with myocardial infarction, 
hypertension, or atrial fibrillation. The impact of diabetes on the development of vascular 
disease has been established earlier whereas, non-ischemic heart failure associated with 
diabetes termed as diabetic cardiomyopathy has received less attention compared to coronary 
and cerebrovascular events. 
Diabetic cardiomyopathy is a chronic complication in individuals with diabetes which 
is characterized by ventricular dilation and hypertrophy, systolic and diastolic dysfunction, 
eventually resulting in heart failure. Despite being well characterized, the fundamental 
mechanisms leading to diabetic cardiomyopathy are still elusive. Recent studies identified the 
involvement of small non-coding small RNA molecules such as microRNAs (miRNAs) 
playing a key role in the etiology of diabetic cardiomyopathy. Therefore, miRNAs associated 
with diabetic cardiomyopathy represents a new class of targets for the development of 
mechanistic therapeutics, which may yield marked benefits compared to other therapeutic 
approaches. Indeed, a few miRNAs are currently under active clinical investigation, with many 
expressing cautious optimism that miRNAs based therapies will succeed in the coming years.  
MiRNA plays its role by regulating cellular and metabolic processes by modulating 
specific targets. Hence, the selection of miRNA candidates is a major challenge to obtain the 
desired therapeutic effect by its modulation. In this thesis, I focused specifically on miRNA-
320a which projects a distinct effect on apoptosis in diabetic conditions by targeting the insulin 
growth factor-1 gene. Previous studies demonstrated that insulin growth factor-1 plays a major 
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role in the apoptotic signaling pathway which allows me to select this miRNA candidate for 
my modulation study. To date, no study has been specifically designed to validate the onset of 
miRNA-320a expression and correlation with cardiac dysfunction in diabetic conditions. 
Therefore, the overarching aim of this thesis was to investigate the expression of miRNA-320a 
in diabetic human hearts, type-2 diabetic db/db mouse heart, and high glucose-cultured human 
ventricular cardiomyocytes, along with the effectiveness of miRNA-320a modulation by 
CRISPR/Cas9 and Locked Nucleic Acid-anti-miRNA in high glucose-cultured human 
ventricular cardiomyocytes and type-2 diabetic db/db mouse heart respectively.   
We investigated the expression of miRNA-320a in human right atrial appendage tissue 
collected from non-diabetic with no ischemic heart disease, non-diabetic with ischemic heart 
disease, and diabetic with ischemic heart disease patients and evaluated the expression of target 
protein insulin growth factor-1 and apoptotic markers like B-cell lymphoma 2 and cleaved 
caspase-3. By subjecting diabetic vs non-diabetic mice age-matched from 8 weeks up to 32 
weeks, we investigated the onset of miRNA-320a expression and target protein with apoptotic 
markers. Eventually, we extended my study to assess the expression of miRNA-320a, target 
protein, and level of apoptosis in high and normal glucose-cultured human ventricular 
cardiomyocytes. In the next step, we investigate the effect of cell survival after the knockdown 
of miRNA-320a genomic DNA by CRISPR/Cas9. Eventually, we evaluated the cell survival 
in the whole heart of type-2 diabetic db/db mouse after the miRNA-320a knockdown by 
Locked Nucleic Acid-anti-miRNA. Finally, the cardiac functional improvement was measured 
after miRNA-320a knockdown in type-2 diabetic db/db mice.  
In conclusion, this thesis provides evidence that miRNA-320a is a late responding 
miRNA that has no effect on initiating apoptosis and cardiac dysfunction in the diabetic heart. 
Though it may not initiate apoptosis and cardiac dysfunction, but we found this miRNA 
aggravates the process of apoptosis and cardiac dysfunction. Whereas, effective modulation of 
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miRNA-320a can prevent cell death and partially improve cardiac dysfunction in the diabetic 
heart.    
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ZFN Zinc finger nucleases 































The major portion of the work from this chapter has been published as a review article in 
“Cardiovascular Diabetology” [1]. 
1.1 Type-2 diabetes mellitus 
Type-2 diabetes mellitus is a chronic metabolic condition characterized by insulin resistance 
(that is, the body's inability to effectively use insulin) and insufficient pancreatic insulin 
production, resulting in high blood glucose levels (Hyperglycaemia). Type-2 diabetes is 
commonly associated with obesity, physical inactivity, high blood pressure, abnormal lipid 
level, and a propensity to advance thrombosis, which leads to increased cardiovascular risk. It 
is associated with long-term microvascular and macrovascular complications, together with 
reduced quality of life and life expectancy. 
Type-2 diabetes mellitus has emerged as one of the most serious health problems in 
modernized society, affecting 415 million people worldwide [2]. It is estimated that 4.9 million 
global deaths were caused by diabetes in 2014. Of concern, over 68% of diabetic patients will 
develop some form of fatal heart disease or stroke [3]. 
1.1.1 Complications of type-2 
Diabetes complications are common among patients with both type-1 or type-2 diabetes but, at 
the same time, are responsible for significant morbidity and mortality. Especially in type-2, the 
chronic complications are broadly divided into microvascular and macrovascular, with the 
former having a much higher prevalence than the latter [4]. Microvascular complications 
include neuropathy, nephropathy, angiopathy, and retinopathy, while macrovascular 
complications consist of cardiovascular diseases like heart failure or coronary artery disease 
(CAD, stroke, and peripheral artery disease (PAD). Diabetic foot syndrome has been defined 
as the presence of foot ulcers associated with neuropathy, PAD, and infection, and it is a major 
cause of lower limb amputation [5]. Finally, other complications associated with diabetes 
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cannot be included in the two above mentioned categories such as dental disease, reduced 
resistance to infections, and birth complications among women with gestational diabetes [4]. 
1.1.2 Relationship between diabetes mellitus and cardiovascular disease   
A link between diabetes mellitus and cardiovascular disease is indisputable. Indeed, 
hyperglycemia, hypertension, dyslipidemia, and insulin resistance collectively impact the 
myocardium of diabetic patients, triggering several early pathophysiological molecular, 
structural and myocardial abnormalities [6-12], which may include but are not limited to 
coronary endothelial and vascular dysfunction, and left ventricular remodeling and 
dysfunction. Due to these underlying complications, diabetes mellitus increases the risk for the 
development of a range of cardiovascular complications in people living with diabetes mellitus 
as compared to their non-diabetic counterparts.  
1.2 Diabetic heart disease (DHD)   
DHD is a combination of coronary atheroma, cardiomyopathy, microangiopathy, and 
autonomic neuropathy [13]. It was proposed that cardiac complications in diabetes are not the 
same as coronary artery disease since coronary risk factors in diabetes itself unable to account 
for cardiovascular mortality [13]. Therefore, according to the National Institute of Health,  
diabetic heart disease is defined as the presence of heart disease specifically in diabetic patients 
that encompasses coronary artery disease, heart failure, and/or cardiomyopathy [14]. Notably, 
the term DHD encapsulated with a diverse range of myocardial diseases in diabetic conditions 
leading to a variable etiology. Therefore, the mechanisms of DHD are poorly understood. 
Hence, DHD can be a distinct clinical entity and should not be limited to a particular type of 
myocardial disease, rather, characterized as a myocardial disease in people with type-2 diabetes 
mellitus that cannot be attributed to the individual effects of coronary artery disease, 
hypertension, or other known cardiac diseases [15]. Recent findings show that more than 70% 
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of diabetic individuals will develop some form of heart disease during their life span [16]. 
Importantly, diabetes itself is an independent risk factor for cardiovascular disease [17-23]. 
Population-based studies have revealed that the risk of heart failure is augmented 2 to 3 fold 
by diabetes [24, 25]. The occurrence of diabetes considerably accelerates the development of 
heart failure in patients with myocardial infarction [26, 27], hypertension [28], or atrial 
fibrillation [29]. The impact of diabetes on the development of vascular disease has been 
established earlier but non-ischemic heart failure associated with diabetes has received less 
attention than coronary and cerebrovascular events.  
1.2.1 Diabetic Cardiomyopathy (DCM) 
According to the National Institute of Health (NIH) and the American Heart Association 
(AHA), cardiomyopathy is a collective term, which refers to the disease of the myocardium 
that leads to chronic and progressive damage. Several factors associated with diabetes can 
trigger the development of abnormal structural and functional alterations which altogether 
leading to the development of heart failure [30-32].  
 DCM was first discovered during an autopsy performed on a patient diagnosed with 
diabetic-glomerulosclerosis [33]. Despite being discovered almost four decades ago, a 
considerable amount of information on its pathogenesis and clinical manifestation is still not 
clear. Diabetic heart exhibits higher fatty acid catabolism and reduced glucose metabolism 
leading to insufficient energy production. This provokes the excitation-contraction coupling in 
the diabetic heart increasing its susceptibility to ischemia-reperfusion injury [34]. Further, 
diabetes also induces microvascular rarefaction in the heart thereby diminishing the coronary 
perfusion, eventually resulting in contractile dysfunction [35-37]. DCM often exhibits a 
prolonged subclinical period [38, 39] making it difficult for clinicians to diagnose the disease 
at the early stage. Recent studies from us and others suggest that abnormal molecular alterations 
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from the early stages of the disease form the basis for the development of structural and 
functional deterioration at the later stages [40-42].  
1.2.2 Molecular mechanisms underlying DCM  
Diabetes associated metabolic changes initiate a series of molecular events in the myocardium 
(summarized in Fig.1.1). Advanced glycation end products (AGE) become glycated in 
presence of sugar leading to an alteration in its functional properties [43]. Importantly increased 
formation of AGE alters structural proteins increasing the crosslinking of collagen fibers 
eventually progressing to fibrosis [44]. AGEs produce its action through AGE receptors 
(RAGE) which are activated by oxidative stress in the diabetic myocardium [45]. Aragno et al. 
suggested that the nuclear factor kappa (NF-kB) signaling pathway has been indirectly 
activated by RAGE, which may contribute to the switch towards increased expression of the 
β-myosin heavy chain (β-MHC) isoform in diabetic hearts [45]. On other hand, treatment with 
dehydroepiandrosterone counteracts oxidative stress-induced RAGE activation, normalizes 
NF-kB signaling pathway, and β-MHC isoform shift, in streptozotocin (STZ) induced diabetic 
Wistar rats, which are early events in DCM [46].  Diabetic myocardium also displays cross-
linked AGEs on the sarcoplasmic reticulum (SR) calcium ATPase pump, which impairs SR-
Ca2+ reuptake in myocytes [46, 47]. Inter-myofibril and perivascular fibrosis is commonly 
observed in DCM due to the activation of transverse growth factor β (TGF-β) and connective 
tissue growth factor (CTGF) leading to increased collagen deposition [48, 49]. Chiu et al. 
suggested that elevation in TGF-β may be due to the activation of poly-ADP-ribose-
polymerase-1 (PARP-1) [49]. On other hand, matrix-metalloproteinase (MMP) also plays a 
crucial role in extracellular matrix degradation leading to increased deposition of connective 
tissue in the diabetic heart [50]. Activation of inflammatory cytokines also plays a key role in 
the pathogenesis of DCM [51-55]. Increased expression of inter-cell adhesion molecules-1 
(ICAM1), vascular cell adhesion molecule-1 (VCAM1) and inflammatory cytokines like 
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interleukin (IL) IL1β, IL6, IL18, tumor necrosis factor-α (TNFα) and transverse growth factor-
β (TGF-β) leads to myocyte inflammation in the diabetic heart [56-59]. Increased fibrosis and 
inflammation leads to activation of the pro-apoptotic signaling pathway [60-63]. 
On other hand, ob/ob mouse model of type-2 diabetes demonstrated, higher intracellular 
resting Ca2+ concentration, prolonged intracellular resting Ca2+ decay, reduced 
sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2) activity, and impaired sarcoplasmic 
reticulum (SR)-Ca2+ reuptake [64, 65]. Impairment in intracellular Ca2+ handling in the heart 
also occurred in rodent models of type-1 diabetes, leading to increased resting Ca2+ levels, 
attenuated SR-Ca2+ release and reuptake, delayed recovery of the intracellular Ca2+ transient, 
reduced expression of SERCA-2a and the Na+–Ca2+ exchanger, and compromised 
mitochondrial Ca2+ handling [66-72]. Diabetes also induces modifications of Ca2+/calmodulin-
dependent protein kinase 2 (CaMK-II) which has a direct relation with SERCA, linked with 
the pathophysiology of contractile dysfunction [73, 74].  
Insulin signaling is an important regulator of myocardial autophagy [75]. Studies from 
Katare’s laboratory demonstrated that type-2 diabetes aggravates the autophagy of 
cardiomyocytes through activation of Beclin-1 (Beclin-1 is a mammalian homolog of the yeast 
autophagy-related gene 6) [76]. On the contrary, this study has shown attenuation of autophagy 
in the type-1 diabetic heart suggesting that autophagy might play a different role in the 
pathogenesis of type-2 versus type-1 diabetes. Another study revealed that the stress granule 
(SG) biogenesis by AMP-activated protein kinase (AMPK) upregulates autophagy in the type-
2 diabetic human heart through the promotion of the Beclin-1[77].On other hand, Mellor et al. 
showed increased autophagy markers such as microtubule-associated protein 1A/1B-light 
chain 3 and nucleoporin p62 in male C57Bl/6 mice fed with a high carbohydrate diet for 12 
weeks [78]  Similarly, Munasinghe et al demonstrated marked activation of autophagy in type-
2 diabetic db/db mice and human right atrial appendage [76]. Phosphatidylinositol 3-kinase 
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(PI3K)/Akt signaling can negatively regulate autophagy by inhibiting the mammalian target of 
rapamycin (mTOR) and changes in autophagy were associated with reduced PI3K/Akt 
signaling in insulin-resistant hearts [79, 80].  
The above evidence provides a strong molecular association in the pathogenesis of the 
diabetic heart. The current understanding in the regulation of cardiac gene expression is at the 
transcriptional level, where transcriptional factors are known to govern the activation of 
specific genes. However, recent studies revealed that a single gene can be controlled by 
multiple regulators at the post-transcriptional level via microRNAs (miRNAs) [81, 82]. 
 
Fig. 1.1 Mechanisms involved in the pathophysiology of diabetic cardiomyopathy. 
Schematic representation of the multiple potential mechanisms that have been implicated in 
the pathophysiology of diabetic cardiomyopathy. The steady increase in reports presenting 
novel mechanistic data on this subject expands the list of potential underlying mechanisms. 
This image has been published in “Cardiovascular Diabetology” [1]. 
 
1.3 MicroRNAs (miRNAs)  
The miRNA was originally discovered in Caenorhabditis elegans, found in most eukaryotes, 
including humans [83-85]. It is predicted that miRNA account for 1-5% of the human genome 
and regulate at least 30% of protein-coding genes [86-89]. Alles et al demonstrated that 2300 
true human mature miRNAs have been identified, of which 1115 miRNAs are currently 
annotated in “miRBase V22; University of Manchester ” (http://www.miRNAbase.org/) [90]. 
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Although still, a lot is unknown about the specific targets and biological functions of miRNA 
molecules, it is evident that miRNA plays a crucial role in the regulation of gene expression 
controlling diverse cellular and metabolic pathways [91-97]. The miRNA is a small non-coding 
RNA molecule that binds with target mRNA to prevent protein production by one of two 
distinct mechanisms. Mature miRNA is produced through the cleavage of primary-miRNA 
(pri-miRNA), which integrates into the effector complex RNA-induced silencing complex 
(RISC). The miRNA functions as a guide by base-pairing with target messenger RNA (mRNA) 
to negatively regulate its expression. The level of complementarity between the guide and 
mRNA target determines which silencing mechanism will be employed; the cleavage of target 
mRNA with subsequent degradation or translation inhibition [83, 98].  
1.3.1 Biogenesis of miRNAs 
MiRNAs undergo a series of processing before maturation as discussed next. RNA polymerase-
2 transcribe the miRNA coding genes to form several kilo-bases (kb) long pri-miRNA. This is 
cleaved further by DROSHA RNase-3 endonuclease enzyme and DGCR-8 at the basal level of 
stem-loop to form 70kb long precursor-microRNAs (pre-miRNAs). Pre-miRNAs are next 
exported to the cytoplasm with the help of a transporter protein, Exportin-5, which is further 
cleaved by DICER RNase-3 endonuclease enzyme and ARGONAUTE-2 (AGO-2) protein into 
small interfering RNA (siRNA) like imperfect duplex comprising of one mature-miRNA strand 
and a complementary sequence. Next, the mature sequence is incorporated into 
ribonucleoprotein to form a miRNA-associated silencing complex while the complementary 






Fig. 1.2 Biogenesis of miRNA. Canonical pathway of miR biogenesis in which miRs are 
transcribed by RNA polymerase II from intergenic, intronic, or polycistronic loci to long 
primary transcript, called pri-miRNA, which consists in a stem, a terminal loop, and single-
stranded RNA segments at both the 5′- and 3′-UTR sides. Microprocessor complex (Drosha 
and DGCR8 cofactor) cleaves the stem-loop and releases a small hairpin-shaped RNA, called 
precursor miRNA (pre-miRNA). Following, pre-miRNA is exported into the cytoplasm by the 
transport complex formed by protein Exportin 5, pre-miRNAs are cleaved by a ternary complex 
formed by Dicer, producing small RNA duplexes (miR–miR). Next, these are loaded onto an 
Argonaute 2 protein (AGO2) to form an immature RNA-induced silencing complex (RISC) or 
pre-RISC. AGO protein separates the two strands to generate a mature RISC efector. Finally, 
RISC binds the target mRNA through complementary binding of 6–8 base pairs of the miR, 
with a specifc sequence of the target resulting in the gene silencing. This image has been 
published in “Cardiovascular Diabetology” [1]. 
 
1.3.2 Pathological role of miRNAs in DCM  
MiRNAs have been described as the “micromanagers” of gene expression [99].  The discovery 
of miRNAs as the regulators of multiple cardiac genes has added a new mechanistic link 
between gene regulation in the normal and diseased heart at the post-transcriptional level. 
Recently, miRNAs have been identified as a key element involved in cardiac gene remodeling 
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in the diabetic heart [100, 101]. As these processes involve the dysregulation of multiple genes, 
it is reasonable to hypothesize that miRNAs play a key role in the pathogenesis of DCM (Table 
1.1). Alterations in the synthesis and in the levels of specific miRNA have been shown to play 
critical roles in cardiac remodeling and the development of heart failure [102-104]. In addition, 
miRNA can affect other epigenetic changes such as alterations in histone H2A mRNA levels, 
histone deacetylase (HDAC), and DNA methyltransferases (DNMT), resulting in the 
modulation of gene expression [105]. Further miRNAs can be transferred between the cells or 
to the distant tissue through circulation where they remain stable [106]. This ability of miRNAs 
to remain stable in circulation makes them a promising diagnostic tool for various diseases 
including cardiovascular diseases [42, 107]. Taken together, miRNA may play a potential 













Table: 1.1 List of some selected miRNA candidates involved in the progression of DCM 
miRNAs Expression 
pattern 
Regulatory genes Pathophysiological role Expression 
pattern 











apoptosis, heart failure, 
arrhythmia, oxidative 
stress 
Cardiac & skeletal 
muscle 
Transgenic mice with Akt overexpression, 
exercise-induced hypertrophy model in rats, 
hypertrophic human atria and ventricles, 
STZ-diabetic mice, HG-exposed rat 








Upregulation Pim-1, Hsp60 Cardiac apoptosis Cardiac muscle STZ-diabetic rat & mouse heart  [111] 
miRNA-
195 
Upregulation SIRT-1, BCL-2 Cardiac apoptosis & 
hypertrophy 
Cardiac muscle Db/db mice, CEC, STZ- diabetic mouse [112] 
miRNA-
34a 





Downregulation Nrf2 Cardiac apoptosis & 
oxidative stress 







IGF-1R Cardiac apoptosis 
Cardiac hypertrophy 





Upregulation IGF-1, BCL-2 Cardiac apoptosis  Cardiac muscle H9c2 cells, STZ-diabetic mouse heart [118] 
miRNA-
320a 
Upregulation VEGF-c, IGF-1, 
FLK-1 





Upregulation FOXO-3a Cardiac pyroptosis Cardiac muscle HFD induced rat heart [123] 





Upregulation GATA4, Thrap-1 Cardiac hypertrophy Cardiac muscle STZ-diabetic mouse [110, 125] 
miRNA-
133a 
Downregulation SGK1, IGF-1R,  
TGF-β1 
Cardiac hypertrophy & 
fibrosis 
Cardiac & skeletal 
muscle 
STZ-diabetic mouse heart [126, 127] 
miRNA-
373 
Downregulation MEF2c Cardiac hypertrophy & 
oxidative stress 
Cardiac muscle High glucose-induced neonatal rat 
ventricular cardiomyocytes, STZ- diabetic 
mouse heart 
[108, 128] 
miRNA-21 Upregulation DUSP8 Cardiac fibrosis Cardiac muscle HG-induced primary NRCFs [129] 
miRNA-29     Upregulation MCL-1 Disorganization or loss 
of myofibril bundles 
Cardiac muscle ZDF rat heart [130] 
miRNA-
208 
Upregulation Β-MHC, TR-α Cardiac remodeling Cardiac muscle Human RAA and ventricular tissue, HL-1 




Downregulation TGFβR1, CTGF Cardiac fibrosis Cardiac muscle Human RAA and ventricular tissue, and 









Human RAA and ventricular tissue, 




Upregulation ARC  Cardiac apoptosis Cardiac muscle Human RAA and ventricular tissue, Human 
ventricular cardiomyocytes (AC-16), and 




Table 1: Abbreviation in Table 1: STZ: streptozotocin, HG: high glucose, IHVC: immortalized 
human ventricular cardiomyocytes, NRCF: neonatal rat cardiac fibroblast, ZFD: Zucker 
diabetic fatty rat, HFD: high-fat diet, GK: Goto-Kakizaki, CEC: cardiac endothelial cells, 
MVEC: microvascular endothelial cells, MHC: Myosin heavy chain, TR-α: Thyroid hormone 
receptor alpha, VEGF: Vascular endothelial growth factor, Spred1: Sprouty-related, EVH1 
domain-containing protein 1, TGFβR1: Transforming growth factor-beta receptor I, CTGF: 
Connective tissue growth factor. This table has been published in “Cardiovascular 
Diabetology” [1]. 
 
1.3.2.1 MiRNAs involved in cardiac cell death 
The miRNA-1 has been reported to control muscle differentiation by targeting Hand2 (heart 
and neural crest derivatives-expressed protein), a transcription factor that regulates the 
expansion of ventricular cardiomyocytes [136]. Interestingly, the expression pattern of 
miRNA-1 is regulated by serum response factor (SRF), myocyte enhancer factor-2 (MEF2), 
and MyoD [82, 136, 137]. The role of miRNA-1 in the diabetic heart has been recently 
demonstrated by Moore et al. which showed marked upregulation of miRNA-1 in type-2 mouse 
and human diabetic hearts [110]. They further demonstrated that increased miRNA-1 is 
associated with significant downregulation of the pro-survival proto-oncogene 
serine/threonine-protein kinase (Pim-1) kinase, the direct protein target for miRNA-1 [138]. 
This was associated with increased cardiomyocyte apoptosis. Earlier studies by Katare et al. 
showed significant attenuation of diabetes-induced cardiomyocyte apoptosis following the 
restoration of Pim-1 levels via systemic administration of Pim-1 conjugated to adeno-
associated virus (AAV) [139].  
On other hand, evidence suggests that the expression of miRNA-195 alters in diabetic 
conditions. Herrera et al. and Mortuza et al. showed upregulation of miRNA-195 in the liver 
and retina of type-2 diabetic rats [140] and STZ-induced diabetic rats [141] respectively. 
Collectively, Zheng et al. demonstrate that both type-1 and type-2 diabetes mellitus promote 
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the expression of miRNA-195 in the heart [112] leading to apoptosis and hypertrophy in 
cardiomyocytes [142, 143].  
MiRNAs-34a has been abundantly expressed in cardiomyocytes [144, 145] which is 
associated with the regulation of several proteins like Bcl-2 [113], Akt (serine/threonine-
specific protein kinase) [146], phosphatase 1 nuclear targeting subunit (Pnuts) [144], and 
sirtuin 1 (SIRT1) [147], all of which have a relevant role to the diabetic heart. SIRT1 plays a 
major role in senescence in the diabetic heart [148]. Fomison-Nurse et al. demonstrated that 
either diabetes or high glucose markedly increases the expression of miRNA-34a in the human 
heart and cardiomyocytes leading to the downregulation of SIRT-1  which is a direct target of 
miRNA-34a [41]. Similarly, another study showed an elevated expression pattern of miRNA-
34a in pre-diabetic and newly diagnosed type-2 diabetic individuals [149]. Using in vitro 
cultured cardiomyocytes, Zhao et al. demonstrated marked upregulation of miRNA-34a levels 
by high glucose which was associated with the downregulation of anti-apoptotic Bcl-2 and 
increased cardiomyocyte apoptosis [113]. They also demonstrated a significant decrease in 
Bcl-2 expression following treatment with miRNA-34a mimic, whereas treatment with anti-
miRNA-34a increased the Bcl-2 expression and reduced high glucose-induced cardiomyocyte 
apoptosis [113].  
 Recent studies by Yu et al demonstrated that nuclear factor-erythroid 2-related factor 2 
(Nrf2) was a direct target of miRNA-144 in adult cardiomyocytes [114]. In addition, repression 
of miRNA-144 prevented myocardial apoptosis by mitigation of oxidative stress in STZ-
challenged diabetic mice [114]. Treatment with miRNA-144 mimics aggravates high glucose-
induced oxidative stress and apoptosis which was reversed by treatment with Nrf2 activator, 
indicating that miRNA-144 is a direct regulator of Nrf2 [114]. This was also replicated in vivo 
where treating diabetic mice with anti-miRNA-144 enhanced the expression of Nrf2 in hearts 
and reduced apoptosis. Additionally, miRNA-378 is a key regulator of apoptosis, which is 
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significantly overexpressed in the diabetic heart and intensive glycemic control was unable to 
revert these changes [117]. Knezevic et al. suggested that overexpressed miRNA-378 reduced 
the expression level of endogenous insulin growth factor-1 receptor (IGF-1R), whereas 
treatment with anti-miRNA-378 aggravates the endogenous level of IGF-1R beyond normal 
[116]. This evidence suggested that the reduction of IGF-1R leads to apoptosis of 
cardiomyocytes. Moreover, the upregulation of miRNA-483-3p in diabetic hearts increased 
apoptosis by downregulating the expression of the anti-apoptotic protein Bcl-2 and IGF1 
respectively. Hence, miRNA-483-3p enhance cell death by miRNA-483-3p- Bcl-2  and IGF 
pathway [118].  
 The miRNA-30d and miRNA-30a belong to the miRNA-30 family, abundantly 
expressed in cardiomyocytes and adipose tissue respectively [123, 150]. Li,X et al. 
demonstrated that the elevated expression of  miRNA-30d  in high glucose treated 
cardiomyocytes and in the diabetic heart suppress fork-head box-O3 (FOXO-3a; a crucial 
regulator of cell cycle arrest, oxidative scavenging, cell proliferation, and survival) which 
promote pyroptosis [123]. Similarly, the miRNA-9 family includes miRNA-9a1, miRNA-9a2, 
miRNA-9b, and miRNA-9c mainly expressed in the heart muscle and brain. The role of 
miRNA-9 in high glucose-induced inflammation or cardiac pyroptosis and its effect on 
cardiovascular diseases is very limited. Jeyabal et al. demonstrated that the downregulation of 
miRNA-9 leading to elevation of  ELAV-like protein 1 (ELAVL1) in the human diabetic heart 
[124] which is associated with elevated caspase-1 and IL-1b expression. This study also 
revealed that ELAVL1 is a direct target of miRNA-9 in cardiomyocytes.  
1.3.2.2 MiRNAs involved in cardiac hypertrophy, fibrosis, and structural damage 
Diabetes eventually induces hypertrophy, fibrosis oxidative stress, and structural damage 
which are typically a compensatory response for cardiomyopathy. Several miRNAs have been 
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associated in those events, including miRNA-1, miRNA-133a, miRNA-373, miRNA-378, 
miRNA-23b, miRNA-181, miRNA-30c, miRNA-208, miRNA-195, and miRNA-451 having a 
role in hypertrophy (both hypertrophic and anti-hypertrophic).  
MiRNA-208a is a cardiac-specific miRNA that is encoded within Myh6 gene-encoded 
with myosin heavy chain-α (MHCα). The MHCα and MHCβ are the major contractile proteins 
of cardiomyocytes, which differ in their ability to convert ATP to mechanical work at different 
rates which affect the contractility of the cardiac sarcomeres [151, 152]. Increased expression 
of MHCβ is a common feature of cardiac hypertrophy and heart failure that reduces contractile 
performance [153-155]. Interestingly, the miRNA-208a mediated hypertrophic growth is only 
accompanied by augmented MHCβ expression in a subset of hypertrophied cardiomyocytes.  
In contrast, the deletion of miRNA-208a resulted in decreased MHCβ expression in the adult 
heart [156]. Upregulated MHCβ expression in miRNA-208a transgenic mouse hearts is 
associated with regional fibrosis [157]. The miRNA-208a post-transcriptionally represses the 
expression of Thrap-1, a component of the thyroid hormone nuclear receptor complex. Studies 
have also shown that increasing the level of miRNA-208a in transgenic mouse hearts reduced 
Thrap-1 levels and induced hypertrophic growth, provide a link between the action of miRNA-
208a and thyroid hormone in cardiac hypertrophy. GATA-4 is also directly targeted by 
miRNA-208a thus, altering miRNA-208a expression affects the delicate regulation of potent 
cardiac transcription factors. Moreover, Rawal et al demonstrated that the miRNA-208a gets 
activated by MHCα in the early stages of diabetes [131]. The activated miRNA-208a altered 
the downstream signaling pathway leading to the development of cardiac hypertrophy with the 
remodeling in type-2 diabetic db/db mouse heart [131]. 
The miRNA-195 was found abundantly in the blood of type-2 Individuals with or 
without metabolic syndrome [42]. This miRNA is pro-apoptotic, and also plays a crucial role 
in hypertrophy [112]. Zheng et al shown, in response to elevated expression of miRNA-195, 
17 
 
Bcl-2 and SIRT1 expression has been decreased in both STZ-induced type 1 and type-2 
diabetic db/db mice heart, which can be attenuated by anti-miRNA administration [112]. 
Similarly, Kuwabara et al. showed upregulation of miRNA-451 in type 2 diabetic (C57BL/6 
transgenic) mice and neonatal rat cardiomyocytes in response to an excess supply of saturated 
fatty acids which causes DCM [158]. On other hand, the direct target of Calcium-binding 
protein 39 (CAB39) is miRNA-451 which is an upstream kinase of AMP-activated protein 
kinase (AMPK). The alteration of CAB39 by miRNA-451 has a direct relation with cardiac 
hypertrophy.  
MiRNA-133 and miRNA-1 are reported to be expressed specifically in cardiac and 
skeletal muscles [90]. MiRNA-133 family includes miRNA-133a-1, miRNA-133a-2 (both of 
them expressed in cardiac and skeletal muscles), and miRNA-133b which is specifically 
expressed in cardiac muscle. Each of them shares a common bicistronic unit with miRNA-1 
and miRNA-206. However, all these miRNAs are expressed as separate transcripts and exhibit 
different phenotypes [159]. For the first time, Care at al. demonstrated the targets of miRNA-
133 as, RhoA (GDP-GTP exchange protein), Cdc42 (signal transduction kinase), and Nelf-
A/WHSC2 (nuclear factor), among them RhoA and Cdc42 have a distinct role in regulating 
cardiac hypertrophy [160]. Similarly, Young et al demonstrated the beneficial role of miRNA-
133 overexpression, in terms of reducing the glucose transporter and insulin-induced glucose 
uptake in cardiomyocytes by repressing insulin-regulated glucose transporter-4 (GLUT4) and 
protein Krüppel-like factor 15 (KLF15) [161]. In support of the above finding, another study 
demonstrated a marked decrease in the level of miRNA-133a facilitates hypertrophic 
progression in STZ induced type 1 diabetes model [126]. On other hand, miRNA-133a is also 
involved by myocyte enhancer factor-2C (MEF-2C) which is a key transcription factor for 
myocardial hypertrophy and fibrosis through activation of p300 gene [162, 163]. The reduced 
expression of miRNA-133a leads to the upregulation of serum and glucocorticoid regulated 
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kinase-1 (SGK-1) and IGF-1R resulting in the activation of MEF-2C [163]. Another anti-
hypertrophic miRNA; miRNA-373 shows evidence of correlation with p38, which is a member 
of the mitogen-activated protein kinase (MAPK). MiRNA-373 is transcriptionally regulated by 
p38 MAPK and miRNA-373 can protect against glucose-induced hypertrophy by repressing 
the MEF2C (hypertrophic protein) [128]. Similarly downregulated miRNA-378 also produces 
a hypertrophic response in relation to IGF-1R [164]. Similarly, miRNA-1 (muscle-specific 
miRNA); has a pro-apoptotic and anti-hypertrophic character that has impacts on 
cardiomyocyte growth by negatively regulating calmodulin and the nuclear factor of activated 
T-cells (NFAT) signaling. Ryanodine receptor Ca2+ release channel complex (RyR2) located 
in the sarcoplasmic reticulum is a target protein for miRNA-1 in the diabetic heart, which exerts 
a vital role in Ca2+ transport and cardiomyocyte contractility [108]. Moreover, miRNA-1 
targets the MEF-2A, GATA-4, and other key cardiac-specific transcriptional factors such as 
heart and neural crest derivatives expressed 2 (Hand2) [109, 110].  
Disorganization of cardiomyocytes and myofibril bundles leads to cardiac structural 
impairments. MiRNA like miRNA-29a have deep significance in myocardial structural 
impairments. The human miRNA-29 family involves a cluster of three precursors, with 
miRNA-29a and miRNA-29b1 being transcribed from chromosome-7, and miRNA-29b2, 
which has an identical sequence to miRNA-29b1, as well as miRNA-29c being transcribed 
from chromosome-1 [165] and the clusters of miRNA-29 has been transcribed as polycistronic 
units [104, 166]. Arnold et al. suggested dysregulation of anti-fibrotic miRNA-29b, leads to 
cardiac structural impairment (disorganization or loss of myofibril bundles) in Zucker diabetic 
fatty (ZDF) rat [130]. Moreover, insulin suppressed the expression of the miRNA-29 family in 
HL-1 mouse cardiomyocyte cells and increase the pro-survival protein myeloid-cell-leukemia-
1 (MCL-1) [130]. MCL-1; an anti-apoptotic Bcl-2 protein is highly expressed in the 
myocardium and according to Thomas et al, cardiomyocyte-specific MCL-1 knockout mice 
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rapidly develop cardiomyopathy and died [167]. Ultrastructural analysis showed disorganized 
sarcomeres and swollen mitochondria in cardiomyocytes along with impaired autophagy 
process in MCL-1 deficient heart [167]. Therefore, evidence suggests that miRNA-29 is 
another potential miRNA, plays a role in the progression of DCM. Although limited, 
collectively all those miRNAs play an important role in the pathogenesis of DCM.    
1.3.2.3 Other selected miRNAs involved in oxidative stress 
Mitochondria is the major source for the production of reactive oxygen species (ROS) in living 
cells. Elevated production ROS is associated with high glucose exposure resulting in the 
damage of cellular components. Dysregulation of certain miRNA s including miRNA-144, 
miRNA-1, miRNA- 133, miRNA-499, miRNA-195, miRNA-34a, miRNA-141, miRNA-200a, 
miRNA200c, miRNA- 19b, miRNA27a, miRNA-125b, miRNA-155 miRNA-146a, miRNA-
210, miRNA-373 and miRNA-221 have been associated with oxidative stress [114, 117, 168]. 
Yildirim et al. has shown that miRNAs such as miRNA-499, miRNA-1, and miRNA-133 are 
unusually repressed in high glucose-treated cardiomyocytes, while treatment with the 
antioxidant N-acetylcysteine restored those miRNAs expression [108]. On other hand, altered 
expression of miRNA-373 is associated with high glucose-induced oxidative stress in the heart 
[128]. Further, high glucose treatment elevated ROS production in response to decreased 
miRNA-144 expression by targeting nuclear factor-erythroid 2-related factor-2 (Nrf-2) which 
is a central mediator of cellular response to oxidative stress [163]. Likewise, the miRNA-200 
family, in particular  miRNA-200a, miRNA-200c  and miRNA-141, and miRNA-429 [169], 
play a crucial role in oxidative-stress dependent endothelial dysfunction in diabetes and 
obesity. The p38α a mitogen-activated protein kinase (MAPK) which is an oxidative stress 
sensor, has also been potentially regulated by miRNA-200a and miRNA-141 [170, 171]. All 




1.3.2.4 MiRNA-320a (reason for the selection of miRNA-320a in this thesis) 
The miRNA-320a is expressed abundantly in cardiomyocytes and myocardial microvascular 
endothelial cells (MMVEC) [120, 172]. Wang et al. demonstrated the correlation between 
miRNA-320a expression and high glucose by co-culturing of cardiomyocytes and MMVEC 
under high glucose conditions. Interestingly, high glucose-induced secretion of miRNA-320a 
from cardiomyocytes into the culture medium and was uptaken by MMVECs via exosomes 
[120]. To confirm the exosomal transport, the cells were treated with exosomes inhibitor GW-
4869 which reduced the uptake of miRNA-320a by the MMVEC cells, clearly indicating that 
miRNA-320a was biosynthesized in cardiomyocytes which can produce its action in other cells 
also [121]. MiRNA-320a has the potential to target multiple angiogenetic genes such as fetal 
liver kinase-1 (FLk-1), vascular endothelial growth factor-c (VEGF-c), fibroblast growth 
factors (FGFs), and anti-apoptotic genes such as IGF-1[120]. In support of this, an increase in 
miRNA-320a expression was associated with the downregulation of IGF-1 which increased 
apoptosis [120].  Interestingly, activation of IGF-1 exaggerated the expression of pro-
angiogenetic VEGF and FLK-1. Further, overexpression of miRNA-320a in cardiomyocytes 
reduced the expression of anti-apoptotic protein Bcl-2 while increasing the expression of pro-
apoptotic proteins Bax and caspase-3, leading to cell death [122]. Moreover, a previous study 
from Katare’s laboratory demonstrated the expression pattern of several miRNAs in the human 
diabetic heart [133] where the upregulated trend was observed in miRNA-320a. That study has 
not revealed the actual pathological role of miRNA-320a in the diabetic heart. Although all the 
previous studies demonstrated the expression pattern of miRNA-320a but didn’t establish the 
pathological role in the diabetic heart. Therefore, we wanted to establish the pathological role 
of miRNA-320a in terms of apoptosis in diabetic cardiomyocytes through IGF-1 signaling 
pathway. Moreover, we also wanted to know the onset of miRNA-320a expression to establish 
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whether miRNA-320 initiates cardiac apoptosis as well as dysfunction in diabetic heart. Hence 
we selected miRNA-320a as a candidate miRNA for this project.  
1.3.2.4.1 Other pathological role of miRNA-320 family 
It is proven that due to target variation, one miRNA can produce different pathological actions 
by targeting different genes [173]. In the case of miRNA-320 family plays a different role in 
different disease conditions [174]. The miRNA-320 family is comprised of miRNA-320a 
(chromosome-8), miRNA-320b (chromosome-1), miRNA-320d (chromosome-13 and 
chromosome-X), miRNA-320c (chromosome-18), and miRNA-320e (chromosome-19) [174].  
The global miRNA and gene expression profiling during adipocyte differentiation of 
human mesenchymal stem cells identified the expression of the miRNA-320 family (miRNA-
320a, 320b, 320c, 320d, and 320e) [175]. Overexpression of miRNA-320c in human 
mesenchymal stem cells enhanced adipocyte differentiation and accelerated the formation of 
mature adipocytes in ex vivo cultures [175]. This study revealed an upregulated expression of 
miRNANA-320c during adipocyte differentiation of human mesenchymal stem cells by 
targeting several novel genes like mindbomb E3 ubiquitin protein ligase 1 (MIB1), Paired box 
protein 6 (Pax-6), 14-3-3 protein eta YWHAH, runt-related transcription factor 2 (RUNX2). 
Concordant with that, lentiviral-mediated stable expression of miRNA-320c at physiological 
levels (~1.5-fold) promoted adipocyte and suppressed the osteogenic differentiation of human 
mesenchymal stem cells. Luciferase assay validated RUNX2 as a bona fide target for the 
miRNA-320 family. Therefore, this study suggested the miRNA-320 family as a possible 
molecular switch promoting adipocyte differentiation of human mesenchymal stem cells.  
The role of miRNAs in colorectal cancer is currently being discovered at a rapid pace. 
MiRNA-320b was found to be among those up-regulated in the patient group with metastasis 
[176]. The study performed by Zhou et al found that miRNA-320b, opposite of its homolog, 
miRNA-320a that differs by only a single nucleotide, functions in promoting colorectal cancer 
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cell proliferation and invasion [176]. Moreover, overexpression of exogenous miRNA-320b 
can up-regulate the target genes of microRNA-320a including β-catenin, Neuropilin-1, and 
Rac-1, which are all known to promote tumor proliferation, invasion, and metastasis. These 
results suggest that miRNA-320b may function in competing with miRNA-320a. It is found 
that miRNANA-320a target genes like SRY-Box Transcription Factor-4 (SOX-4), Forkhead 
box protein M1 (FOXM1), and Forkhead box Q1 (FOXQ1) [177-179] are significantly 
upregulated in colorectal cancer patients promoting the progression of this cancer. Moreover, 
a recent study demonstrated significant downregulation of the miRNA-320 family (miRNA-
320a, b, c, d, and e) in primary colorectal tissue and cell lines [180]. In this study, (Vishnubalaji 
et al) demonstrated inhibition of colorectal cancer progression and migration in HCT116 cells 
(colorectal cancer cell lines) by miRNA-320c-mimic administration through lentivirus [180]. 
The lentiviral mediated miRNA-320c-mimic administration reverses the expression of the 
above-mentioned genes in colorectal cancer cell lines which promises miRNA-320c 
modulation as a potential therapeutic strategy of colorectal cancer.    
On other hand, Chen et al demonstrated that dysregulated expression of miRNA-320d 
has been associated with several cancer developments and progression [181]. Chen et al 
evaluated the expression profile of miRNA-320d and FOXM1 in human gastric cardiac 
adenocarcinoma tissues and gastric cardiac adenocarcinoma cell lines (OE-19 and SK-GT2 
cells) and found a reduced expression of miRNA-320d leading to upregulation of FOXM1. The 
mechanism analysis of miRNA-320d/ FOXM1 showed that FOXM1 has two miRNA-320d 
binding sites in its 3′-untranslated region, which contributes to the regulation of the cell 
biological behaviors. Taken together, this study suggested that miRNA-320d acts as a tumor 
suppressor in gastric cardiac adenocarcinoma by directly targeting FOXM1 and thus potentially 
serves as a therapeutic tool for gastric cardiac adenocarcinoma patients [181]. 
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MiRNAs have a central role in the signaling network of the lung tumor 
microenvironment. In that consequence, Fortunato et al observed high miRNA-320a 
expression in the neutrophils of heavy-smokers promoted an M2-like pro-tumorigenic 
phenotype through the downregulation of signal transducer and activator of transcription-
4 (STAT-4) when shuttled into macrophages [182]. The study also exposed the potential role 
of miRNA-320a in lung cancer metastasis by downregulating tumor suppressor signal 
transducer and activator of transcription-3 (STAT-3) and neuropilin-1 genes (NRP-1; a 
membrane-bound coreceptor to a tyrosine kinase receptor) [183-186]. Based on this finding, it 
can be suggested that modulation of macrophage phenotype toward an anti-tumor polarization 
through miRNA-320a inhibition either to block tumor growth or to induce an immune response 
against malignant cells.  
In terms of mother-fetus mortality, preeclampsia is a major concern in pregnancy-
specific pathologic complications. Xie et al revealed interleukin-4 (IL-4 ) as a direct target of 
miRNANA-320a in HTR-8/SVneo cells (trophoblast cells derived from the human placenta) 
[187]. Moreover, this study demonstrated that the reduced expression of miRNA-320a in the 
human placenta elevates the progression of preeclampsia by aggravating the proliferation and 
invasion of trophoblast. Overexpression of miRNA-320a by mimic administration induced a 
marked reduction in cell proliferation in HTR-8/SVneo cells [187] revealing miRNA-320a-
mimic administration as a potential therapeutic approach in the treatment of preeclampsia.  
1.4 Techniques involved in modulation of miRNAs 
As discussed above miRNAs form an integral part of several disease processes including the 
evolution of DCM providing a novel therapeutic approach for the treatment of DCM. While 
the therapeutic potential of miRNAs is promising, it does come with several hurdles such as 
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stability and poor efficiency following delivery. Therefore, synthetic oligonucleotides need to 
be designed in such a way that can overcome stability and delivery-related problems.  
1.4.1 Designing of therapeutic miRNAs 
The goal of miRNA replacement therapy using synthetic exogenous miRNAs is to achieve the 
same biological functions as the endogenous miRNAs. Therefore, synthetic miRNAs and anti-
miRNAs should possess the ability to adhere to the RNA-induced silencing complex (RISC). 
The double-stranded miRNA containing both guide and passenger strands was more potent 
than the single-stranded [188, 189] to enable the appropriate formation of RISC. Therefore, 
designing miRNA-mimics with a double-stranded structure has become the path of therapeutic 
development. Synthetic miRNAs precursors with longer sequences have also been proposed as 
therapeutic agents [190]. Since pre-miRNAs undergoes processing inside the nucleus to form 
mature miRNAs, different strategies are required for the delivery of different types of miRNA-
mimics and anti-miRNAs to their target domain [191]. Due to the limited sequence variation 
of miRNAs, chemical modification is the major approach to tackle this problem.  
1.4.1.1 Structural modification of miRNAs 
RNAs are extremely fragile to serum nucleases enzyme. Therefore modifications of the RNA 
duplexes can minimize immunogenicity and reduce off-target effects [192]. A number of 
factors like position and type of modification need to be considered for the successful 
modification of endogenous miRNAs [193].  The majority of this class of oligonucleotides 
function is reversed by hybridization with exogenously introduced anti-miRNAs to block RISC 
loading [194]. Anti-miRNAs may also be designed to trigger miRNA cleavage by RNase-H 
although this approach is less common [195]. A typical anti-miRNA is a perfect complement 
to the endogenous target miRNA which has chemical modifications to enhance nuclease 
stability and target binding affinity [195]. The central position of the guide strand miRNA and 
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the 5′ phosphate and 5′proximal part are the significant part of the RNA duplex for the 
interaction with the RISC [196, 197] (Fig. 1.3). By contrast, chemical modifications at the 
entire passenger strand and the 3′ proximal part and 3′ projection of the guide strand would 
have the least influence on the specificity and function of the RNA [198]. The major types of 
chemical modifications that are being investigated in the preclinical setting are locked nucleic 
acid modification, ribose-2´- OH modification and phosphorothioate (PS) modification 








Table: 1. 2 Selected miRNA candidates using chemical modification and their delivery 
Target miRNAs miRNA 
modification 
Delivery of therapeutic 
miRNAs 
Pathophysiological role Model system Reference 
miRNA-16, miRNA-122, 
miRNA-192, miR-194 






Metabolic disturbance  
C57BL/6 mice 




miRNA-199b 2´-O-Me Lipid-based Fibrosis & functional 
impairment  
B6CBA/F1 mice [200] 
miRNA-34a LNA+PS 
LNA 
Direct & lipid-based 
Lentivirus 
Myocardial infarction 
Contractile dysfunction  
C57BL/6 mice & 
cardiomyocytes 


























































F/MOE & LNA 
LNA+PS 
Lipid-based & Direct 
 
Direct 
Fibrosis & functional 
impairment 
 







miRNA-322 2´-O-Me Lentivirus cardiomyocyte apoptosis Cardiomyocytes [212] 
miRNA-137 2´-O-Me Lentivirus cardiomyocyte apoptosis Cardiomyocytes [213] 
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Table 2 Abbreviation in Table 2: O-Me: O-methyl, LNA: locked nucleic acid, MMVEC: 
myocardial microvascular endothelial cells, F/MOE: fluro/methoxyethyl, AAV: adeno-
associated virus, PS:  phosphorothioate. This table has been published in “Cardiovascular 
Diabetology”[1]. 
1.4.1.1.1 Locked nucleic acid (LNA) modifications 
LNA is a modified RNA nucleotide and is often referred to as inaccessible RNA. These are a 
class of nucleic acid analogs in which the ribose ring is “locked” by a methylene bridge 
connecting to an oxygen and a carbon atom in 2′ and 4′ position respectively (Fig. 1.3 A). The 
bridge attaches the 3ʻ- endo confirmation in the form of a duplex (possible double-helical 
structure) [214]. LNA nucleotides contain the common nucleobases that appear in DNA and 
RNA and can form base pairs according to standard Watson-Crick base-pairing rules. 
However, by "locking" the molecule with the methylene bridge the LNA is constrained in the 
ideal conformation for Watson-Crick binding which makes the pairing with a complementary 
nucleotide strand more rapidly, thereby increasing the stability of the duplex. This modification 
improves RNA duplex stability by increasing its resistance to nuclease degradation [215, 216]. 
In order to be efficient, synthetic miRNAs must be designed in such a way that it helps the 
selection of the projected guide strand by the RISC to minimize off-target effects. The strong 
binding properties of LNA make them particularly useful in anti-miRNA applications, where 
short sequences can be necessary for miRNA specificity [217]. Moreover, LNA modification, 
in general, reduces the immune response by preventing the immunogenic sequence-motifs 








Fig.1.3 Chemical modifications of miRNA oligonucleotides. Structures of chemical 
modification. (a) Structures of the most commonly used chemical modifications in 
oligonucleotide chemistry; locked nucleic acid (LNA) is a bicyclic RNA analog in which the 
ribose is locked in a C3′-endo confirmation by the introduction of a 2′-O,4′-C methylene 
bridge, (b) the nonbridging phosphate atom is replaced with a sulfur atom to give a 
phosphorothioate (PS) modification, (c) six-membered morpholine ring replaces the sugar 
moiety in morpholino oligomers. (d) In the ribose 2′-OH group modification: the 2′-OH group 
is modified with 2′-O-methyl (2′-O-Me), (e) 2′-OH group is modified with 2′-fluoro (2′-
F), (f) 2′-OH group is modified with 2′-O-methoxyethyl (2′-MOE) [1]. 
 
1.4.1.1.2 Phosphorothioate (PS) modification  
The PS modification is also termed as a backbone modification of oligonucleotides. Backbone 
modifications are mainly used to increase the stability of nucleic acids against nuclease 
resistance by substituting the phosphodiester linkages with other linkages. In this process of 
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modification, a sulfur atom in the phosphate group has been replaced by the non-bridging 
oxygen atom (Fig. 1.3 B) [218] which is referred to as PS backbone modifications. 
Phosphorous has four non-identical ligands which can be arranged chirally (the Greek word 
for hand). During chemical synthesis, two compound forms, called diastereomers (Sp and Rp), 
with different configurations around the phosphorus atom (Fig. 1.4 A & B). These two 
diastereomers can be expected to interact differently with enzymes [219] thereby providing a 
variation in nuclease resistance [220, 221]. In addition, sulfur is a “soft” atom that coordinates 
preferentially with “soft” metal ions, whereas oxygen is a “hard” atom that coordinates with 
“hard” metal ions. Therefore, the use of PSs also permits the identification of metal-ion binding 
sites in biological systems. The PS-inter-nucleotide linkage is considerably more stable than 
the phosphodiester bond toward nucleases, and this feature makes it useful for in vitro and in 
vivo studies [220]. These two diastereomers (Sp and Rp), helps in the formation of 3´-
phosphorothioate and 5´-phosphorothioate inter-nucleotide linkage (Fig. 1.4 C & D) which 
enhance the binding ability of PS-backbone to plasma proteins, leading to reduced clearance 
by glomerular filtration and urinary excretion. Thus, PS-modified oligonucleotides exhibit 
markedly improved pharmacokinetic properties compared to phosphodiester bonds, facilitating 
their delivery into many peripheral tissues in vivo [188]. 
Similarly, the non-bridging oxygen atom can also be replaced by using morpholino 
oligomers, in which a six-membered morpholine ring replaces the sugar moiety (Fig. 1.3 C) 
[222]. Morpholine oligomers are uncharged, sequence-specific, non-toxic resistant to nucleases 
degradation which provides a slight increase in binding affinity towards both pri-miRNAs and 







Fig. 1.4 Isomeric configuration phosphorothioate modification. Formation of diastereomers 
by phosphorothioate (PS) backbone modifications. (a, b) Chiral arrangements of Sp and Rp 
diastereomers. (c, d) Formation of 3′-phosphorothioate and 5′-phosphorothioate inter-
nucleotide linkage from Sp and Rp diastereomers. I developed this image and it has been 
published in “Cardiovascular Diabetology” [1].   
 
1.4.1.1.3 Ribose-2´-OH modification 
Modification of the ribose 2′-OH group is another modification in RNA duplex design to 
enhance its stability [224]. Apart from enhancing nuclease stability, ribose 2′-OH modifications 
decrease immune activation of the RNA duplex [225]. Ribose 2′-OH group modification of 2′-
O-methyl (2′-O-Me), 2′-fluoro (2′-F) and 2′-methoxyethyl (2′-O-MOE) substitution in 2´- the 
position has been demonstrated to effectively improve the stability of RNA duplex (Fig.1.3 C, 
D & E) [226]. For example, Davis et al. identified a chimeric 2´-F/MOE as a potent inhibitor 
of miRNA activity in vivo which does not involve degradation of the miRNAs [227]. This 
specialty of 2´-F/MOE modification is crucial for interpreting miRNA inhibition studies.  
Taken together, each of the chemical modifications has a significant advantage with 
few drawbacks. Hence, the selection of chemical modification is a vital step in the modulation 
of miRNAs. Moreover, to get the best possible results, it is sometimes necessary to use more 
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than one modification or simultaneously all the modifications at a time based on the model 
system used. Among all the modifications discussed, LNA is still the best choice for chemical 
modification of miRNA which has been successfully tested in several in vitro and in vivo 
studies. 
1.4.2 Clustered regularly interspaced short palindromic repeats (CRISPR/Cas9)  
CRISPR is a class of DNA sequences recognized for the first time in the genome of the 
prokaryotic organism [228]. These sequences are derived from DNA fragments from viruses 
that have previously infected the prokaryote and are used to detect and destroy DNA from 
similar viruses during subsequent infections. Hence these sequences play a key role in the viral 
defense system of prokaryotes. On other hand, “Cas9” is an enzyme that accompanying 
CRISPR sequences and acts as a guide to recognizing and cleavage the specific DNA strand, 
complementary to the CRISPR sequence.  
CRISPR system consists of mainly two components. A guide RNA (gRNA) or signal-
guided RNA (sgRNA) and a CRISPR-associated endonuclease (Cas protein). The gRNA is a 
short synthetic RNA, composed of a scaffold sequence necessary for the binding of Cas-protein 
to the target site. Additionally, a user-defined ∼20 nucleotide spacer sequence must be attached 
with the component which defines the genomic target to be modified. Thus, it is easy to change 
the genomic target of the Cas protein by simply changing the target sequence present in the 
gRNA [229]. After accomplishment to the target site, Cas protein cuts the genomic DNA 
sequences and generates double-strand DNA break (DSB), which can be patched by the repair 
system in a non-homologous end joining (NHEJ) manner with variable sizes of insertions or 
deletions (indels) [230] which leads to a frameshift mutation in the coding region (Fig.1.5) 
[231]. Though the primary established role of CRISPR/Cas systems is adaptive antiviral 
defense in bacteria, evidence indicates that it also plays a critical functional role, such as 
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endogenous transcriptional control, maintaining genome homeostasis as well as strategic 
adaptation to the environment [232]. This opens new avenues for the investigation of 
CRISPR/Cas systems and their functional characterization beyond adaptive immunity [233].  
 
 
Fig. 1.5 Schematic diagram of the CRISPR/Cas9 system.  Site-specific DNA cleavage 
bynuclease Cas9 is directed by complementary between a guide RNA (gRNA) and the target 
sequence upon the presence of a protospacer-adjacent motif (PAM) on the opposite strand. 
 
1.4.2.1 Knocking out of miRNA genes by CRISPR/Cas9 
For the last two decades, several strategies have been developed to knock down miRNAs, such 
as antisense inhibitors and sponges. However, the specificity, stability, and robustness of those 
strategies are not satisfied. CRISPR/cas9 is emerging as a novel and promising genome editing 
tool in biological and translational research, but its application in miRNA research has not yet 
been studied extensively. CRISPR/cas9 shows an exclusive benefit as of overcoming off-target 
effects on miRNAs in the same family or with highly conserved sequences [234]. More 
significantly, the Cas9 component produces stable knockdown in both in vitro and in vivo 
models [235]. Before the introduction of CRISPR/Cas9, genome editing approaches like zinc 
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finger nucleases (ZFNs) or transcription-activator-like effector nucleases (TALENs) are 
required to design and generate a new nuclease pair for every genomic target. Due to its 
comparative simplicity and adaptability, CRISPR/Cas9 has rapidly become the most popular 
genome editing approach.  
In recent years, the opportunities for handling several diseases and disorders have been 
achieved by the progression of gene editing tools. As a consequence, investigation of the causal 
and functional study of miRNA expression is important to elucidate the disease propagation 
pathway. However, knockout of protein-coding genes is relatively straightforward by deletion 
or insertion of specific gene sequences which leads to disruption of the open reading frame 
without hampering the synthesis of a gene product. On other hand, a small deletion or insertion 
in the miRNA gene may cause functional knockout because the formation of pri-miRNA is a 
direct transcript of the miRNA gene processed by Drosha and Dicer to form short mature 
miRNA. In this regard, it has been demonstrated that both the flanking and internal structure 
of pri-miRNA dictate the efficiency of RNase-III-type Drosha processing and, in turn, the 
biogenesis of miRNA [236]. Therefore, by using the CRISPR/cas9, there is a higher possibility 
to repress miRNA expression by targeting the terminal loop or 5´ region of pre-miRNA [237]. 
On this consequence, the CRISPR/cas9 has been employed for targeting the sequences either 
in or adjacent to Drosha and Dicer processing sites in the secondary stem-loop structure of 
primary miRNAs, which are reported to be critical for processing miRNA biogenesis [238].     
1.5 Can modulation of miRNA-320a, prevent increased apoptosis in the diabetic heart?  
Regardless of all the possible efforts made to reduce the impairment, DCM is still a challenge 
to researchers as well as clinicians. Hence, an attempt to prevent or treat the disease from its 
base level can be effective for clinical management. However, this is not always achievable as 
the patients often progressed to the advanced stage of the disease. Consequently, my project 
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focused on the management of apoptosis-mediated cardiac complications in the diabetic heart 
via modulation of miRNAs. Thus, I selected miRNA-320a as my target miRNA based on one 
of its established target genes IGF-1 [120]. IGF-1 exhibits a beneficial anti-apoptotic effect by 
preventing mitochondrial damage and maintain the structural integrity of the myocardium [239, 
240]. Additionally, it is evident that during the ischemic condition IGF-1 was downregulated, 
and importantly this is associated with elevated expression of miRNA-320a [172]. Therefore, 
an effective modulation of miRNA-320a might be helpful to develop a possible apoptosis-
mediated therapeutic approach.   
1.6 Thesis overview and outline 
DCM is one of the major contributors to the increased morbidity and mortality in the diabetic 
population. Despite significant advancements in medical research and the long clinical history 
of anti-diabetic treatments, there is an exponential increase in the prevalence of heart failure in 
people with diabetes [241]. The evidence-based study suggested that glycemic control alone 
was not sufficient in preventing or treating DCM because the progression of DCM starts way 
earlier before it has been diagnosed. Moreover, currently, no therapeutic approach exists which 
can target the root molecular etiological factor responsible for the DCM.    
Surprisingly, over two decades since their first discovery in humans, miRNAs have 
already provided important insight into the biology of several cardiovascular diseases. Their 
emergent potential as biomarkers in clinical diagnostics as well as therapeutic modulators for 
the treatment of a variety of diseases is truly exciting. The potential for the miRNA candidates 
to be used as therapeutic tools for diseases such as DCM is widely promising but remains an 
open question to be answered. MiRNA mediated molecular pathway analysis will not only 
results in more insight into their therapeutic potential but in vivo study will also lead to 
important information about the pharmacokinetics of such exogenous miRNAs as drugs and 
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safety data. In the near future, this may pave the way for large-scale mechanism-orientated 
miRNA-based therapeutic trials in cardiovascular medicine.  
1.6.1 General hypothesis, aim, and objective of the thesis 
Hypothesis  
Inhibition of miRNA-320a in diabetic heart reduces cardiomyocyte apoptosis.  
Aim  
The overarching aim of my thesis is to modulate the dysregulated cardio-enriched miRNA-
320a to treat cardiac dysfunction in the diabetic heart.  
Objectives 
1. To determine the expression of miRNA-320a target protein and apoptotic markers in 
diabetic human myocardial tissue, type-2 diabetic mouse myocardial tissue, and high-
glucose cultured human ventricular cardiomyocytes.  
2. To determine if in vitro knockdown of cardio-enriched miRNA-320a genomic DNA by 
CRISPR/Cas9 improves the survival of high-glucose cultured human ventricular 
cardiomyocytes. 
3. To determine if in vivo inhibition of miRNA-320a by locked nucleic acid (LNA)-anti-
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2.1 Ethics for human sample collection and animals to use for experiments 
The human myocardium study was approved by the Health and Disability Ethics Committee 
of New Zealand and the Human Ethics Committee at the University of Otago, Dunedin, New 
Zealand. All the patients provided written consent for the collection and use of samples in this 
study. All animal experimentation conducted as part of this PhD thesis was approved by the 
University of Otago Animal Ethics Committee and complied with the University of Otago 
Code of Ethical Conduct for the Use of Animals. In-house bred obese C57BL/KsJ-leprdb/leprdb 
(db/db) and age-matched lean control heterozygotes (db/+) mice (mixed gender) were obtained 
from the Hercus-Taieri Resource Unit (HTRU), Dunedin. The housing room temperature was 
maintained between 22-25°C under 12:12 hour light-dark cycle and all mice had ad libitum 
access to water and a standard chow diet. 
2.2 Human myocardial tissue collection  
Right atrial appendage (RAA) tissue was collected from both ischemic heart disease patients 
having no history of diabetes  (non-diabetic-ischemic heart disease; ND-IHD, N=12) and 
ischemic heart disease patients with history of diabetes (diabetic-ischemic heart disease; D-
IHD, N=12) undergoing coronary artery bypass grafting surgery at Dunedin hospital 
(Represented in Appendix-1.1; Table S1 Non-diabetic-ischemic heart disease patient 
samples and Table S2 Diabetic-ischemic heart disease patient samples). On other hand, 
myocardial tissues were collected from cadaver samples (non-diabetic with no ischemic heart 
disease; ND-NIHD, N=11) having no known history of diabetes and any other cardiac disease. 
Tissue samples were immediately snap-frozen in liquid nitrogen and stored at -80°C for further 
molecular analysis. The selection of diabetic patient samples was done based on the duration 
of diabetes (suffered from diabetes for 5 to 20 years) regardless of the patient's medical status. 




variability in patient's medical status might contribute to the variability in some of the data 
reported in the result section which was a major limitation working with human samples.  
2.3 Experimental animal study design  
2.3.1 Reason for the selection of type-2 diabetic db/db mouse as a reliable in vivo model 
for DCM 
The main reason for the selection of type-2 diabetic db/db mouse model for this project because 
this was a well-established model system for diabetic heart research in Katare’s laboratory. 
Though other models like ob/ob and diet-induced models were extensively used for diabetic 
research, our focus was on diabetes not on obesity. Moreover, the diet-induced model was time-
consuming.  Therefore, the type-2 diabetic db/db mouse model was selected for this project 
instead of other model systems.  
2.3.1.1 Type-2 diabetic db/db mouse model demonstrates features, similar to the clinical 
condition of type-2 diabetes 
The leptin resistance yields through a point mutation from guanine to thymine in the leptin 
receptor gene which is a well-established characteristic of type-2 diabetic mice [242]. Leptin 
is a cytokine (adipokine) secreted from adipose tissue which is responsible for the maintenance 
of energy intake and homeostasis through the leptin receptor [243]. Therefore, leptin receptor 
deficiency spontaneously facilitates hyperglycemia, hyperinsulinemia, polyuria, polydipsia, 
and obesity in the type-2 diabetic mouse which mimics the clinical phenotype of type-2 
diabetes [242, 244-249]. 
2.3.1.1.1 Systolic and diastolic dysfunction in type-2 diabetic mouse 
The assessment of systolic functional parameters including ejection fraction (EF), fractional 




purposes. Importantly, the reduction in any of these parameters could be an indication of 
imminent heart failure (HF) [250, 251]. On other hand, Semeniuk et al. and Cassidy et al. 
demonstrated that deterioration of cardiac systolic function in type-2 diabetic mice closely 
resembles the clinical phenotype of DCM [252, 253]. Moreover, two studies from Katare’s 
laboratory (Rawal et al and Lew et al ) also revealed the correlation of cardiac functional 
deterioration in the type-2 diabetic mouse which resembles the clinical phenotype of DCM 
[131, 134]. Taken together, impaired cardiac function appear to be highly prevalent in diabetic 
individuals, and importantly db/db mouse reflects the systolic dysfunction pattern observed in 
type-2 diabetic humans.  
It is a fact that diastolic dysfunction precedes systolic dysfunction, however, a growing 
body of evidence suggests that both systolic and diastolic dysfunction coexists together [254-
258]. According to Frank-Starling’s law, an increase in cardiac relaxation time allows more 
ventricular filling, eventually enhancing cardiac output in a non-failing heart [259]. Diastolic 
dysfunction can be measured based on the ratio of early ventricular filling velocity (denoted as 
E) and late ventricular filling velocity (dented as A) (E/A ratio) [251, 260]. Similar to the 
systolic dysfunction Semeniuk et al, Cassidy et al, Rawal et al, and Lew et al also demonstrated 
diastolic dysfunction in type-2 diabetic db/db mouse heart resembling DCM phenotype [131, 
134, 252, 253]. Taken together, the high prevalence of diastolic dysfunction in diabetic 
individuals resembles impaired diastolic functions in type-2 diabetic db/db mice [131, 134, 
258, 261-263]. 
2.3.2 Determination of miRNA-320a, target protein, and apoptotic markers expression 
in type-2 diabetic db/db mouse heart 
BKS.Cg-m+/+Leprdb/J mice (db/db) and their non-diabetic C57BL/ksJ-lepr+ littermates 




terminal anesthesia, myocardial tissue samples were collected from both the groups at seven 
different time points (8, 12, 16, 20, 24, and 32 weeks of age, N=5 each) Fig.2.1.  
 
 
Fig. 2.1 Age-dependent heart sample collection in type-2 diabetic mice  
 
Immediately after excision, the heart was dissected into three sections and each section 
comprised both the left and right chambers of the heart (the aorta and vessels were removed 
carefully), which were used for either RNA extraction, immunohistochemistry, or protein 
extraction (Fig. 2.2). The heart tissue samples that were to be used for RNA and protein 
extraction were quickly snap-frozen in liquid nitrogen and stored in -80°C freezer and the 
remaining part for immunohistochemistry were fixed in 4% paraformaldehyde solution at 4°C, 
which was replaced with 1X phosphate buffer saline (PBS) buffer after 24 hours. The tissues 
were then suspended in 30% sucrose in PBS buffer until tissues sunk which causes 





Fig. 2.2 Mouse heart tissue dissection for molecular analysis 
 
2.3.3 In vivo modulation of miRNA-320a by LNA-anti-miRNA-320a 
The detailed explanation of the “in vivo modulation of miRNA-320a by LNA-anti-miRNA-
320a” with molecular analysis, cardiac performances, and the immunohistochemical study has 
been described in Chapter: 5.0.  
2.4 Maintenance of Human ventricular cardiomyocyte cells (AC-16 cells) in culture 
Human ventricular cardiomyocytes (AC-16) cells were purchased from Davidson Laboratory 
at the University of Colombia in New York and cultured as per the developer’s protocol [264]. 
In brief, cells were seeded at a T-75 flask in complete Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F12 (DMEM/F12) medium (DMEM/F12 medium [Gibco; ThermoFisher 
Scientific, New Zealand] + 10 % Fetal Bovine-serum Albumin (FBS) [ThermoFisher 
Scientific, New Zealand] + 1X Penicillin-Streptomycin Solution [Gibco; ThermoFisher 
Scientific, New Zealand]). The cultures were maintained at 37°C with a gas mixture of 5% 
CO2 with 95% air. Cells are supplemented with freshly prepared DMEM/F12 medium (37°C) 
after 24 hours of seeding. When the cells reach 80% confluent, the medium is removed, cells 




Zealand) and later supplemented with 5 mL of TrypLE (Gibco; ThermoFisher Scientific, New 
Zealand). The flask was then incubated for 2-3 minutes at 37°C. After digestion and 
detachment of cells, 5 mL of complete DMEM/F12 medium was added to the flask for the 
inactivation of TrypLE which prevents further lysis of cells. The cell suspension was collected 
in a 15 ml tube and centrifuged at 300 X g for 3 minutes. The supernatant was removed and 
resuspended in the required volume of complete medium. Whole steps were repeated for 
several-passages to get a sufficient amount of cells required for downstream experiments.     
2.4.1 High glucose exposure of AC-16 cells  
Before exposure to high glucose (30 mM), cells were cultured for 4 passages in Dulbecco’s 
Modified Eagle Medium: low glucose (5.5 mM) (DMEM low glucose) [Gibco; ThermoFisher 
Scientific, New Zealand] to control the high proliferation rate of AC-16 cells. According to 
National Institute for Health and Care Excellence 4 to 5.4 mM/L was considered as normal and 
11.1 mM/L as diabetic blood glucose concentrations in adult humans [265]. We used 5.5 mM 
glucose as low or normal physiological glucose concentration which was quite similar to 
human condition. On other hand, we used 30 mM (though it was higher than clinical diabetic 
condition) glucose for high glucose experiment because because it was an established glucose 
concentration for in vitro hyperglycaemia experiments [266, 267].   
 After fourth passage in DMEM low glucose medium, 2.5-3 X 104 cells per well in 12 
well plate or 4-5 X 103 cells per well in 96 well plate or 2.5-3 X 105 cells per 60 mm dish were 
seeded and exposed to 30 mM high D-Glucose (HG) (Sigma-Merck, NZ) or 30 mM D-
Mannitol (NG) (Sigma-Merck, NZ) (as osmotic control) for 24 to 120 hours. At each time point 
(24, 48, 72, 96, and 120 hours), cell samples were collected for RNA and protein extraction.  




The detailed explanation of CRISPR/Cas9 mediated miRNA-320a gene editing study design 
with CRISPR construct, transfection to the cells, and molecular analysis has been described in 
Chapter: 4.0.  
2.6 RNA isolation from tissue and cells 
Total RNA from heart tissue (human RAA tissue and mouse heart tissue) and AC-16 cells were 
isolated using QIAzol reagent [268]. In brief, 50 to 100 mg of heart tissues were homogenized 
in 700 µL of QIAzol reagent with metal beads in a bullet blender for 3 minutes followed by 
immediate incubation on ice for 1 minute and repeated homogenization for 2 more times. Cells 
were directly incubated with 400 µL of QIAzol reagent. Next, for phase separation, chloroform 
(140 µL for tissue sample and 80 µL for cell sample) was added to each homogenate and 
centrifuged at 12,000 x g at 4°C for 15 minutes. Following centrifugation, the upper aqueous 
layer was transferred to separate tubes and incubated with (350 µL tissue sample and 200 µL 
for cell sample) of 100% isopropanol (for precipitation of larger species) at room temperature 
for 10 minutes and subjected to centrifugation at 12,000 x g at 4°C for 10 minutes. After 
discarding the supernatant, RNA pellets were washed with 75% ethanol and air-dried at room 
temperature until the pellets turned translucent. The RNA pellets were then dissolved in 20-50 
μl of RNase-free water by incubating at 55°C-60°C for 10-15 minutes. Total RNA was 
quantified using Nanodrop One (Thermo Scientific) Spectrophotometer to determine their 
quality and purity.  
2.6.1 Real-time polymerase chain reaction (PCR) 
2.6.1.1 Revers-transcription (RT) 
cDNA was synthesized by the reverse-transcription reaction of total RNA using reverse-
transcriptase master mix prepared from TaqMan® MicroRNA Reverse Transcription Kit 




manufacturer’s protocol [269]. Twenty ng of total RNA was reverse transcribed using either 
miRNA-320a or U6 (internal control) specific reverse-transcription (RT) primer (Applied 
Biosystems, USA).  In brief, the reverse-transcription reaction was set up by preparing the 
master-mix (listed in Table 2.1) and respective primers for individual miRNAs. Finally, the 
RNA (20 ng) samples were added to the mixture (For each reaction, the volume of master-mix 
=7 µL, primer = 3 µL, and RNA= 5 µL. Total volume = 15 µL). All the tubes were loaded into 
a thermal cycler (BioRad) and first incubated at 16°C for 30 minutes followed by incubation 
at 42°C for 30 minutes and 85°C for 5 minutes to heat inactivate the reverse transcriptase 
(Table 2.2). The reverse transcriptase (RT) is as critical to the success of qRT-PCR as the DNA 
polymerase. It is important to choose an RT that not only provides high yields of full-length 
cDNA, but also has good activity at high temperatures. High-temperature performance is also 
very important for the denaturation of RNA with secondary structure whereas, an RT retains 
its activity at higher temperatures and allows to use of gene-specific primer with a high melting 
temperature (Tm), increasing specificity and reducing background. 
Table 2.1 Reagents used for Revers-transcription 
Reagents Volume/1 reaction 
100 mM dNTPS 0.15 µL 
Multiscribe reverse transcriptase 1 µL 
10X Reverse transcription buffer 1.5 µL 
RNase inhibitor 0.19 µL 
Nuclease free H2O 4.16 µL 
5X miRNA-320a specific revers-transcription (RT) primer 3 µL 
Total 10 µL 
   
Table 2.2 Thermal cycler protocol 
Steps Temperature Time  
Step-1 16°C 30 minutes 
Step-2 42°C 30 minutes 
Step-3 85°C 5 minutes 





2.6.1.2 cDNA amplification 
Amplification of cDNA was performed according to manufacturer’s instruction using iTaq 
Universal SYBR® Green Supermix (BioRad) master mix (reagents and volume listed in 
Table 2.3 and 2.4 respectively) and target miRNA and negative control U6 were listed in 
Table 2.2. The real-time PCR was performed by adding 6.50 μl of the master mix, 0.5 μl of 
20X target miRNA primer, and 1 μl of target cDNA template or negative control (reaction 
temperatures and times were listed in Table 2.5). All reactions were performed in triplicates 
and any sample with a cycle threshold (Ct) value of more than 35 was discarded.  
Table 2.3 miRNA primer information 
miRNA Target sequence Product number 
miRNA-320a AAAAGCUGGGUUGAGAGGGCGA 002277 







Table 2.4 Reagents used for Revers-transcription 
Reagent Volume/1 reaction 
iTaq Universal SYBR® Green Supermix 6.50 µL 
20X miRNA-320a specific TaqMan (TM) primer 0.5 µL 
cDNA 1 µL 
RNase free H2O 4.75 µL 
Total 12.75 µL 
  
Table 2.5 Real-time PCR reaction set up 
Steps Temperature Time  
Step-1 95°C 30 seconds 
Step-2 95°C 5 seconds 
Step-3 60°C 30 seconds 





2.6.1.3 Real-time PCR data analysis  
The whole real-time PCR reaction was repeated 2 to 3 times for each sample. Tissue-derived 
miRNA expressions were normalized to reference gene U6 snRNA [270, 271]. The relative 
expression (ΔCt) of miRNA was based on the subtraction of the Ct value of a target miRNA 
gene vs the Ct value of a reference gene. The expression of target miRNA was expressed as 2-
ΔCT according to the MIQE guidelines [272]. All results were expressed as relative expression.  
2.7 Preparation of tissue and cell lysate for western blotting 
2.7.1 Lysate preparation and protein quantification 
Cardiac tissues and cells were homogenized in ice-cold (illustrated in Table 2.6) RIPA-buffer. 
The protein quantification was performed using Bradford assay (BioRad) where the 
concentration was extrapolated against bovine serum albumin (BSA). All the samples were 
prepared in such a way that, each of them has 20 µg of proteins. 
Table 2.6 RIPA buffer preparation protocol 
Reagent Concentration  
Tris-HCL (pH 4.4) 50 mM 
NaCl 150 mM 
Sodium dodecyl sulfate (SDS) 0.1% 
Ethylenediamine tetra-acetic acid (EDTA) 1 mM 
TritonX-100 1% 
Complete protease-inhibitor cocktail 1 X 
Phenylmethane sulfonyl fluoride (PMSF) 100 mM 
 
2.7.2 Protein separation  
Acrylamide gels (15% of resolving gel) were cast using 1.5 mm spacer plates (BioRad) and 15 
well combs were placed over 4% of stacking gel (Table 2.7). After polymerization, the comb 
was removed and gel assembly was subjected to the gel tank. Next, the tank was filled with 1x 




first well was loaded with a protein ladder (BioRad) and the remaining wells were loaded with 
an equal amount of protein samples [(20 µg; diluted with 6x loading buffer (Table 2.8)]. The 
empty wells were loaded with 6x loading buffer. The proteins were separated initially at a 
constant voltage (90 V) until samples reached the bottom of the stacking gel, then the voltage 
was increased to 150 V and ran until proteins reached the bottom of the resolving gel.  
Table 2.7 SDS gel recipe for 1 gel 
Reagent Resolving gel (15%) Stacking gel (4%) 
MQ H2O 1.8 mL 2.1 mL 
Tris-HCL (1.5 M; pH 8.8) 2 mL - 
Tris-HCL (1.5 M; pH 6.8) - 0.875 mL 
10% SDS 80 µL 35 µL 
30% Acrylamide  4 mL 0.4655 mL 
10% Ammonium persulfate 80 µL 35 µL 
Terta-methyl-ethylene-diamine (TEMED) 8 µL 3.5 µL 
 
Table 2.8 6X loading buffer recipe  
Reagent Concentration 




Bromophenol Blue 0.004%  
 
2.7.3 Protein transfer 
Activation of poly-vinylidene-difluride (PVDF) membrane was carried out by submerging in 
absolute methanol for 30 seconds, then the membrane, filter papers, and sponges were 
equilibrated in ice-cold 1x transfer buffer (Table 2.9) for at least for 5 minutes. The transfer 
sandwich was assembled (Sponge-filter paper-gel-PVDF membrane-filter paper-sponge) 
and transferred to the tank containing ice-cold 1x transfer buffer with an ice pack. The protein 
transfer was carried out at 100 V for 2 hours. Once the transfer was completed, the PVDF 




(Sigma) solution for 5 minutes. The stained PVDF membrane was scanned using Syngene 
imaged pxi4 imager (Syngene, USA). The membrane was washed thoroughly with 1X TBST 
to remove the Ponceau S stain.  
Table 2.9 1X transfer buffer recipe 
Reagent Concentration 
Tris-Base 48 mM 
Glycine 39 mM 
Methanol 20% 
  
Table 2.10 1X TBST recipe  
Reagent Concentration 
Tris-Base 50 mM 
NaCl 150 mM 
Tween 20 0.1% 
 
2.7.4 Probing with antibody and western blot analysis 
The PVDF membranes were blocked with 5% bovine serum albumin (BSA) dissolved in 1x 
TBST for 2 hours at room temperature to avoid nonspecific antibody binding followed by 
incubation in respective primary antibodies (Table 2.11) overnight at 4°C. After primary 
antibody incubation, the membranes were incubated with an appropriate secondary antibody 
(Table 2.11) for 2 hours at room temperature. Membranes were then washed with 1x TBST 
for 5 minutes (repeated for 4 times). Protein expressions were detected by incubating 
membranes in ECL blotting substrate (BioRad) for 5 minutes (excess ECL reagent was 
removed) and visualized using Syngene imaged pxi4 imager (Syngene, USA).  
Western blot experiment was repeated 2 to 3 times for each sample. Protein expression 
was quantified using ImageJ software (https://imagej.net/Fiji). Based on our previous 




protein (-actin) in diabetic condition. Therefore we used Ponceau S stain (total protein 
expression) as a ratio to total protein signal to normalized the protein bands [273, 274].  
Table 2.11 Antibody information and dilutions for western blotting 
Primary antibody 
Antibody Dilution Species Manufacturers  
IGF-1 1:1000 Rabbit, polyclonal BioRad 
BCL2 1:1000 Rabbit, polyclonal Cell Signaling  




1:10,000 Rabbit Sigma 
 
2.8 Caspase-3/7 and CyQUANT proliferation assay 
The AC-16 cells were seeded in 96 well plates (4000 cells/well) in triplicates and exposed to 
high glucose or normal glucose with mannitol as an osmotic control. At 120 hours, the media 
was removed and washed with PBS. The Caspase reagent (25 µL) (reconstructed according to 
the manufacturers’ protocol) (Promega, USA) and 25 µL of fresh media was added to each 
well and gently mixed on a plate shaker at 250 RPM for 1 minute and incubated at room 
temperature for 30-60 minutes. For blank measurement, 25 µL Caspase reagent and 25 µL of 
fresh media were added to the empty wells in triplicate. Following incubation, luminescence 
was measured using a plate reader (SpectraMax® i3x; Molecular Devices, USA).   
Following the Caspase assay, 2 x concentrated of CyQUANT reagent was prepared 
(Table 2.12) and 50 µL was added to each well. The plate was incubated at room temperature 
for 10 minutes (protected from light) and fluorescence was measured by the plate reader 
(excitation at 480 nm and emission at 520 nm) (SpectraMax® i3x; Molecular Devices, USA). 
Caspase activity (relative luminescent units, RLU) was normalized to cell number (relative 





Table 2.12 Working CyQUANT reagent preparation 
CyQUANT reagent 
Reagents Initial concentration Final concentration Volume 
Lysis buffer 20X 1X 97.5 µl 
MiliQ-H2O - - 900 µl 
CyQUANT dye 400X 1X 2.5 µl 
Total   1000 µl 
 
2.9 Statistical analysis 
All statistical analyses were performed using the software GraphPad Prism (version 7). All the 
data were expressed as mean ± standard error of the mean (SEM). Shapiro-Wilk test was used 
to check the normality before all the analysis. A one-way ANOVA followed by a non-
parametric Kruskal-Wallis test or two-way ANOVA followed by a Tukey’s posthoc test or 
student’s t-test was performed for all the analysis. A P-value <0.05 was predetermined as the 



























Determination of miRNA-320a expression in diabetic 
human myocardial tissue, type-II diabetic mouse 
myocardial tissue, and in high glucose exposed human 


















3.1 Introduction  
MiRNA is appealing to be a progressive domain of research in recent years. However, the 
research is limited in relation to the role of miRNA in DCM. As mentioned in Chapter:1.0, 
miRNA plays a crucial role in regulating cellular and metabolic processes by modulating 
specific targets [1], therefore, it is obvious that miRNA expression is directly interlinked with 
the progression of DCM [1, 101]. Irrespective of all the possible efforts made to reduce the 
impairment, treatment of DCM is still a big challenge for the researcher as well as clinicians. 
Therefore, an attempt to prevent or treat the disease by modulating miRNAs can be effective 
for clinical management. Hence, for the approach of prevention or treatment, the selection of 
miRNA candidates is challenging, because evidence revealed that several miRNAs are 
involved in this pathophysiological process [1, 101]. Therefore, this chapter has been focused 
specifically on miRNA-320a  mediated apoptotic progression in the diabetic heart as well as in 
high glucose cultured human ventricular cardiomyocytes.  
As mentioned earlier, several miRNA candidates are involved in the progression of 
DCM  [1, 101], whereas, very little research work has been performed on miRNA-320a 
involved in cardiac apoptosis. On other hand, one of the established targets of miRNA-320a is 
the IGF-1 gene [120] which acts to maintain the structural integrity of the myocardium [275, 
276]. Eventually, IGF-1  plays protective roles through the mitochondrion-dependent pathway 
where it prevents mitochondrial damage during apoptosis [239, 240]. Moreover, the 
downregulation of IGF-1 occurred during ischemia which was associated with overexpression 
of miRNA-320a [172]. Hence, it is crucial to evaluate the role of miRNA-320a in apoptosis in 






3.1.1 Pathophysiological role of miRNA-320a  
3.1.1.1 Role of miRNA-320a in ischemic heart disease 
A recent study provides an insight that altered expression of miRNAs is associated with 
ischemia/reperfusion injury [277]. Tian et al noted a substantially higher amount of cell death 
in hypoxia-induced H9c2 cells with a significant elevation of miRNA-320a expression [278]. 
This study showed overexpression of miRNA-320a potentially promotes loss of mitochondrial 
membrane potential eventually leading to apoptosis by targeting (a kinase interacting protein 
1) AKIP1 protein whereas, anti-miRNA-320a oligonucleotides administration reversed the 
effect [278].  
On other hand, heat shock protein-20 (cardio protective protein), which is another target 
of miRNA-320a downregulates in the ischemic-reperfusion injury in vivo and ex vivo model 
(B6129SF2/JF2 mouse) [279]. Both Fan et al and Ren et al demonstrated that the miRNA-320a 
targets Hsp20 which produces cardio protection against ischemic injury [280, 281]. Fan et al 
found that the miRNA-320a gets upregulated in ischemic conditions leading to downregulation 
of Hsp20 and eventually cell death.  
Furthermore, IGF-1 is one of the important regulators to maintain myocardial structural 
integrity and homeostasis. Song et al. found IGF-1 expression was downregulated in the 
ischemic-reperfusion model, which is another target of miRNA-320a [172]. Further 
investigation proposed that the downregulation of IGF-1 reduced the expression of Bcl-2 and 
activates the levels of phosphorylated-apoptosis-signal-regulating-kinase-1 (p-ASK1), 
phosphorylated-Jun-N-terminal kinases (p-JNK), phosphorylated-p38 mitogen-activated 
protein kinases (p-p38), Bax, and caspase-3 leading to elevated apoptosis.   




Wang et al. reported upregulation of miRNA-320a in myocardial microvascular endothelial 
cells (MMVEC) from Goto-Kakizak rats, may be responsible for the altered expression of IGF-
1 protein [120]. Interestingly, this study further reported that exogenous activation of IGF-1 
improved the expression of angiogenesis activity in MMVEC. In another study, Wang et al. 
demonstrated the transportation of miRNA-320a via exosome from cardiomyocytes to 
cardiac endothelial cells  (CECs) under high glucose conditions [282]. To confirm the 
intracellular transportation of miRNA-320a through exosomes, they treated the cells with 
exosomes inhibitor GW-4869 which reduced the uptake of miRNA-320a by the endothelial 
cells [282].  
In summary, by examining the expression level of miRNA-320a, this chapter aimed to 
expose the link between miRNA-320a expression and cell death in cardiac muscle in diabetic 
conditions and also in high glucose culture human ventricular cardiomyocytes.  
3.2 Study aim 
It is proven that miRNA plays a major role in diabetic heart disease as well as DCM. As a 
selected miRNA candidate (miRNA-320a) for this project, it is reasonable to predict that 
diabetes can change the expression of miRNA-320a [120, 172, 278, 279] which can modulate 
the apoptotic signaling pathway. Therefore, the overall aim of this chapter is to determine the 
expression of miRNA-320a in non-diabetic with no ischemic heart disease, non-diabetic with 
ischemic heart disease, and diabetic with ischemic heart disease human right atrial appendage 
(RAA) tissue sample. Further extended to the time-dependent expression of miRNA-320a in 
non-diabetic lean and age-matched type-2 diabetic db/db mouse heart tissue sample and normal 
and high glucose exposed human ventricular cardiomyocyte cell lines (AC-16). Finally, 





Therefore, I hypothesized that diabetes can increase the expression of miRNA-320a in 
the heart as well as in cardiomyocytes and leading to cell death which is one of the primary 
pathological factors for the progression of DCM.  
3.3 Methods and materials 
Please refer to “Chapter:2.0” (General methods and materials) for a detailed description of 
all experimental procedures.  
3.3.1 Ethics for human sample collection and animals to use for experiments 
As described in chapter “Chapter: 2.0”.  
3.3.2 Human myocardial tissue collection 
Human RAA tissue was collected from ischemic-non-diabetic (ND-IHD) (N=12) patients and 
ischemic-type-2 diabetic (D-IHD) (N=12) patients with preserved ejection fraction undergoing 
on-pump coronary artery bypass graft surgery (General parameters of the patients were 
represented in Appendix-1.1; Table S1 Non-diabetic-ischemic heart disease patient samples 
and Table S2 Diabetic-ischemic heart disease patient samples).  Myocardial tissue samples 
from non-diabetic with no ischemic heart disease (ND-NIHD, N=11) were collected from 
cadavers without any known history of ischemic heart disease. Tissue samples were 
immediately snap-frozen in liquid nitrogen and stored at -80°C for further molecular analysis  
3.3.3 Experimental animal study design for baseline experiments 
BKS.Cg-m+/+Leprdb/J mice (db/db) and their non-diabetic C57BL/ksJ-lepr+ littermates 
(db/+) were used for the study (N=5 in each group). Experimental design for the animal study 





Table 3.1 Grouping, experiments and the total number of animal used for the baseline 
study 












Age in weeks 













































3.3.4 In vitro cell culture and high glucose experiments  
Human ventricular cardiomyocytes (AC-16) were cultured in DMEM (normal glucose; NG; 
5.5 mM) media with 30 mM D-Mannitol (Sigma Aldrich) (as osmotic control) and in high D-
Glucose (HG; 30 mM) (Sigma Aldrich) for 24 to 120 hours. At each time point (24, 48, 72, 96, 
and 120 hours), cell lysates were collected for RNA and protein extraction (explained in 
“Chapter:2.0”).  
3.3.5 RNA isolation from tissue and cells 
Total RNA was isolated from tissue and cell samples using QIAzol reagent as described in 
“Chapter: 2.0”. 
3.3.6 Quantitative real-time RT-PCR  
Twenty nanograms of total RNA (derived from tissue or cells) was reversed transcribed using 
miRNA-320a specific reverse transcription primers (Life Technologies, NZ). Following 




expression of miRNA-320a, which was normalized to internal negative control U6, as 
described in detail in “Chapter:2.0”.   
3.3.7 Western blot analysis 
Trypsinized cells and tissues were homogenized in ice-cold RIPA-buffer. The protein 
quantification was performed using Bradford assay (BioRad) where the concentration was 
extrapolated against bovine serum albumin (BSA). Finally, western blotting was performed to 
study the expression of miRNA-320a target protein (IGF-1), anti-apoptotic Bcl-2, and pro-
apoptotic cleaved caspase-3 as described in “Chapter:2.0”. 
3.3.7 Caspase-3/7 and CyQUANT proliferation assay 
After normalizing the cell proliferation by CyQUANT (Invitrogen) proliferation assay, the 
caspase activity (Promega) was measured in normal and high glucose exposed human ventricular 
cardiomyocytes (AC-16 cells) (described in “Chapter:2.0”). 
3.3.8   Statistical analysis 
All statistical analyses were performed using the software GraphPad Prism (version 7). All the 
data were expressed as mean ± standard error of the mean. Shapiro-Wilk test was used to check 
the normality before all the analyses. A one-way ANOVA, followed by a non-parametric 
Kruskal-Wallis test was used for the analysis of miRNA-320a expression and a student’s t-test 
was performed for the analysis of IGF-1, Bcl-2, and cleaved caspase-3 in human heart samples 
(Due to the insufficient samples from ND-NIHD patients (control sample), western blot 
analysis for the human study was restricted to only ND-IHD and D-IHD tissue samples). A 
two-way ANOVA, followed by Tukey’s multiple comparisons test was performed to analyze 
the expression of miRNA-320a, IGF-1, Bcl-2, and cleaved caspase-3 in mouse heart samples. 
Similarly, a two-way ANOVA, followed by a Tukey’s multiple comparisons test was 




t-test was performed to compare the expression of IGF-1, Bcl-2, cleaved caspase-3, and 
Caspase-3/7 and CyQUANT proliferation in human ventricular cardiomyocyte cell samples 
(AC-16 cells). A P-value <0.05 was predetermined as the level of significance for all statistical 
analyses.  
3.4 Results 
3.4.1 Validation of miRNA-320a expression in human myocardium 
The relative expression of miRNA-320a in diabetic human myocardium was quantified using 
real-time PCR. The analysis of RAA tissue samples from ND-NIHD (control) tissue sample 
(P=0.006) similarly, diabetic-ischemic heart disease (D-IHD) tissue demonstrated significant 
upregulation of miRNA-320a compared to non-diabetic with no ischemic heart disease (ND-
NIHD) (control) tissue sample and ND-IHD tissue sample (P=0.001 and P=0.002), illustrated 






Fig. 3.1 Changes in the expression of miRNA-320a in human right atrial appendage (RAA) 
tissue. The bar with scatter plots showing quantitative RT-PCR analysis of RAA samples in non-
diabetic with no ischemic heart disease (ND-NIHD; N=11) (control) tissue sample, non-
diabetic-ischemic heart disease (ND-IHD; N=12) tissue sample, and diabetic-ischemic heart 
disease (D-IHD; N=12) tissue sample. Relative expression was based on the Ct of target 
miRNA vs. a Ct of a reference miRNA (2-ΔCt). U6 was used as an endogenous control. Values 
are mean ± SEM. Shapiro-Wilk test was used to check the normality. All the data were analyzed 
by one-way ANOVA with Tukey’s multiple comparisons. *Significantly different from ND-
NIHD (**P< 0.01 and ***P<0.001). *Significantly different from ND-IHD (**P< 0.01)  
 
3.4.1.1 Altered expression of the target protein and apoptotic markers in the human 
diabetic heart  
After confirming the dysregulated expression of miRNA-320a in the human RAA sample, my 
next aim was to establish the underlying relation between the upregulation of miRNA-320a 
and the target protein as well as the apoptotic signaling pathway involved in cell death. To 




insulin growth factor-1 (IGF-1),  which is a validated target of miRNA-320a [120]. Due to the 
insufficient samples from ND-NIHD patients (control sample), western blot analysis for the 
human study was restricted to only ND-IHD and D-IHD tissue samples. The diabetic RAA 
tissue demonstrated a significant reduction in the expression of anti-apoptotic IGF-1 protein 
(Fig.3.2 A) compared to non-diabetic with the ischemic heart disease (ND-IHD) sample 
(P=0.0024).  
The downregulation of Bcl-2 promotes apoptosis via the caspase-3 dependent pathway. 
This was confirmed in my study showing significant downregulation of Bcl-2 in diabetic RAA 
tissue with the ischemic heart disease (D-IHD) compared to non-diabetic with the ischemic 
heart disease patient sample (ND-IHD) (P=0.0006) (Fig.3.2 B) and marked activation of 
cleaved caspase-3 in diabetic with the ischemic heart disease (D-IHD) patient sample 
















Fig. 3.2 Changes in target protein and apoptotic markers in hearts from diabetic patients 
with ischemic heart disease. Representative western blotting image and quantitative bar graph 
with scatter plots showing relative expression of IGF-1 (A), Bcl-2 (B), and (C) cleaved caspase-3 
protein in human RAA tissue samples collected from non-diabetic-ischemic heart disease (ND-
IHD; N=11) patients and diabetic-ischemic heart disease (D-IHD; N=11) patients. Total protein 
(ponceau) was used as a reference control for western blot analysis. Values are mean ± SEM. 
Shapiro-Wilk test was used to check the normality. All the data were analyzed by unpaired-
student-t-test with the Mann-Whitney test. *Significantly different from ND-IHD (IGF-1; 
**P<0.01, Bcl-2; ***P<0.001, and *P<0.05). (The whole western blot and the corresponding 
Ponceau images were represented in the Appendix; Fig. S2.1). 
 
3.4.2 Age-dependent miRNA-320a expression in type-2 diabetic db/db mouse heart  
While the human RAA tissue samples confirmed the marked upregulation of miRNA-320a in 
human RAA tissue  (Fig.3.1), it is not clear whether the upregulation of miRNA-320a is a cause 
or consequence of cardiac dysfunction in the diabetic heart. So, it is crucial to distinguish the 
exact time for the onset of miRNA-320a upregulation in diabetic myocardium. Since the age-




determined in the myocardial tissue samples collected from 8 weeks to 32 weeks old mice 
(db/db) and their age-matched non-diabetic mice as control (N=5 in each group) as described 
in Table 3.1. The samples used in this study were collected from the same animals which were 
used for the age-dependent cardiac functional changes and apoptotic study performed 
previously in Katare’s laboratory (Shruti Rawal PhD thesis) and [76]. The results 
demonstrated a significant increase in miRNA-320a at 28-week old type-2 diabetic-db/db mice 
compared to non-diabetic-lean control mice (P=0.042) and persisted until 32 weeks (P=0.033) 
as represented in Fig. 3.3.  
  
Fig. 3.3 Age-dependent changes in the expression of miRNA-320a in type-2 diabetic db/db 
mouse heart tissue. The bar with scatter plots showing quantitative RT-PCR analysis of mouse 
heart samples in non-diabetic-lean mouse (N=5) and diabetic-db/db mouse (N=5). Relative 
expression was based on the Ct of a target miRNA vs. a Ct of a reference miRNA (2-ΔCt). U6 
was used as an endogenous control. Values are mean ± SEM. Shapiro-Wilk test was used to 
check the normality.  All the data were analyzed by two-way ANOVA followed by Tukey's 




points of the study. *Significantly different from non-diabetic lean mice (*P<0.05 for both 28 
and 32 weeks). Non-significant = N.S 
 
The echocardiographic confirmation of cardiac functional deterioration was not shown here 
as this has been published because, previously one of the members from Katare’s laboratory 
(Rawal et al) established the age-dependent cardiac performances of type-2 diabetic db/db 
mice [131, 132].     
3.4.2.1 Altered expressions of the target protein exhibit changes in apoptotic signaling 
pathway in mouse diabetic heart 
The study has been designed to determine the expression of IGF-1 in mouse heart samples 
collected from 8 weeks to 32 weeks old mice (db/db) and their age-matched non-diabetic mice 
as control, described in Table 3.1. The result demonstrated a significant decrease in IGF-1 at 
28-weeks type-2 diabetic-db/db mice compared to non-diabetic-lean control mice and persisted 
till 32 weeks of age (28 weeks; P=0.0138 and 32 weeks; P=0.0124) (Fig. 3.4 A). No significant 
changes were observed in IGF-1 expression from 8 weeks to 24 weeks of mice. 
As mentioned earlier in “section 3.4.1.1” that, IGF-1 regulates the apoptotic signaling 
pathway by altering the expression of Bcl-2 and cleaved caspase-3, my next aim was to 
determine the expression of Bcl-2 and cleaved caspase-3 protein in diabetic mouse heart. Since 
my research is focused on miRNA-320a expression mediated cell death in diabetic hearts, 
where we observed altered expression of miRNA-320a at the late stage (28 weeks persisted till 
32 weeks) (Fig.3.4 A), therefore we restricted the apoptotic signaling pathway analysis study 
to the above mentioned time point only. The result demonstrated a significant downregulation 
of Bcl-2 at 28-weeks (P=0.0001) and 32-weeks (P=0.0156) type-2 diabetic-db/db mice 
compared to non-diabetic-lean control mice whereas, cleaved caspase-3 was significantly 
upregulated at the following two time-points (cleaved caspase-3; 28 and 32 weeks; P=0.0340 














Fig. 3.4 Time-dependent expression of IGF-1 and downstream apoptotic markers in db/db 
mouse heart. Representative western blotting image and quantitative bar graph with scatter plots 
showing relative expression of (A) IGF-1, (B) Bcl-2, and (C) cleaved caspase-3 proteins in diabetic 
db/db mouse heart samples (N=5 in all the groups). Total protein (ponceau) was used as a 
reference control for western blot analysis. Values are mean ± SEM. Shapiro-Wilk test was 
used to check the normality. All the data were analyzed by two-way ANOVA followed by 
Tukey's multiple comparisons. *Significantly different from non-diabetic lean mouse heart 
sample (IGF-1; 28 and 32 weeks; *P<0.05), (Bcl-2; 28 and 32 weeks; ***P<0.001 and *P<0.05 
respectively) and (cleaved caspase-3; 28 and 32 weeks; *P<0.05 and ***P<0.001 
respectively). Non-significant = N.S. (The whole western blot and the corresponding Ponceau 
images were represented in the Appendix; Fig. S2.2). 
 
 
3.4.3 Time-dependent miRNA-320a expression in high glucose cultured human 
ventricular cardiomyocytes (AC-16 cells) 
In order to confirm that the changes observed in the expression of miRNA-320a from the 
myocardial tissue were from the cardiomyocytes, the expression of miRNA-320a was 
determined in human ventricular cardiomyocytes (AC-16 cells), exposed to high glucose to 
mimic the diabetic condition. Quantitative RT-PCR analysis showed no significant changes in 
the expression of miRNA-320a up to 72 hours of high glucose exposure. However, there was 
a significant increase in the expression of miRNA-320a expression at 96 (P=0.0040) hours 
which persisted till 120 hours (P=0.0001) (Fig.3.5). The findings were consistent with the 
results from mouse heart samples, which demonstrated significant changes in miRNA-320a 
expression at the late stage of the disease progression. Based on these observations, the time 
point just before the upregulation of miRNA-320a started (72 hours) was selected as an ideal 
time for in vitro transfection of cells for miRNA-320a modulation study (Objective 2 & 3; 








Fig. 3.5 Time-dependent changes in the expression of miRNA-320a in high glucose cultured 
human ventricular cardiomyocytes (AC-16 cells). The bar with scatter plots showing 
quantitative RT-PCR analysis of AC-16 cell samples in normal glucose and high glucose culture 
(N=9 in both groups). Relative expression was based on the Ct of the target miRNA vs. a Ct of 
the reference miRNA (2-ΔCt). U6 was used as an endogenous control. Values are mean ± SEM. 
All the data were analyzed by two-way ANOVA followed by Tukey's multiple comparison test 
was used to compare miRNA-320a expression in AC-16 cells at all the time points. Shapiro-
Wilk test was used to check the normality. *Significantly different from normal glucose 
cultured cells (**P<0.01 for 96 hours and ****P<0.0001 for 120 hours). Non-significant = N.S 
 
3.4.3.1 Altered expression of the target protein and apoptotic markers in high glucose 
cultured AC-16 cells 
The high glucose exposed AC-16 cells at 120 hours demonstrated significant downregulation 
of IGF-1 compared to normal glucose treated cells (P=0.0001), whereas other time points 
demonstrated no significant changes in IGF-1 expression (Fig. 3.6 A). Since my research is 
focused on miRNA-320a expression mediated cell death and observed altered expression of 




pathway analysis study to the time point where IGF-1 expression was altered. Consequently, 
Bcl-2 and cleaved caspase-3 expression was determined in high glucose treated AC-16 cells at 
120 hours compared to normal glucose treated cells. The result demonstrated a significant 
downregulation of Bcl-2 (P=0.0001) and upregulation of cleaved caspase-3 (P=0.0078) in high 
glucose treated cells at 120 hours (Fig. 3.6 B & C). In addition, high glucose treated cells 
showed a significant increase in caspase activity indicating increased apoptotic cell death at 
120 hours (P=0.0078) (Fig. 3.6 C). Therefore, it is reasonable to suggest that enhanced 
expression of miRNA-320a might be one of the root causes to enhance apoptosis in the diabetic 











Fig. 3.6 Time-dependent expression of IGF-1 and downstream apoptotic markers in AC-16 
cells. Representative western blotting image and quantitative bar graph with scatter plots showing 
relative expression of (A) IGF-1 (B) Bcl-2,  (C) cleaved caspase-3, and  (D) caspase activity in 
normal and high glucose exposed AC-16 cells at 120 hours (N=9 in all the groups). Total protein 
(ponceau) was used as a reference control for western blot analysis. Values are mean ± SEM. 
Shapiro-Wilk test was used to check the normality. All the data were analyzed by two-way 
ANOVA followed by Tukey's multiple comparisons. *Significantly different from normal 
glucose cultured AC-16 cells at 120 hours (IGF-1; ****P<0.0001), (Bcl-2; ****P<0.0001), 
(cleaved caspase-3; **P<0.01) and (Caspase 3/7-CyQANT proliferation multiplexed assay; 
**P<0.01). Non-significant = N.S. (The whole western blot and the corresponding Ponceau 
images were represented in the Appendix, Fig. S2.3). 
 
3.5 Discussion  
For the first time, my study has revealed the association of cardiac-enriched miRNA-320a in 
the pathophysiology of diabetes-induced cardiac cell death. In this chapter, we investigated the 
expression pattern of miRNA-320a in diabetic human myocardial tissue (RAA tissue), type-2 
diabetic mouse myocardial tissue, and high glucose cultured human ventricular cardiomyocyte 
cells (AC-16 cells). Moreover, this study also revealed the changes in the expression pattern of 




human RAA tissue does not determine whether the upregulation of miRNA-320a is a cause or 
consequence of cardiac dysfunction in the diabetic heart. To eliminate the dilemma, an age-
dependent study of miRNA-320a expression was carried out with type-2 diabetic db/db mouse 
as a model of type-2 diabetes. The type-2 diabetic db/db mouse develop type-2 diabetes by 8 
weeks of age with progressive cardiac dysfunction due to its genetic makeup which mimics the 
cardio-diabetic pathological phenotype of human with DCM [283]. Additionally, the molecular 
analysis from collected heart tissues at the different age groups of type-2 diabetic db/db mice 
facilitated in understanding the series of pathological events (corresponding with miRNA-320a 
expression) during the advancement of the disease. Interestingly, we observed that miRNA-
320a expression does not change considerably in the early stages of diabetes before the 
development of cardiac dysfunction [131], suggesting that upregulation of miRNA-320a (at 
28-weeks of age) could be a possible reason which facilitates cardiac cell death at the late stage 
of diabetes. This finding was supported by a late surge in miRNA-320a expression (at 120 
hours) after exposing the human cardiomyocytes (AC-16 cell lines) to high glucose.  
3.5.1 Underlying relation between miRNA-320a expression and cardiomyocyte cell death 
3.5.1.1 Upregulation of miRNA-320a in diabetic heart and in high glucose cultured 
human cardiomyocytes  
The cardinal features of DCM are principally associated with cardiac cell death, myocardial 
fibrosis and hypertrophy with diastolic dysfunction, and subsequent progression to systolic 
dysfunction and finally clinical heart failure [1, 80, 101, 284-286]. Underlining mechanisms 
involve oxidative stress, increased formation of AGEs, impaired mitochondrial Ca2+ handling, 
mitochondrial dysfunction, inflammation, activation of the renin-angiotensin-aldosterone 
system (RAAS) and sympathetic nervous system (SNS), cardiac autonomic neuropathy, 
endoplasmic reticulum stress, microvascular dysfunction, and cardiac metabolic disorders are 




strong link between miRNAs and various cardiac pathophysiological events including cell 
death [1, 101]. 
Fabbri et al reported that the miRNA-15 family is a key pathogenic factor of chronic 
lymphocytic leukemia, regulated by p53 protein [287]. The tumor suppressor p53 is one of the 
most frequently mutated genes in cancer and also plays a pro-apoptotic role in cardiomyocyte 
death [288, 289]. Moreover, a study from Katare’s laboratory demonstrated down-regulation 
of miRNA-15a/b (a potential marker of fibrosis), in the ischemic human heart where this 
miRNA expression was further downregulated in patients with diabetes [132]. This study also 
revealed that apoptosis may be triggered in diabetic myocardium via p53 mediated suppression 
of  sirtuin-1 protein [132]. Fomison-Nurse et al demonstrated a significant upregulation of 
miRNA-34a in the type-2 diabetic human myocardium and cardiac stem cells with marked 
downregulation of anti-aging protein sirtuin-1 (target protein). Treatment with anti-miRNA-
34a in high glucose cultured cardiomyocytes reversed the downregulation of sirtuin-1 [41]. In 
another study, Rawal et al demonstrated decreased expression of angiogenic-miRNA-126 and 
-132 leading to increased apoptosis of diabetic endothelial cells [133].  
Previous research demonstrated that diabetes can alter several miRNAs expression in 
the heart leading to different cardiac-pathological events [1, 101]. As discussed earlier (section 
3.1.2) elevated expression of miRNA-320a exhibits a pro-apoptotic role in ischemic heart 
disease [172] whereas, this study demonstrated diabetes-induced elevation of miRNA-320a 
exhibits the pro-apoptotic role in the diabetic and high glucose cultured human cardiomyocytes. 
In this chapter, the comparison has been done between non-diabetic-ischemic patients and 
diabetic-ischemic patients samples (where ischemia is a common pathological condition) along 
with a control group where the individuals were unaffected by diabetes or ischemia. The results 
showed an upregulation of miRNA-320a in patients with ischemia and diabetes compared to 




demonstrated upregulation of miRNA-320a at 28 and 32 weeks in type-2 diabetic db/db mice 
compared to an age-matched non-diabetic lean mouse. Moreover, this study was extended 
towards exploring the underpinned molecular mechanism of miRNA-320a mediated cell death 
in human ventricular cardiomyocytes (AC-16 cells) exposed to high glucose stress, where we 
observed the high glucose exposure significantly elevated the expression of miRNA-320a (at 
the late stage; 96 and 120 hours). Therefore, the finding from this chapter was consistent with 
the previous observations from Katare’s laboratory [41, 132, 133], in which dysregulation of 
miRNA-320a in the heart, and human cardiomyocytes, was associated with diabetes or high 
glucose exposure.  
3.5.1.2 The possible reason for miRNA-320a upregulation in diabetic cardiomyocytes  
The deprived uptake of glucose into the cell can be caused by insulin resistance. Intracellular 
hypoglycemia causes glucogenesis and gluconeogenesis leading to diabetic ketoacidosis and 
reduced gamma-globulins which causes cachexia, polyphagia, and impaired wounds healing 
[290]. Evidence suggested that glucose transporter-4 (GLUT-4) plays a major role in insulin 
resistance [291]. The insulin-mediated GLUT-4 expression governs the cellular uptake of 
glucose from the bloodstream, however,  high levels of insulin signaling can produce a negative 
effect on GLUT-4 expression [292]. Beyond the optimal insulin level, the cell demonstrates a 
downward shift in GLUT-4 expression leading to the desensitization of insulin in peripheral 
tissue which causes intracellular oxidative stress [292, 293]. A recent study from Katare’s 
laboratory demonstrated a reduction in GLUT-4 protein expression in diabetic type-2 diabetic 
db/db mouse heart at 20 weeks and persisted until the end of the experiment (32 weeks) (Eng 
Leng Saw PhD thesis) which causes severe insulin resistance leading to reduced cellular 
glucose uptake in type-2 diabetic db/db mouse heart [294, 295]. Moreover, this study also 
demonstrated the deprivation of membrane GLUT-4 protein in insulin-resistant high glucose 




On other hand, it is a well-known fact that diabetes causes altered expression of several 
miRNAs in the heart leading to the expression of numerous pathological phenotypes [41, 120, 
132, 133, 172] but the actual molecular mechanism involved in the alteration of miRNAs 
expression in the diabetic heart is still not very clear. Evidence suggests that the reduction in 
intracellular glucose caused by insulin resistance may be responsible for the upregulation of 
miRNA-320a [296]. In support of this notion, this study has shown the upregulation of miRNA-
320a at the late stage of diabetes (28 and 32 weeks in type-2 diabetic db/db mouse heart and 
96 and 120 hours in high glucose cultured human cardiomyocytes; AC-16 cells) when the 
decrease in intracellular glucose uptake due to reduced GLUT-4 protein expression was at its 
peak (Eng Leng Saw PhD thesis). Therefore,  the possible reason for miRNA-320a 
upregulation can be caused by reduced intracellular glucose caused by deprivation of GLUT-4 
which was consistent with the previous observations from Katare’s and other laboratories Eng 
Leng Saw PhD thesis and [296]. 
3.5.1.3 The role of miRNA-320a in orchestrating apoptosis in the diabetic heart as well as 
in vitro high glucose cultured human ventricular cardiomyocytes (AC-16 cells)  
Morphologically, apoptosis is characterized by chromatin condensation, nuclear 
fragmentation, and the loss of the mitochondrial inner transmembrane potential, which results 
in plasma membrane blebbing, with cells breaking into small membrane-surrounded fragments 
(apoptotic bodies) that are cleared by phagocytosis [297]. It is proven that cardiomyocytes are 
extremely susceptible to apoptosis in diabetic conditions [298]. The process of apoptosis (cell-
specific) can be initiated and or inflated by several aetiological factors. Among numerous stress 
aetiological factors, diabetes aggravates cardiomyocyte apoptosis [1, 41, 62, 120, 132, 133, 
172, 239, 240, 299-306]. Barouch et al and Shen et al demonstrated cardiomyocyte apoptosis 
in type-2 diabetic db/db mice heart due to leptin insufficiency which is associated with Ras-




dinucleotide phosphate (NADPH) and mitochondrial derived reactive oxygen species [307, 
308]. Additionally, activation of the renin-angiotensin system (RAS) associated with increased 
oxidative stress, apoptosis, and necrosis in cardiomyocytes and endothelial cells in the hearts 
of patients with diabetes and end-stage heart failure, thereby representing another potential 
mechanism for cell death [62, 309]. In this regard, along with other molecular factors, miRNA 
also controls apoptosis signaling pathways in the diabetic heart [1, 41, 120, 132, 133, 172, 239, 
240, 303-306].  
The growing body of evidence demonstrates and validates the role of pro-apoptotic 
miRNAs as a crucial factor for apoptotic cell death in diabetic myocardium. In particular, 
Moore et al and Katare et al demonstrated marked upregulation of miRNA-1 is associated with 
downregulation of the pro-survival proto-oncogene serine/threonine-protein kinase (Pim-1) 
kinase leading to cardiomyocyte apoptosis [110, 138, 139]. Similarly, Zheng et al. demonstrate 
elevated expression of miRNA-195 in the heart [112] leading to apoptosis and hypertrophy in 
cardiomyocytes under both type-1 and type-2 diabetic conditions [142, 143]. On the other hand, 
the upregulation of miRNA-30c and miRNA-181 leads to cardiomyocyte apoptosis by 
targeting p52 and p21[310-319]. Moreover, Fomison-Nurse et al demonstrated the 
upregulation of miRNA-34a facilitates apoptosis in high glucose cultured cardiomyocytes 
(AC-16 cells) where they observed a marked decline of anti-apoptotic sirtuin-1protein [41]. 
Additionally, declined expression of IGF-1 protein leading to higher myocardial cell death in 
response to the elevated miRNA-320a expression [120, 172].  
As mentioned earlier in section 3.1.2, the IGF-1 gene is the established target of 
miRNA-320a. IGF-1 is a well-characterized growth factor in a variety of cells that plays a role 
in maintaining the integrity of myocardial structure and function [320]. Evidence confirmed, 
the reduction of IGF-1 protein deteriorates muscle survival, myocardial contraction, 




[320-323]. On other hand, Opgaard et al proposed that IGF-1 activates the p13K/Akt and 
Mitogen-activated protein kinase (MEK)/ ERK pathways to produce its anti-apoptotic effect 
[324]. Other evidence revealed the protective effect of IGF-1 by enabling Bcl-2 protein which 
prevents the cleaving of caspase protein [239, 240, 303-306]. Evidence suggests that inhibition 
of the multi-gene family of Bcl-2 protein and others such as elevation of Bax promote apoptosis 
which is one of the best-known regulators of the apoptotic process [325-327]. Elevation of Bcl-
2 expression in cardiac tissue bypassing Bax expression provides a protective effect from 
apoptosis [328-331]. On other hand, it is a well-established fact that initiator caspases (caspase-
8, caspase-9, and caspase-10) stimulate effector caspases (caspase-3, caspase-6, and caspase-
7) whereas, evidence suggested that the caspase-3 and caspase-7 are indistinguishably 
stimulated by initiator caspases to produce the apoptotic stimuli [332, 333]. Moreover, 
evidence suggests that the activation of caspases is regulated by Bcl-2. Of note, Song et al 
showed downregulation of IGF-1 occurred during the ischemic condition, was associated with 
overexpression of miRNA-320a [172]. In another study, Wang et al demonstrated elevation of 
miRNA-320a downregulates IGF-1 and facilitates endothelial cell death reducing the 




Therefore, it is reasonable to put forward that diabetes has a distinct correlation with 
the altered expression of miRNA-320a and IGF-1 which was found to be one of the 
determinants of cardiac apoptosis. We observed a noticeable reduction of pro-survival IGF-1 
and Bcl-2, and aggravated the cleaving of caspase-3 in diabetic-human myocardium (Fig. 3.2 
A, B & C) which may be due to the altered expression of miRNA-320a. Hence, it is a fact that 
the altered expression of miRNA-320a in diabetes is indispensably related to the alternation of 
the apoptotic signaling pathway which is consistent with the previous findings [120, 172, 239, 
240, 303-306]. On other hand, we observed significant downregulation of target protein IGF-
1 at 28 and 32 weeks in diabetic type-2 diabetic db/db mice compared to non-diabetic lean 
mice [172]. As a result, anti-apoptotic marker Bcl-2 and pro-apoptotic caspase-3 were also 
altered significantly at the time of miRNA-320a overexpression (28 and 32 weeks of age) (Fig. 
3.4 A, B & C) [172]. On other hand, a study from Katare’s laboratory revealed significant 
overexpression of cleaved caspase-3 starts from 16 weeks and persists till 32 weeks of age in 
diabetic type-2 diabetic db/db mice (Shruti Rawal PhD thesis) and [76] which indicates the 
process of apoptosis starts way before the onset of miRNA-320a overexpression. Although I 
did not measure the expression of cleaved caspase-3 from the early stages. Therefore, it is 
reasonable to put forward that the process of apoptosis likely to be aggravated by the 
upregulated expression of miRNA-320a.This statement was further aligned with the miRNA-
320a expression and apoptosis study in high glucose treated human ventricular cardiomyocytes 
(AC-16 cell lines).  
In support of this notion, we further extended my research towards exploring the 
underpinned molecular mechanism of miRNA-320a mediated cell death in human ventricular 
cardiomyocytes (AC-16 cells) exposed to high glucose stress where it has been demonstrated 
that the high glucose exposure significantly decreases the expression of IGF-1 at 120 hours 




Eventually, we observed marked alteration in Bcl-2 and cleaved caspase-3 protein expression 
(Fig. 3.6 B & C) in response to high glucose stress at the same time when IGF-1 gets 
downregulated. To further support this, the Caspase 3/7-CyQANT proliferation multiplexed 
assay demonstrated significantly higher caspase activity at 120 hours in response to high 
glucose stress (Fig. 3.6 D), which eventually elevates apoptotic cell death.  
Taken together, my observation is consistent with the previous findings from Katare 
and other laboratories [1, 41, 110, 112, 120, 138, 142, 143, 310, 334], in which it has been 
established that, diabetes-induced changes in the expression of miRNAs are one of the leading 
cause of apoptotic cell death in cardiomyocytes and miRNA-320a may aggravate the process 
of cell death.  
3.5.2 The relation between miRNA-320a expression and cardiac dysfunction 
Having demonstrated marked dysregulation of miRNA-320a expression in the human heart 
(RAA tissue), mouse myocardium, and human ventricular cardiomyocytes (AC-16 cells), 
exposed to high glucose stress, does not establish any relation between miRNA-320a 
expression and cardiac dysfunction. Li, H et al demonstrated the expression pattern of miRNA-
320a correlating cardiac functional deterioration in high-fat diet-induced diabetic type-2 
diabetic db/db mice and streptozotocin-induced diabetes model where they observed 
overexpression of miRNA-320a, aggravated lipid accumulation in the heart leading to diastolic 
dysfunction [296]. Although Li, H et al established a relation between miRNA-320a expression 
and cardiac functional changes, but unable to correlate between miRNA-320a expression and 
onset of cardiac functional deterioration especially in diabetic conditions. However, a study 
from Katare’s laboratory demonstrated significant cardiac dysfunction starts from 20 weeks of 
age and persists till 32 weeks in diabetic type-2 diabetic db/db mice [131]. By using the same 
samples used in Rawal et al’s study [131] we demonstrated that the miRNA-320a 




the experiment (32 weeks). Therefore, it is reasonable to accomplish that miRNA-320a 
upregulation does not initiate cardiac functional deterioration even though miRNA-320a 
aggravates the process of apoptosis leading to the deterioration of cardiac function [120, 172, 
296]. 
3.6 Consideration/Limitations of the study   
 This chapter cannot exclude the possibility that other pro-apoptotic-miRNAs, which were 
not tested in this study, may also be involved in facilitating the apoptosis process.  
 Due to the insufficiency of human tissue samples from non-diabetic with no ischemic heart 
disease (ND-NIHD) patients (control sample), the western blot study was restricted to only 
non-diabetic with ischemic heart disease (ND-IHD) and diabetic with ischemic heart 
disease (D-IHD) tissue samples. 
 Due to the delayed expression, miRNA-320a cannot be considered as a biomarker for 
diabetic heart disease or DCM.   
 MiRNA-320a appeared to be a promising factor to aggravate apoptosis in high glucose 
stress/diabetes. However, this observation needs to be validated in a large population.  
3.7 Conclusion 
The findings from this chapter demonstrate that the upregulation of miRNA-320a facilitates 
the process of apoptosis in high glucose stress/diabetic conditions. Of note, this study also 
reveals, miRNA-320a does not have any role in initiating cardiac functional deterioration. 
However, this study provides a foundation for future studies that aimed to explore the potential 













Knockdown of miRNA-320a stem-loop genomic sequence 
using CRISPR/Cas9 to prevent apoptosis in high glucose 




















The previous chapter (Chapter: 3.0) has demonstrated that elevated expression of miRNA-
320a in the diabetic heart may be associated with the apoptotic signaling cascade leading to 
cell death. This pathway could be synchronized by dysregulation of the IGF-1 gene causing 
downregulation of the respective protein. Downregulated IGF-1 induced significant 
downregulation of anti-apoptotic Bcl-2 and activation of pro-apoptotic cleaved caspase-3 
expression. Activation of miRNA-320a was observed after the onset of functional deterioration 
in the diabetic heart of type-2 diabetic db/db mouse as well as in high glucose exposed human 
cardiomyocytes (AC-16 cells). Therefore, the next question is whether modulation of miRNA-
320a can prevent high glucose-induced cell death. While the therapeutic potential of miRNA 
modulation is promising, it does come with several hurdles such as stability and poor efficiency 
following delivery [335]. Among all other existing gene-editing techniques, the CRISPR/Cas9 
system can hinder the biogenesis process of miRNA candidates by very precisely and robustly 
disrupting the target sequence from the genome. Given the pitfalls of current methodologies in 
miRNA silencing versus the robustness of CRISPR/Cas9 system in gene editing, it has been 
hypothesized that CRISPR/cas9 mediated gene editing could be an innovative strategy in the 
modulation of miRNA expression.  
4.1.1 Why CRISPR/Cas9 is superior compared to other gene-editing techniques? 
Genome editing techniques such as ZFNs, TALENs, and CRISPR/Cas9 systems have been 
widely employed for the study of gene function as well as the loss-of-function studies in 
numerous in vitro and in vivo model systems [336]. Among all three techniques, CRISPR/Cas9 
stands the most convenient, inexpensive, and most efficient technique.  
 The real breakthrough in genome editing emerged with the ability to design a nuclease 




were the ZFNs, which were based on naturally occurring transcription factors (zinc finger 
proteins) fused with the restriction endonuclease, Fok-1 [337]. ZFNs recognize trinucleotide 
DNA sequences and multiple, interlinked zinc finger domains can be combined bind to provide 
target specificity [338-340]. However, the zinc finger motifs aligned in an array can influence 
the specificity of neighboring zinc fingers, which makes the designing of the zinc finger array 
more challenging and time-consuming. Moreover, the target specificity of this system is hard 
to predict because the double-stranded DNA cleavage occurs at the site of binding of two ZFNs 
to the opposite DNA strands [339]. Similar to ZFNs, TALENs were designed to edit specific 
target sequences. In this system, one nucleotide is recognized by a single transcription 
activator-like effector (TALE) motif and an array of TALEs can be produced for longer 
sequences [340]. Like ZFNs, TALE motifs are also associated with Fok-1 endonuclease which 
require dimerization to occur for the cleavage [341, 342], resulting in less target specificity and 
time-consuming to design the array. Whereas, CRISPR/Cas9 system perform DNA cleavage 
by Cas9 nuclease through the double-strand brick (wild type), or to single-strand break while 
using the mutant variant of Cas9 [343]. The recognition of the site is controlled by RNA-DNA 
interactions and offers advantages over ZFN and TALEN system, including easy design, less 
off-target effects, and the ability to target multiple sites for mutation simultaneously [229, 343]. 
The usage of a newer variant of Cas9, not only increases the precession gene editing but also 
facilitates higher on-target specificity [344-347].  
 The deletion of protein-coding genes with the CRISPR/Cas9 system is relatively 
straightforward because the disruption of the open reading frame can be caused by a small 
mutation resulting in the interference of gene product synthesis [348] which designates 
CRISPR/Cas9 as a well-established gene-editing tool. Where in the case of miRNA-gene 
modulation, a small mutation in the Drosa processing site (pri-miRNA-sequence present in the 




to repress the mature miRNA expression by targeting the terminal-stem-loop region of the pri-
miRNA sequence by using the CRISPR/Cas9 component [348-350]. Moreover, CRISPR/Cas9 
mediated miRNA-gene editing demonstrated promising results by avoiding off-target effects 
among miRNA members [232, 351]. The off-target mediated DNA damage causes cellular 
toxicity [352] leading to unwanted chromosomal rearrangements such as inversion, 
translocation, and deletion occurs due to repair of the off-target-double-strand-bricks [353] 
which may cause deprivation of tumor suppressor genes or activation of oncogenes. Hence, the 
target specificity and progression of mutation profusely depends on gRNA designing and 
screening with multiple gRNAs to get the desired outcome [343, 354-357]. 
4.1.2 CRISPR/Cas9 facilitated gene editing   
In recent years, it has been acknowledged that gene editing can be a potential tool to investigate 
many diseases and disorders. This can be achieved by knockout or insertion of protein-coding 
genes leading to interruption of the open reading frame without hampering the synthesis of the 
gene product. Several approaches to genome editing have been developed, and the most recent 
one is the short for clustered regularly interspaced short palindromic repeats and associated 
protein-9 mediated gene editing, commonly known as CRISPR/Cas9. The CRISPR/Cas9 
system has generated a lot of excitement in terms of gene editing because of its accuracy and 
robustness compared to other existing genome editing methods [336, 358].   
4.1.2.1 CRISPR/Cas9 construct 
As mentioned in “Chapter:1.0”, CRISPR/Cas9 was adapted from an inbuilt genome editing 
tool in bacteria. The bacteria have a mechanism to capture a scrap of DNA from invading 
viruses which has been transformed into DNA segments known as CRISPR arrays. The 
CRISPR arrays act as a memory for further viral genome invasion or any closely related 




DNA and use Cas9 or a similar enzyme to cut the DNA apart, which disables the virus [228, 
359]. 
The CRISPR/Cas9 gene-editing system works similarly to the bacterial defense 
mechanism. It consists of two principal components, the guide RNA (gRNA) and CRISPR 
associated endonuclease protein (Cas). The gRNA is a short synthetic RNA molecule with a 
scaffold sequence, essential to bind with the target site by “Cas protein” and a ∼20 
nucleotide spacer sequence (user-defined) that modifies the target site. Changing the gRNA 
sequence allows the researchers to change the target site and making the CRISPR/Cas9 system 
extremely lucid for gene editing [229]. The Cas9 or related protein chops the target gene 
sequence by generating a double-strand DNA break (DSB) which is then repaired by non-
homologous end-joining (NHEJ) manner [230] leading to a frameshift mutation in the coding 
region [231].  
4.1.2.2 Broder spectrum of gene-editing with CRISPR/Cas9 and its limitation  
Generally, the high efficient gene editing can be easily achieved through ex vivo culture and 
eventually transplanted into an organism. However, in vivo genome editing involves the 
delivery of the machinery to the native tissues which makes it extremely challenging, 
depending on the delivery vector and mode of administration. With all those difficulties, the 
progressive development of gene editing tools has vastly eased the generation of gene-edited 
animals [360]. For instance, the study of Duchenne muscular dystrophy (DMD)  has been 
complemented by the development of a new rabbit model via CRISPR/Cas9 thus offering a 
new alternative for preclinical studies [361]. Beyond animal models, hypertrophic 
cardiomyopathy causing gene (MYBPC3) correction by CRISPR/Cas9 was achieved in human 




and the sperm cells (heterozygous for MYBPC3 mutation) at the M-phase of the cell cycle 
[362].  
CRISPR/Cas9 as well as other genome editing techniques have a lot of ethical concerns 
when it is used to alter human genomes [363-366]. To date, editings are limited to somatic cells 
to restrict inheritance. Based on concerns about ethics and safety, germline cell and embryo 
genome editing are currently illegal in many countries.  
4.1.2.3 CRISPR/Cas9 gene-editing strategies in cardiovascular disease 
In terms of understanding gene function and the development of new strategies in 
cardiovascular disease, gene manipulation has always played a key role. In the future, genome 
editing may prove to be an effective tool for developing therapies to cure certain genetic forms 
of cardiovascular diseases [367].  
The use of CRISPR/Cas9 mediated gene editing as a therapy for cardiovascular disease 
is progressively emerging. CRISPR/Cas9 mediated gene editing approach demonstrated 
immense potential in correcting the genetic mutation in iPSCs in terms of cardiac disease, like 
Barth syndrome, an  X-linked cardiac and skeletal mitochondrial myopathy caused by mutation 
of the gene encoding tafazzin (an acyltransferase responsible for normal acylation of 
cardiolipin, which is the major phospholipid of the mitochondrial inner membrane) [368-373].  
Recently, CRISPR/Cas9 has also been used to introduce a frameshift mutation of “titin gene” 
(encodes titin protein which is responsible for the passive elasticity of muscle and provides 
integrity to myosin molecules) in iPSC derived dilated cardiomyopathy model [374]. 
Additionally, CRISPR/cas9 induced gene editing demonstrated promising results in terms of 
normalizing abnormal electrophysiology by an excised mutant allele in iPSCs derived from 
two independent groups of patients with Jervell and Lange-Nielsen syndrome (JLNS), which 




was successfully used to knock out a noncoding DNA sequence adjacent to intronic single 
nucleotide polymorphism in phosphatase and actin regulator 1 (PHACTR1) gene located in 
chromosome 6 in human-derived iPSCs. This approach strongly prevents premature 
myocardial infarction [376]. The CRISPR/Cas9 system has further shown tremendous potential 
in correcting genetic defects in postnatal or adult mice [377]. Ding et al demonstrated 
disruption of pro-protein convertase subtilisin/kexin type 9 (PCSK9) gene by CRISPR/Cas9 in 
adult mice, aids to reduce low-density lipoprotein (LDL) level, leading to lowering the risk of 
developing coronary artery disease [378].  
4.1.2.4 MiRNA gene editing by CRISPR/Cas9 component 
As discussed in Chapter: 1.0, section 1.3.2, investigation of the causal and functional study 
of miRNA-expression is important to elucidate the relevance of the miRNA-mediated disease 
pathway. During biosynthesis, these small non-coding RNA molecules are loaded into 
Argonaute (AGO) proteins to form an effector complex known as RNA-induced silencing 
complex (RISC) along with other proteins [379-381]. Partially complementarity between a 
miRNA and its target mRNA leads to disruption or translational repression of target mRNA, 
whereas full or nearly full complementarity between the miRNA and its target mRNA leads to 
cleavage of the target mRNA at specific positions [382]. Likewise, a tiny alteration in the 
miRNA gene may cause an interruption in the formation of pri-miRNA which is a direct 
transcript of the miRNA gene leading to the biogenesis of mature miRNA [236]. Hence, by 
using the CRISPR/cas9 system, there is a higher possibility to repress miRNA expression by 
targeting the terminal loop or 5´ region of pre-miRNA [237]. In line with this, the CRISPR/cas9 
system has been employed for targeting the sequences either in or adjacent to Drosha and Dicer 
processing sites in the secondary stem-loop structure of primary miRNAs, which are reported 
to be critical for processing miRNA biogenesis [238]. Chang et al demonstrated that, knockout 




knockout is far more stable and robust compared to siRNA mediated knockdown [232]. The 
miRNA-141 target Zinc finger E-box-binding homeobox (ZEBs) gene, eventually upregulate 
E-cadherin to inhibit epithelial-mesenchymal transition (EMT) protein [232]. On other hand, 
miRNA-17-92 cluster targets cyclin-dependent kinase inhibitor 1 (CDKN1A), transcription 
factor-E2F1, and phosphatase and tensin homolog (PTEN) cause uncontrolled cell 
proliferation [383]. Moreover, the CRISPR/Cas9 tool was used to target the special loop region 
adjacent to the palindromic sequence of the pre-miRNA region of miRNA-21 and miRNA-
30a, which was demonstrated to be oncogenic in HeLa cells [350]. 
4.1.2.5 Challenges in miRNA editing  
By the transcriptional, post-transcriptional, and translational modification,  miRNA plays its 
signature role by repressing the expression of multiple protein-coding genes  [384]. Moreover,  
miRNA expression differs between cell types and different pathological conditions [385], 
which enables miRNA editing to be a promising tool for translational research.  Unlike DNA 
mutations, miRNA editing is transient and is associated with several hurdles such as stability 
and poor efficiency following delivery [1].  In regard, it is desirable to experimentally create 
an alteration in the miRNA-genome interrogating its effects in an in vitro system. However, 
methods to manipulate miRNAs in vivo for therapeutic purposes should become more precise 
in the near future. To achieve this goal, modification (mutation) of the miRNA-genome is the 
most reliable and robust approach for the loss-of-function study of miRNAs. As a consequence, 
the rapid development of the CRISPR/Cas9  system in the miRNA-gene-editing has greatly 
accelerated the development in recent years [234, 348, 386].  
In summary, the CRISPR/Cas9 component seems to be a fascinating tool for the whole 
genome as well as miRNA gene editing for both in vitro and in vivo studies. The constant 




the endless optimization of experimental conditions has enabled consistent practices that are 
completely reliable for the generation of point mutations useful for cardiac gene editing and 
exploration of potential gene therapy [388, 389].  
4.2 Study aim 
The overall aim of this chapter is to determine whether in vitro knockout of miRNA-320a stem-
loop genomic DNA sequence by CRISPR/Cas9 can prevent apoptosis in high glucose cultured 
human ventricular cardiomyocytes (AC-16 cells). 
I hypothesized that CRISPR/Cas9 mediated miRNA-320a stem-loop genomic DNA 
sequence knockout in high glucose cultured human ventricular cardiomyocytes (AC-16 cells) 
can prevent high glucose-induced apoptosis.  
4.3 Methods and materials  
Please refer to “Chapter:2.0” for general methods used for experimental procedures and 
specific methods are described in this chapter.  
4.3.1 CRISPR/Cas9 component design and preparation 
4.3.1.1 Guide RNA (gRNA) design  
Four different gRNAs were designed to target the stem-loop structure of miRNA-320a using 
the Benchling design tool (URL: Benchling.com), which allows the prediction of potential off-
target regions corresponding to genomic loci. The potential target gRNAs were ranked based 
on a comprehensive quality score, which reflects the on-target specificity. Scores greater than 
50/100 were considered to be potentially reliable candidates for CRISPR editing [355]. 
Therefore, the four gRNAs selected for this purpose were predicted to have high target 
specificity and low off-target activity. Oligonucleotides for the 4 gRNAs were ordered from 




Table 4.1 gRNAs and corresponding PAM sequences 
Name Target sequence PAM  
gRNA-1_Forward /5Phos/ CACCGTCCCGGAGTCGGGAAAAGCT GGG 
gRNA-1_Reverse /5Phos/ aaacAGCTTTTCCCGACTCCGGGAC GGG 
gRNA-2_Forward /5Phos/ CACCGTCCCGACTCCGGGAAGAACC GGG 
gRNA-2_ Reverse /5Phos/ aaacGGTTCTTCCCGGAGTCGGGAC GGG 
gRNA-3_Forward /5Phos/CACCGAACCGGGAAGAGAAGGCGGA GGG 
gRNA-3_ Reverse /5Phos/aaacTCCGCCTTCTCTTCCCGGTTC GGG 
gRNA-4_Forward /5Phos/CACCGACCCAGCTTTTCCCGACTCC GGG 
gRNA-4_ Reverse /5Phos/aaacGGAGTCGGGAAAAGCTGGGTC GGG 
 
Table 4.1 Sequences for respective Forward and Reverse gRNAs are shown in the table. 
Overhang sequences are shown in lower case.  
4.3.1.2 Plasmid construction   
PX330-based plasmid; SpCas9 was purchased from “Zhang Lab” through “Addgene” USA 
(Table 4.2).  
Table 4.2 Plasmid used for CRISPR/Cas9 construction 
Plasmid Catalog Antibiotic resistance Strain  
SpCas9(SpCas9n, 
D10A nickase) 
#42230 Ampicillin E.coli (Stbl3) 
 
4.3.1.3 Oligo annealing and cloning into the backbone vector 
4.3.1.3.1 Plasmid culture 
Bacterial strain (E. coli; Stbl3) was cultured in Lysogeny Broth (LB) (refer Table 4.3 for LB 
medium recipe) medium with Ampicillin (100 µg/mL) overnight in a shaker at 200-230g 







Table 4.3 LB medium recipe for 500 mL 
Reagent Volume (500 mL) 
Bacto-tryptone 5 gm 
Yeast extract 2.5 gm 
Sodium chloride (NaCl) 5 gm 
Agar (Only for LB-agar plate) 7.5 gm 
MQ H2O Make up the volume 500 mL 
 
4.3.1.3.2 Plasmid DNA isolation 
Plasmid DNA from the bacterial strain (Stbl3) was isolated using ZyppyTM plasmid miniprep 
kit according to the manufacturer’s protocol. In brief, 100 µL of 7X Lysis buffer was mixed 
well with 600 µL of the bacterial culture grown in LB. Next, 350 µL of Neutralization buffer 
was added to this mixture, shaken vigorously and centrifuged at 16,000 x g for 2 minutes. The 
supernatant was transferred to Zymo-spinTM IIN column connected with the collection tube 
and centrifuged for 15 seconds. After discarding the flow-through, 200 µL of Endo-Wash 
buffer was added to the column and centrifuged for 30 seconds followed by the addition of 400 
µL of ZyppyTM Wash buffer and further centrifugation for 1 minute.  The column was then 
transferred to a clean 1.5 mL tube and 30 µL of ZyppyTM Elution buffer was added and 
centrifuged for 30 seconds to get the final elute containing plasmid DNA. 
4.3.1.3.3 Digestion and gel purification of plasmid DNA 
Digestion of plasmid DNA was performed using 10X FastDigest Buffer and FastDigest Bbsl 
in a 20 µL total reaction volume at 37°C for 30 minutes (Table 4.4). The digested product was 
subjected to 2% agarose gel and purified using Zymo research Gel Extraction kit with wash 
buffer according to the manufacturer’s instruction (Table 4.5). In brief, the DNA fragment 
from agarose gel was excised using a razor blade and transferred to a 1.5 mL tube. 
Approximately an equal volume of Agarose Dissolving Buffer (ADB) was added to the tube. 




dissolved. The melted agarose solution was transferred to Zymo-SpinTM column with a 
collection tube and centrifuged at 16,000 x g for 1 minute. After discarding the flow-through, 
200 µL of DNA wash buffer was added to the column and centrifuged at 16,000 x g for 1 
minute (repeated the step twice). Finally, 10 µL of DNA elution buffer was added and the 
column was placed into a 1.5 mL tube and centrifuged at 10,000 x g for 1 minute to get the 
ultra-pure DNA.  
Table 4.4 Digestion and dephosphorylation of plasmid DNA 
Reagent Volume 
Plasmid DNA 1.00 µL 
10XFastDigest Buffer 2.00 µL 
FastDigest Bbsl 1.00 µL 
S Alkaline phosphate  1.00 µL 
MQ H2O 15 µL 
Total volume  20 µL 
Incubate for 30 minutes at 37°C 
 
Table 4.5 Recovery of plasmid DNA 
Reagent Volume for 1 mL mixture 
Excised agarose gel 500 µL 
Agarose Dissolving Buffer (ADB) 500 µL 
Incubated at 55°C for 10 minutes or until the gel slice was completely dissolved 
DNA wash buffer 200 µL 
DNA elution buffer 10 µL 
 
4.3.1.3.4 Annealing of each pair of gRNA oligonucleotides 
Annealing was performed using 10XT4 Ligation Buffer with forward and reverse sequences 
of each pair of forward and Reverse gRNAs (10 µM concentration) listed in Table 4.1. 






Table 4.6 Annealing reaction reagents 
Reagent  Volume  
10XT4 Ligation buffer 1 µL 
MQ H2O 7 µL 
gRNAs (forward oligo) 1 µL 
gRNAs (Reverse oligo) 1 µL 
Total 10 µL 
 
Table 4.7 Temperature required for the reaction 
Steps Temperature Time  
Step-1 37°C 30 minutes 
Step-2 95°C 5 minutes and then ramp 
down to 25°C at 
5°C/minutes 
 
4.3.1.3.5 Ligation and transformation 
Each oligonucleotide duplex (1:200 dilution) (referred to Table 4.1) was ligated into the 
digested plasmid vector at room temperature for 10 minutes. Ligation was performed using T4 
DNA Ligase, incubated 10 minutes at room temperature (for reagent details, refer to Table 
4.8).  
Ligated plasmid construct was added to competent cells (E. coli; DH-5α) (Thermo 
Fisher) and incubated on ice for 30 minutes. After incubation, the competent cells were heat-
shocked at 42°C for 30 seconds on a heating block followed by rapid cooling on ice for 5 
minutes. The recovery of the bacteria was performed by incubating competent cells in 125 μl 
Super Optimum Medium (SOC medium) (Invitrogen; 2% tryptone, 0.5% yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) at 37°C in a shaking 
incubator for 1 hour at 220 revolutions per minute (RPM). While incubating the competent 
cells, LB-agar plates with ampicillin were prepared (refer to Table 4.3). For this, after 
autoclaving, ampicillin (100 µg/mL) was added and the medium was poured into 10 cm 




After incubation for 1 hour, the competent cell suspension was spread on LB-agar plates 
using a sterile L-shaped glass spreader and allowed to dry for 10 minutes at room temperature, 
following which they were incubated at 37°C in a humidified incubator overnight to form 
colonies. Then the colonies were picked using sterile pipette tips and submerged into a 1.5 mL 
sterile tube containing 600 µL of LB medium with 100 µg/mL ampicillin. The tubes were 
incubated at 37°C for 24 hours in a shaking incubator at 230g rotation. 
Table 4.8 Ligation of gRNAs with plasmid 
Reagent Volume 
Digested plasmid DNA  2 µL 
Oligo duplex (1:200 dilution) 1 µL 
10X Ligase buffer 1 µL 
T4 DNA Ligase 1 µL 
MQ H2O 5 µL 
Total  10 µL 
 
4.3.1.3.6 Diagnostic PCR-screening and Sanger Sequencing    
The successful ligation and transformation were confirmed by PCR screening and Sanger 
sequencing which will help to authorize the final CRISPR/Cas9 construct to transfect into the 
cells. For this, the DNA was extracted as per the manufacturer’s protocol using ZyppyTM 
plasmid miniprep kit (explained in section 4.3.1.3.2). The extracted DNA was diluted 
(1:10,000) and PCR amplified in the presence of SpCas9 forward and Reverse primer (Table 
4.9) with FastStart Taq Polymerase (Roche), incubated for 4 min at 95ºC to heat-activate the 
Taq polymerase, followed by 15 min at 72 ºC (primer sequences, reagents and reaction time 
listed in Table 4.9, 4.10 and 4.11). The PCR products were validated by electrophoresis on 
2% agarose gel. Validated clones for each construct were confirmed by Genetic Analysis 
Services, University of Otago. The confirmed clone was then further propagated in 200 mL LB 
broth with 100 µg/mL ampicillin selection. After overnight culture at 37 ºC in shaking 




Plasmid Purification Kit (Invitrogen), as per manufacturer’s protocol. Each construct was lastly 
screened again by Genetic Analysis Services, the University of Otago for confirmation before 
stored at 4ºC, ready for transfection.  
Table 4.9 SpCas9 primer sequences 
SpCas9 primer 
Primer Sequence Manufacturers 
Forward (F) 5´-GGACTATCATATGCTTACCGTAACTTGA -3´ Integrated DNA 
Technologies 
Reverse (R) 5´- GGCCATTTACCGTAAGTTATGTAACG -3´ Integrated DNA 
Technologies 
 
Table 4.10 Reagent use for PCR-screening 
Reagent Volume 
10X FastStart Buffer 2.0 µL 
MgCl2 1.2 µL 
dNTPs 1.0 µL 
Diluted DNA (1:10,000)  1.0 µL 
SpCas9 Forward (10 µM) 1.0 µL 
SpCas9 Reverse (10 µM) 1.0 µL 
FastStart Taq polymerase 0.2 µL 
H2O 2.6 µL 
Total 10 µL 
 
Table 4.11 PCR-screening protocol 
Steps Temperature Time 
Step-1 95°C 4 minutes 
Step-2 94°C 30 Seconds 
Step-3 50°C 30 Seconds  
Step-4 72°C 3 minutes 
Step-5 Go to Step-2 Repeat x 34 
Step-6 72°C 5 minutes 






4.3.2 In vitro culture of human ventricular cardiomyocytes (AC-16 cells) at low glucose to 
quantify the efficacy of CRISPR/Cas9 component 
AC-16 cells were cultured in Dulbecco’s Modified Eagle Medium: low glucose (5.5 mM) 
(DMEM low glucose) [Gibco; ThermoFisher Scientific, New Zealand] with 5% FBS 
[ThermoFisher Scientific, New Zealand] and 1X Penicillin-Streptomycin Solution [Gibco; 
ThermoFisher Scientific, New Zealand] in T75 flask. The cells were trypsinized, when they 
reached 80% confluently. After trypsinization, cells were seeded at the density of 2.5-3 X 104 
cells per well in 24 well plates, and 2.5-3 X 106 cells per 60 mm dish and continued growing 
for 120 hours (explained in Chapter:2.0).  
4.3.3 High glucose exposure of AC-16 cells 
For high glucose exposure, cells were exposed to 30 mM high D-Glucose (HG) (Sigma 
Aldrich) or 30 mM D-Mannitol (NG) (Sigma Aldrich) (as osmotic control) for 120 hours 
(explained in Chapter:2.0).  
4.3.4 CRISPR/Cas9 transfection  
4.3.4.1 Selection of gRNA  
The miRNA-320a expression study demonstrated significant upregulation of miRNA-320a at 
96 and 120 hours of high glucose culture (Chapter:3.0, Fig.3.5). Based on this finding, we 
decided to transfect the cells before miRNA-320a was significantly upregulated. To maintain 
consistency in transfection time point (irrespective of normal glucose or high glucose culture), 
the AC-16 cells were cultured in normal glucose and transfected (Fig.4.1 A & B) at 72 hours 
with CRISPR/Cas9 plasmid DNA ligated with individual gRNA and empty plasmid DNA (as 
negative control) at an equal concentration (2µg/µL) using LipofectamineTM 3000 
(ThermoFisher Scientific, NZ) according to the manufacturer’s instructions (Table 4.12). At 




RT-PCR. Based on the RT-PCR result, the best gRNA ligated with CRISPR/Cas9 component 
was selected for further studies.  
4.3.4.2 MiRNA-320a knockdown using CRISPR/Cas9 in high glucose exposure 
To determine the expression of miRNA-320a after the knockdown of the respective gene, AC-
16 cells were seeded in different plates (24 well plates for RNA isolation, 96 well plates for 
Caspase-3/7 activity, and 6 well plates for protein isolation) and cultured in high glucose (30 
mM) and transfected at 72 hours with an equal concentration of CRISPR/Cas9 component 
ligated with the gRNA (the best gRNA for miRNA-320a knockdown was selected based on 
RT-PCR) and empty plasmid DNA (as negative control) with  LipofectamineTM 3000 as per 
manufacturers instruction (transfection protocol with DNA concentration and plate setup 
was mentioned in Fig.4.1 A & C, and Table 4.12). At the end of the total culture time (120 
hours), media was aspirated and cells were used for total RNA extraction, protein isolation, 












Fig.4.1 Transfection flow diagram of CRISPR/Cas9 component with LipofectamineTM 3000 
and plate setup of CRISPR/Cas9 transfection for gRNA selection and functional study. (A) 
The flow diagram represents the step by step transfection method. (B) Three individual wells 
were selected for each gRNA-CRISPR/Cas9 construct and three wells for empty plasmid DNA 
in a 24 well plate. After seeding the cells, the equal concentration of DNA was added to the 
individual well and toped up with 1000 µL of normal glucose (5.5 mM) containing DMEM 
medium. (C) In a 24 well plate, 12 wells were toped up with normal glucose media. Among 
those 12 wells, six individual wells were used for the selected gRNA-CRISPR/Cas9 constructs 
with the equal concentration of DNA, and the other six wells were transfected with empty 
plasmid DNA. The remaining 12 wells were toped up with high glucose media, transfected 
with selected gRNA-CRISPR/Cas9 constructs, and empty plasmid DNA with equal 
























Table 4.12 Stepwise protocol for transfection of cells with LipofectamineTM 3000 
(ThermoFisher Scientific, USA) 
Sl.No Steps Components 96 wells 24 wells 6 wells 
1 Seeding AC-16 to be 
70-90% confluent 






3000 reagent in 
optimum medium (2 
tubes) 
Serum-free media  10 µL 50 µL 250 µL 
LipofectamineTM 
3000 
0.3 µL 1.5 µL 7.5 µL 
3 Preparation of  
master mix of DNA 
by diluting DNA in 
optimum medium, 
add P3000 
Serum-free media  10 µL 50 µL 250 µL 
DNA (2µg/µL ) 0.2 µg 1 µg 5 µg 
P3000TM Reagent 0.4 µL 2 µL 10 µL 
4 Add diluted DNA to 
each tube of diluted 
LipofectamineTM 
3000 (1:1) 
Diluted DNA (with 
P3000) 




5 µL 25 µL 125 µL 






Add DNA lipid 
complex to cells 
DNA-lipid 
complex 
10 µL 50 250 µL 
 
DNA amount 100 µg 500 µg 2500 µg 
 
 










Incubated cells for 48 hours at 37°C. Then analyzed 







4.3.5 RNA isolation from CRISPR/Cas9 transfected AC-16 cells 
Total RNA was isolated from cell samples using QIAzol reagent as described in “Chapter: 
2.0”. 
4.3.6 Real-time polymerase chain reaction (PCR) 
Twenty nanograms of total RNA (derived from cells) were reverse transcribed using miRNA-
320a specific reverse transcription primers (Life Technologies, NZ). Following Reverse 
transcription, specific Taqman hybridization probes (Life Technologies, NZ) were used to 
quantify the expression of miRNA-320a, which was normalized to internal negative control 
U6, as described in detail in “Chapter:2.0”.   
4.3.7 Preparation of cell lysate and western blotting  
Trypsinized cells were homogenized in ice-cold RIPA-buffer. The protein quantification was 
performed using Bradford assay (BioRad) where the concentration was extrapolated against 
bovine serum albumin (BSA). Finally, western blotting was performed to study the expression of 
miRNA-320a target protein (IGF-1), Bcl-2, and cleaved caspase-3 as described in “Chapter:2.0”. 
4.3.8 Caspase-3/7 and CyQUANT proliferation assay 
The caspase activity was normalized with cell proliferation as described in “Chapter:2.0”. 
4.3.9 Statistical analysis 
All statistical analyses were performed using the software GraphPad Prism (version 7). All the 
data were expressed as mean ± standard error of the mean. Shapiro-Wilk test was used to check 
the normality before all the analysis. A one-way ANOVA, followed by a non-parametric 
Kruskal-Wallis test was used for the selection of the ideal gRNA candidate. A two-way 
ANOVA, followed by a Tukey’s multiple comparisons test was performed to analyze the 




CyQUANT proliferation in human ventricular cardiomyocyte cell samples (AC-16 cells) in 
high glucose exposure. A P-value <0.05 was predetermined as the level of significance for all 
statistical analyses.  
4.4 Results 
4.4.1 Confirmation of gel digested plasmid 
After successful digestion (as detailed in section 4.3.1.3.2) the fragments were electrophoresed 
on 2% agarose gel for visualization (Fig. 4.2A). Confirmation of plasmid was based on the 
expected size (14,554 bp or 14.554 kbp) after restriction enzyme digestion. The result 
confirmed the successful digestion of plasmid DNA and based on this result, the whole digested 
DNA was electrophoresed on another 2% gel, and the portion of the gel corresponding to the 






Fig.4.2 Confirmation of purified plasmid. (A) SpCas9 (SpCas9n, D10A nickase) vector was 
confirmed by the original plasmid size (14,554 bp or 14.554 kbp) (red arrow) which appeared 
a little further away from the undigested plasmid. (B) & (C) Represents larger well containing 
digested plasmid and excised area respectively.  
 
4.4.2 Diagnostic screening of gRNA flanking  
For screening the gRNA construct, 17 colonies flanking with gRNA-1 and gRNA-2 
oligonucleotides, 5 colonies flanking with gRNA-3 oligonucleotides, and 9 colonies flanking 
with gRNA-4 oligonucleotides were picked for culture on LB medium (described in section 
4.3.1.3.5). Extracted DNAs from each culture were initially screened using PCR amplification 
to ensure the presence of the correct insert. The amplified product was visualized on 2% 
agarose gel for confirmation, as shown in Fig.4.3. All four gRNAs showed an amplification 
product at the predicted size of 300 bp. Therefore, each gRNA construct was confirmed as 





Fig.4.3 Agarose gel image confirming gRNA flanking by PCR Screening. PCR product for 
each gRNA flanked clone was visualized as shown. The bands of the strong amplification 
product of size (300 bp) were consistent with the respective insert. The bands present in the 
yellow box represent colonies with gRNA-1, the green box represents colonies with gRNA-2, 
the blue box represents colonies with gRNA-3, and the brown box represents colonies with 
gRNA-4. Clones containing correctly-sized PCR products were considered suitable for further 
screening. 
 
4.4.3 Screening of gRNA construct (Sanger sequencing)  
For initial confirmation of successful cloning through electrophoresis, one PCR amplified 
DNA samples from each gRNA construct were randomly selected and subjected for sequencing 
(as described in 4.3.1.3.6). Sequencing data were analyzed by Sequence Scanner v2.0 (Applied 
Biosystems) software. As shown in Fig.4.4, the analysis confirmed that the inserted gRNA 




 Based on the sequencing results, large scale culture was performed with the perfectly 
flanked (flanked with individual gRNA) colonies. Maxiprep isolated DNAs were further PCR-
amplified and Sanger sequenced, which confirmed the correct insertion of the gRNA sequence 
for each clone (Represented in the Appendix; Fig. S3.1).  Therefore, each gRNA construct was 
confirmed as correct and ready for use in transfection. 
 
Fig.4.4 Sanger Sequencing Results Confirming each Correct gRNA Sequence. The 
highlighted area in this figure is each confirmed gRNA sequence that was cloned into the 
plasmid. (A) Cloned with gRNA-1. (B) Cloned with gRNA-2. (C) Cloned with gRNA-3. (D) 
Cloned with gRNA-4. Each of the sequences highlighted was correctly aligned to the original 
sequence with complete homology (zero mismatches). The original cloned sequence is shown 
below each respective sequencing result for reference. Sanger sequencing results were 
Sequence Scanner v2.0 (Applied Biosystems) software.  
 
4.4.4 Selection of the ideal gRNA for the knockdown of miRNA-320a  
The relative expression of miRNA-320a in normal glucose (5.5 mM) cultured AC-16 cells after 




miRNA-320a expression at 120 hours in the cells transfected with plasmid DNA ligated with 
gRNA-1 (P=0.0079) and gRNA-2 (P=0.0002) compared to empty plasmid DNA (negative 
control) transfected group (Fig.4.5). The other two gRNAs (plasmid DNA ligated with gRNA-
3 and gRNA-4) did not show any significant changes in expression compared to the empty 
plasmid DNA (negative control) transfected group (Fig.4.5). Moreover, the plasmid DNA 
ligated with gRNA-2 showed a consistent and less variability in the knockdown competency 
compared to gRNA-1. Based on these observations, gRNA-2 ligated plasmid DNA was 
selected to test the functional effects following in vitro knockdown of miRNA-320a in high 
glucose cultured AC-16 cells.  
 
Fig. 4.5 Changes in miRNA-320a expression in different gRNA transfected normal glucose 
cultured human ventricular cardiomyocytes (AC-16 cells). Quantitative bar graphs with 




without plasmid DNA ligated with gRNA, determined by quantitative RT-PCR analysis (N=6 
in all groups). Relative expression was based on the Ct of the target miRNA vs. a Ct of the 
reference miRNA (2-ΔCt). U6 was used as a reference miRNA. Values are mean ± SEM. 
Shapiro-Wilk test was used to check the normality. All the data were analyzed by one-way 
ANOVA with Tukey’s multiple comparisons. *Significantly different from control group 
(gRNA-1; *P<0.05 and gRNA-2; ***P<0.001). Non-significant = N.S.  
 
Based on the results from RT-PCR, gRNA-2 was selected as the candidate gRNA for 
downstream knockdown of miRNA-320a in high glucose cultured human ventricular 
cardiomyocytes (AC-16 cells).  
4.4.5 Knockdown of miRNA-320a expression by gRNA-2-CRISPR/Cas9-miRNA-320a 
prevented high glucose-induced downregulation of target protein IGF-1 expression in 
AC-16 cells  
Having demonstrated the upregulation of miRNA-320a in diabetic human and mouse 
myocardium and high glucose cultured human ventricular cardiomyocytes (AC-16 cells) 
(Chapter:3.0), my next aim was to confirm if in vitro knockdown of miRNA-320a genomic 
DNA by CRISPR/Cas9 improves the survival of high glucose cultured human ventricular 
cardiomyocytes.  
For this, AC-16 cells were exposed to high glucose stress (as described in 4.3.3 and 
Chapter:2.0.), with 30 mM glucose for 72 hours, after which they were transfected. After 48 
hours of transfection (at 120 hours of cell culture) total RNA was isolated for RT-PCR analysis. 
The relative expression of miRNA-320a was significantly upregulated in empty plasmid DNA 
treated high glucose stressed cells (P=0.0001) (Fig. 4.6) confirming the results shown in 
Chapter: 3.0, section 3.4.3.  Importantly, this was significantly prevented in cells transfected 
with gRNA-2-CRISPR/Cass9-miRNA-320a plasmid in high glucose treated cells (P=0.0001) 
(Fig. 4.6). Interestingly, the level of miRNA-320a expression in high glucose treated cells 




expression of miRNA-320a in normal glucose cultured cells. Therefore, the entire set of results 
represented that, gRNA-2-CRISPR/Cass9-miRNA-320a plasmid is equally competent to 
knockdown miRNA-320a in both normal and high glucose culture. 
 
Fig. 4.6 Inhibition of miRNA-320a expression in CRISPR/Cas9 transfected high glucose 
cultured AC-16 cells. The quantitative bar graph with scatter plots showing RT-PCR analysis 
represents the changes in the expression pattern of miRNA-320a in normal and high glucose 
cultured cells with empty plasmid and gRNA-2-CRISPR/Cas9 plasmid treatment at 120 hours 
(N=9). Relative expression was based on the Ct of a target miRNA vs. a Ct of a reference 
miRNA (2-ΔCt). U6 was used as a reference miRNA. Values are mean ± SEM. Shapiro-Wilk 
test was used to check the normality. All the data were analyzed by two-way ANOVA followed 
by Tukey's multiple comparisons was used to compare miRNA-320a expression at all the 
groups. *Significantly different from high glucose cultured cells with empty plasmid DNA 
(negative control) treatment compared to normal glucose cultured cells with empty plasmid 
DNA (negative control) (****P<0.0001) and high glucose cultured cells with gRNA-2-
CRISPR/Cass9-miRNA-320a plasmid treatment compared high glucose cultured cells with 





Our next aim was to determine if preventing high glucose-induced activation of 
miRNA-320a can improve the survival of cardiomyocytes in high glucose exposure. First, the 
expression of miRNA-320a target protein IGF-1 expression was validated by western blot 
analysis [120].  As in Chapter: 3.0 section 3.4.3.1, the expression of IGF-1 was significantly 
downregulated in high glucose cultured cells compared to empty plasmid DNA (negative 
control) (P=0.0001). The reduction in IGF-1expression was significantly ameliorated by 
gRNA-2-CRISPR/Cass9-miRNA-320a plasmid transfected cells (P=0.0015) (Fig. 4.7). 
Although not significant, the expression of IGF-1 showed an increasing trend in normal glucose 
cultured cells (Fig. 4.7). These results confirm that knockdown of miRNA-320a genomic DNA 
prevents the formation of mature miRNA-320a, hence no duplexing with IGF-1 mRNA. 
Therefore, by hindering the post-transcriptional modification, CRISPR/Cas9 mediated 
knockdown of miRNA-320a partially normalized the anti-apoptotic IGF-1 protein which is 





Fig. 4.7 Determination of target protein (IGF-1) expression in CRISPR/Cas9 transfected 
AC-16 cells under high glucose stress. Representative western blotting image and quantitative 
bar graph with scatter plots showing relative expression of IGF-1 in normal and high glucose 
cultured cells with empty plasmid and gRNA-2-CRISPR/Cas9-miRNA-320a plasmid treatment at 
120 hours (N=9). Total protein (ponceau) was used as a reference control for western blot 
analysis. Values are mean ± SEM. Shapiro-Wilk test was used to check the normality. All the 
data were analyzed by two-way ANOVA followed by Tukey's multiple comparisons was used 
to compare IGF-1 expression for all the groups. *Significantly different from high glucose 
cultured cells with empty plasmid DNA (negative control) treatment compared to normal 
glucose cultured cells with empty plasmid DNA (negative control)  (****P<0.0001) and high 
glucose cultured cells with gRNA-2-CRISPR/Cass9-miRNA-320a plasmid treatment 




(##P<0.01). (The whole western blot and the corresponding Ponceau images were represented 
in the Appendix; Fig. S3.2). 
4.4.6 Knockdown of miRNA-320a expression by gRNA-2-CRISPR/Cas9-miRNA-320a 
plasmid transfection prevented apoptosis in high glucose-induced AC-16 cells  
Having demonstrated the improvement of survival protein IGF-1, our next aim was to 
determine whether miRNA-320a knockdown improves the survival of cardiomyocytes under 
high glucose stress. To address this, downstream signaling proteins such as anti-apoptotic Bcl-
2 and pro-apoptotic cleaved caspase-3 expression was measured. In addition, caspase activity 
was measured using Caspase-3/7 and CyQUANT proliferation multiplexed assay. IGF-1 plays 
a key role in preventing apoptotic cell death, by activation of mitochondrion intermediated anti-
apoptotic stimuli [239, 240]. Accordingly, IGF-1 directly increases the gene expression of anti-
apoptotic Bcl-2, thereby increasing its protein expression. Bcl-2 inhibits the activation of 
caspase, thus reducing apoptotic cell death [303]. The results confirmed that by showing 
significant restoration of Bcl-2 with gRNA-2-CRISPR/Cass9-miRNA-320a plasmid treatment 
compared to empty plasmid DNA (negative control) treatment in normal (P=0.05) and high 
(P=0.0008) glucose cultured cells (Fig. 4.8 A). Though the significant restoration was observed 
with gRNA-2-CRISPR/Cass9-miRNA-320a plasmid treatment in high glucose cultured cells, 
the substantial difference persisted between normal glucose and high glucose cultured cells 
with knockdown of miRNA‐320a (P=0.0001) whereas no significant improvement was 
observed in normal glucose treated cells with miRNA-320a knockdown. On other hand, 
cleaved caspase3 was significantly downregulated in high glucose cultured cells with gRNA-
2-CRISPR/Cass9-miRNA-320a plasmid treatment compared to high glucose cultured cells 
with empty plasmid DNA (negative control) treatment (P=0.0007) (Fig. 4.8 A & B) whereas, 
it was comparable between normal glucose and high glucose cultured cells with knockdown of 
miRNA‐320a. Similarly, Caspase 3/7-CyQANT proliferation multiplexed assay demonstrated 




gRNA-2-CRISPR/Cass9-miRNA-320a plasmid compared to high glucose cultured cells with 







Fig. 4.8 MiRNA-320a genomic DNA knockdown by gRNA-2-CRISPR/Cas9 transfection 
prevented apoptosis in high glucose stressed AC-16 cells. A&B. Representative western 
blotting image and quantitative bar graph with scatter plots showing relative expression of (A) Bcl-
2, (B) cleaved caspase-3 proteins in normal and high glucose cultured AC-16 cells with empty 
plasmid and gRNA-2-CRISPR/Cas9-miRNA-320a plasmid at 120 hours (N=9). C. Quantitative 
bar graph with scatter plots showing the level of caspase activity in normal and high glucose 
cultured AC-16 cells with empty plasmid and gRNA-2-CRISPR/Cas9-miRNA-320a plasmid 
treatment at 120 hours (N=9). Values are mean ± SEM. Shapiro-Wilk test was used to check the 
normality.  All the data were analyzed by two-way ANOVA followed by Tukey's multiple 
comparisons was used to compare the expression Bcl-2 cleaved caspase-3 and caspase activity 
for all the groups. *Significantly different from high glucose cultured cells with empty plasmid 
DNA (negative control) treatment compared to normal glucose cultured cells with empty 
plasmid DNA (negative control) (Bcl-2; ****P<0.0001), (cleaved caspase-3; ****P<0.0001), 
and (caspase activity; ****P<0.0001 ) whereas, high glucose cultured cells with gRNA-2-
CRISPR/Cass9-miRNA-320a plasmid treatment  compared to high glucose cultured cells with 
empty plasmid DNA (negative control) (Bcl-2; ###P<0.001), (cleaved caspase-3; ###P<0.001), 
and (caspase activity; ###P<0.001), normal glucose cultured cells with empty plasmid DNA 
(negative control) compared to gRNA-2-CRISPR/Cass9-miRNA-320a plasmid treatment  
(Bcl-2; δP<0.05), (cleaved caspase-3, and caspase activity= N.S), and difference between 
normal glucose and high glucose with miRNA‐320a knockdown (Bcl-2; ᴪᴪᴪᴪP<0.0001), 
(cleaved caspase-3, and caspase activity= N.S). (The whole western blot and the corresponding 






4.5 Discussion  
This chapter investigated the effect of the stem-loop genomic sequence of the miRNA-320a 
knockdown in normal and high glucose cultured human ventricular cardiomyocytes (AC-16 
cells). The principal findings of this chapter demonstrated that knockdown of the miRNA-320a 
stem-loop genomic sequence prevented hyperglycemia-induced caspase activity that would 
most likely also prevent apoptotic cell death. 
The previous chapter demonstrated (Chapter:3.0) that, miRNA-320a expression 
significantly increased in cardiomyocytes in high glucose stress, considered to be pro-apoptotic 
due to its ability to potentiate apoptosis by regulating the expression of apoptotic factors at the 
post-transcriptional level [120, 172, 278, 390]. Knocking down the miRNA-320a stem-loop 
genomic sequence, partially prevented the process and helped to understand the apoptotic 
signal propagation pathway. This study has also given the insight to develop translational 
strategies in preventing apoptosis-mediated myocardial damage.   
4.5.1 CRISPR/Cas9 construct 
Here, I was able to use SpCas9 (SpCas9n, D10A nickase) plasmid as one of the requirements 
needed for a targeted miRNA-320a gene editing. This plasmid was screened in each step of 
cloning to ensure that the final plasmid has the right components (gRNAs) needed for DNA 
targeting. The strategy of using this plasmid was aligned with the work performed by Chang et 
al, where they targeted miRNA-17, miRNA-200c, and miRNA-141 stem-loop genomic 
sequence by using a similar approach [232]. Moreover, Huo et al demonstrated knockout of 
the miRNA-21 gene by using CRISPR/Cas9 in ovarian cancer [391] whereas, Zhou et al 
targeted the stem-loop structure of miRNA-3188 in hepatocellular carcinoma cells where they 




experiment and the corresponding results are consistent with the previous findings [232, 391, 
392].  
Besides plasmid construction, gRNA design has a large impact on the efficiency of 
targeted gene editing. However, a wide range of tools are now available for the prediction of 
gRNA function. Thus, there is potential value in using multiple different tools for gRNA 
design, where cross-referencing of the different prediction algorithms may help to more 
accurately predict the function of any unique gRNA sequence. This would, in theory, allow for 
a more accurate assessment of a particular sequence, and potentially give superior insight into 
the on- and off-target functions of the corresponding gRNA. Therefore, we used the 
“Benchling.com design tool” to design gRNAs that were used for the miRNA-320a genomic 
DNA editing. This approach is concomitant with the gRNA designing strategies employed by 
DiCarlo et al, Horwitz et al, and Jakociunas et al [393-395].  
On other hand, using molecular biology techniques, the digested plasmid was annealed 
with each pair of gRNA oligonucleotides and cloned into the respective vector (DH-5α). 
Successful ligation was confirmed using a non-proof-reading polymerase enzyme (FastStart 
Taq) for the PCR-based amplification steps described previously in section 4.3.1.3.6 and table 
4.10. Overall, the aim of constructing CRISPR/Cas9 component ligated with respective gRNAs 
was achieved and confirm through sequencing (Fig.4.4).  
4.5.2 CRISPR/Cas9-miRNA-320a plasmid transfection inhibits miRNA-320a biogenesis 
and facilitates IGF-1 protein expression in AC-16 cells under high glucose stress 
The apoptotic pathway was synchronized by the downregulation of the IGF-1 gene causing 
downregulation of the respective protein. In the present study, miRNA-320a expression in high 
glucose exposure was significantly downregulated (Fig. 4.6) by respective gene modification 




experimental studies involving CRISPR/Cas9 mediated miRNA-gene editing [232]. Moreover, 
the miRNA-320a downregulation may partially improve cell survival, acting through 
modulating the apoptotic signaling pathway which was also aligned with previous studies 
[172].  
 As discussed in the earlier chapter (Chapter: 3.0), during ischemia, the insulin-
signaling pathway gets blunted but insulin still produces its action [396]. From a therapeutic 
perspective, the cocktail glucose-insulin-potasium was vastly administered to reduce infarct 
size [397, 398] by protecting from toxic metabolic intermediates (toxic long-chain fatty acid 
metabolites) and activation of protein kinase-B (PKB)/Akt phosphorylation which inactivates 
pro-apoptotic proteins in ischemic condition [399, 400]. On a different pathway, insulin plays 
a protective role by regulating proteins like survivin (anti-apoptotic protein) in cardiac-
ischemia [401-403]. The anti-apoptotic survivin gene is one of the targets of miRNA-320a 
[404]. Yang et al. reported that the elevation of miRNA-320a was associated with diabetes 
leading to the downregulation of survivin expression [404]. This study further revealed the 
improvement of surviving expression by the treatment of insulin. Insulin downregulates the 
expression of miRNA-320a and eventually elevates the anti-apoptotic survivin expression 
leading to protection against ischemia-induced myocardial injury. Collectively, those shreds of 
evidence demonstrated a strong correlation between miRNA-320a expression and insulin 
treatment in diabetic-ischemic heart disease conditions.  
Similar to insulin, IGF-1 plays a protective role acting as same as PKB/Akt pathway 
[324, 405]. It has been proven that the downregulation of IGF-1 occurred during the ischemic 
condition, was associated with overexpression of miRNA-320a [120, 172] where the IGF-1 
expression was restored by the administration of miRNA-320a inhibitor. In another study, 




validates the levels of p-ASK1, p-JNK, p-p38, Bax, and caspase-3 leading to elevated apoptosis 
[120]. Further investigation revealed inhibition of miRNA-320a increased the expression of 
IGF-1 and provided a protective effect.  
In support of this notion, it is reasonable to put forward that diabetes has a distinct 
correlation with the altered expression of miRNA-320a, and IGF-1 which is found to be one of 
the determinants of cardiac apoptosis (explained in detail in Chapter: 3.0) [1, 41, 120, 132, 
133, 172, 239, 240, 303-306]. Consequently, while establishing the underlying relation 
between IGF-1 expression and knockdown of miRNA-320a in high glucose cultured 
cardiomyocytes (to mimic in vivo diabetes), we found, modulation of the genomic sequence of 
miRNA-320a by CRISPR/Cas9 elevated the expression of pro-survival IGF-1 protein (Fig. 4.7) 
which corresponds with the previous findings [120, 172]. Therefore, it is reasonable to state  
that CRISPR/Cas9 modulates the miRNA-320a gene and causes the upregulation of its target 
protein IGF-1.   
4.5.3 Inhibition miRNA-320a biogenesis facilitates cell survival in high glucose stress 
Caspase plays a major role in inducing cell death stimuli [332, 333]. Studies in rats with acute 
myocardial infarction have suggested that caspase has a key role in modulating apoptosis [406]. 
Similarly, in another study, the Co-localization of caspase-3 with apoptotic cardiomyocytes 
has been reported in the myocardial ischemia-reperfusion model [304]. Moreover, Bialik et al 
suggested that the release of cytochrome c from mitochondria may be an important factor for 




In addition to ischemia-induced cell death in the myocardium, chronic diabetic stress 
facilitates the development of cardiac complications that deteriorates with time [407]. The 
mechanisms that underpin myocardial damages are likely to be multifactorial. It is proven that 
programmed cell death or apoptosis is one of the determinants of cardiac damage, instigated 
by several stress factors. Among numerous stress factors involved in apoptosis, high glucose 
has a direct link with myocardial apoptosis. Moreover, Cai et al demonstrated that 
hyperglycemia-induced apoptosis in the myocardium is one of the leading causes of diabetic 
heart disease as well DCM [325]. That study has shown that cytochrome c–mediated caspase-
3 activation was responsible for apoptotic cell death in diabetic myocardium where the 
condition was improved with caspase-3 inhibitor. This study further revealed the generation of 
reactive oxygen species (ROS) in high glucose exposed cardio-myoblast cells (H9c2) by the 
activation of the cytochrome c–activated caspase-3 pathway which established the direct 
relationship between cell death and diabetes [325]. In a similar study, Chowdhry et al reported 
a higher amount of cell death in diabetic human myocardium with elevated caspase-3 
expression [63].   
  Molecular triggering factors like the multigene family of Bcl-2 proteins inhibits 
apoptosis whereas, other such as Bax promotes apoptosis which is one of the best-known 
regulators of the apoptotic process [325-327]. The increased ratio of Bcl-2 and Bax (so-called 
“death switch”) significantly attenuate apoptosis. Elevation of Bcl-2 expression in cardiac 
tissue bypassing Bax expression provides a protective effect from apoptosis [328-331]. 
 Previous evidence suggested that diabetes is associated with altered expression of 
miRNAs leading to apoptosis in the myocardium [1] whereas the modulation of miRNA 
candidates having a high potency to prevent the process. The growing body of evidence 
demonstrated the downregulation of the pro-survival proto-oncogene serine/threonine-protein 




expression of miRNA-1 and the propagation of apoptosis was prevented by anti-miRNA-1 
therapy [110, 138, 139]. Moreover, Fomison-Nurse et al demonstrated the upregulation of 
miRNA-34a facilitates apoptosis in high glucose cultured cardiomyocytes (AC-16 cells) where 
they observed a marked decline in apoptotic stimuli after anti-miRNA-34a therapy [41]. 
Additionally, Similarly, Song et al demonstrated the prevention of apoptosis where the IGF-1-
Bcl-2-caspase-3 pathway was altered by the administration of miRNA-320a anti-miR-320 
lentiviral treatment [120, 172]. 
 While establishing the relation between inhibition of miRNA-320a biogenesis and cell 
survival in high glucose stressed human ventricular cardiomyocytes (AC-16 cell line), it has 
been found that modulation of the genomic sequence of miRNA-320a by CRISPR/Cas9 
elevates the expression of pro-survival Bcl-2 protein and suppresses the overexpression of the 
pro-apoptotic cleaved caspase-3 protein (Fig. 4.8 A, B respectively) in high glucose treated cells. 
Though, a significant improvement was observed in Bcl-2 expression in normal glucose-treated 
CRISPR/Cas9-miRNA-320a transfected cells compared to normal glucose-treated empty 
plasmid transfected cells, whereas the anti-apoptotic cleaved caspase-3 level and caspase 
activity was strikingly unchanged in normal glucose treatment with miRNA-320a knockdown 
which could be possibly due to the involvement of other pro-survival mediators. The 
knockdown of miRNA-320a essentially prevented the increase in caspase 3/7 expression and 
mostly blocked the elevation of caspase activity during high glucose conditions which 
suggested that not all of the inhibitory actions of miRNA-320a knockdown are directly related 
to IGF-1 or Bcl-2 activation. Maybe other unknown targets of miRNA-320a negatively regulated 
the apoptotic signalling pathway. From that findings, it might be suggested that CRISPR/Cas9 
mediated miRNA-320a gene modulation can be one of the factors that prevent high glucose-
induced cell death in human ventricular cardiomyocytes (AC-16 cells). Taken together, my 




41, 110, 120, 132, 133, 138, 139, 172, 239, 240, 303-306, 325-331] which collectively provided 
an insight into the potential therapeutic role of miRNA-320a inhibition in improving apoptosis 
mediated cardiac complication in the diabetic heart.  
4.6 Consideration/Limitations of the study 
 In this chapter, the assessment of miRNA-320a modulation was only limited to the 
phenotypic expression of the miRNA-320a (PCR) after transfection in AC-16 cells which 
cannot exclude the possibility of an off-target effect towards other miRNA or cluster of 
miRNAs.  
 A next-generation-sequencing (MiSeq) study will further confirm the targeting of the 
gRNA to the target site and also authenticate the DNA sequence after editing.  
 This chapter cannot exclude the possibility that, after modulation of the genomic sequence, 
the recovered sequence may involve in abnormal cellular physiology.  
4.7 Conclusion 
The findings from this chapter demonstrate that the knockdown of miRNA-320a genomic DNA 
prevented the downregulation of IGF-1 and Bcl-2 leading to decreased caspase activity in high 
glucose treated human ventricular cardiomyocytes. Therefore, the prevention in upregulation 
of miRNA-320a may be an addition in miRNA modulation mediated therapeutic approach to 
prevent or treat DCM in terms of reducing apoptosis. In doing so, Chapter:5.0 will reflect on 
the translational approach of miRNA-320a modulation by using the LNA-anti-miRNA-320a 
oligonucleotide therapy in the type-2 diabetic db/db mouse model which mimics a human 
diabetic heart disease condition more precisely with DCM. Moreover, this chapter also 
revealed that the downregulation of miRNA-320a by knockdown of the respective genomic 
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The results from previous chapters (Chapter:3.0 and Chapter:4.0) demonstrated elevated 
expression of miRNA-320a in the diabetic heart as well as in high glucose cultured human 
ventricular cardiomyocytes was associated with higher caspase activity. Eventually, 
knockdown of the miRNA-320a gene by using the CRISPR/Cas9 component prevents cell 
death in high glucose cultured ventricular cardiomyocytes. As the in vitro knockdown of the 
miRNA-320a gene prevented apoptosis, modulation (knockdown) of miRNA-320a by using 
anti-miRNA-oligonucleotides could prophylactically prevent cell death and eventually hinder 
the progression of cardiac deterioration in type-2 diabetic mice. Therefore, the next aim is to 
establish whether in vivo modulation of miRNA-320a can prevent apoptotic cell death in the 
type-2 diabetic db/db mice heart and eventually improve the cardiac functional deterioration. 
5.1.1 Why it is necessary to evaluate miRNA-320a modulation in vivo model system? 
A variety of cell culture platforms are now available to assess the mechanisms of potential 
therapeutic efficacy of miRNA candidates in vitro. Primary cells, immortalized cell lines, and 
induced pluripotent stem (IPS) cells are readily available for the manipulation of target 
miRNAs. Indeed, synthetically modified miRNA-oligonucleotides to either overexpress or 
silence miRNA functions are accessible to biomedical research. Moreover, loss or gain of 
function of miRNA can also be achievable through respective in vitro gene editing [234].  
Though in vitro miRNA research expanded the horizon as a diagnostic biomarker or as a 
prognostic tool, validation using a successful preclinical in vivo model is extremely crucial for 
a clinical approach in biomedical research [408, 409].  
5.2 Study aim 
It is proven that miRNA plays a major role in DCM and modulation of miRNA can be a 




for this project, in the previous chapters, it has been shown that diabetes or high glucose-
induced upregulation of miRNA-320a, resulting in increased apoptosis of whole heart or 
cardiomyocytes (Chapter: 3.0). Eventually, the process of high glucose-induced apoptosis in 
cardiomyocytes can be restored by modulation of the miRNA-320a gene (Chapter: 4.0). 
Hence it is reasonable to speculate that, the in vivo modulation of miRNA-320a by external 
anti-miRNA-oligonucleotides administration can prevent the process of apoptosis in type-2 
diabetic db/db mice heart, leading to improvement of cardiac performances. 
Hence, the overall aim of this chapter is to determine the efficacy of miR-320 
knockdown on cardiac function and its ability to reduce diabetes-induced cardiomyocyte 
apoptosis. Therefore, I hypothesized that in vivo modulation of miRNA-320a can prevent the 
diabetes-induced apoptosis in type-2 diabetic db/db mouse heart, eventually leading to the 
improvement of cardiac function.   
5.3 Methods and materials 
Please refer to “Chapter:2.0” for general methods used for experimental procedures and 
specific methods are described in this chapter.  
5.3.1 In vivo modulation of miRNA-320a by Locked Nucleic Acid (LNA); (study design) 
The study design has been represented in Fig.5.1. The baseline echocardiography was 
measured in 24-weeks old BKS.Cg-m+/+Leprdb/J mice (db/db) and their age-matched non-
diabetic C57BL/ksJ-lepr+ littermates (db/+). All the mice were divided into three groups. After 
baseline echocardiography, the LNA-scrambled sequence was injected in nondiabetic lean 
mice (negative control group) and type-2 diabetic db/db mice (positive control group), whereas, 
LNA anti-miR-320 sequence was injected in type-2 diabetic db/db mice (treatment group). All 
the injection has been given as a bolus injection through the intraperitoneal (IP) route [201] 




represented in Fig.5.1). Each animal received 10 mg/kg LNA oligonucleotides (each time) 
for 4 consecutive weeks (4 times with 7 days’ interval; from 24 to 28 weeks of age). Initially, 
I planned to inject the oligonucleotides for 8 consecutive weeks (24 weeks to 32 weeks). 
Unfortunately, the dosing was not being able to continue for 28 to 32 weeks because of the 
lockdown caused by the global COVID-19 pandemic.  The functional effect was determined by 
serial measurement of changes in cardiac function by echocardiography at 28 and 32 weeks.  
At 32 weeks, following echocardiography and under terminal anesthesia, the hearts were 
quickly removed, washed in phosphate buffer saline (PSB), and dissected into three sections 
from apex to base. Each section comprised both the left and right chambers of the heart, which 
were used for either RNA extraction, immunohistochemistry, or protein extraction (Chapter: 
2.0, Fig. 2.2) (all the analysis performed with mouse heart, consistently contains left and right 
chambers in this entire project). The heart tissue samples for RNA and protein extraction were 
quickly snap-frozen in liquid nitrogen and stored in -80°C freezer and the remaining part for 
immunohistochemistry were fixed in 4% paraformaldehyde solution at 4°C, which was 
replaced with 1X PBS buffer after 24 hours. The tissues were then suspended in 30% sucrose 





Fig. 5.1 Study design from in vivo knockdown of miRNA-320a in type-2 diabetic db/db 
mice. 
5.3.1.1 Cardiac function analysis (Echocardiography) 
The systolic and diastolic function was assessed using a transthoracic echocardiography system 
(Vivid E9 ultrasound, GE; USA). Baseline echocardiography was performed at 24 weeks and 
repeated after 4 weeks’ interval until 32 weeks.  The mouse was anesthetized with 5% 
isoflurane and maintained at 1.5 to 2% during echocardiography. The chest fur was removed 
using hair removal cream and the mouse was placed in a supine position on an animal warming 
pad (37°C). The heart was imaged in a parasternal short-axis view as a guide for obtaining 
(LV) M-mode tracings close to the papillary muscle level. Doppler tracings of the mitral inflow 
were obtained at the parasternal long-axis view.   
5.3.1.1.1 Left ventricular systolic function (M-mode measurement)  
The systolic function was acquired based on the published report [410]. To visualize the cross-
sectional view of the left ventricle and papillary muscle, the transducer was placed over the left 
parasternal line. Following parameters were measure; internal diameter of the left ventricle 
(LV) in systole (LVIDS) and diastole (LVIDD), left ventricular posterior wall thickness in 
systole (LVPWS) and diastole (LVPWD), left ventricular anterior wall thickness in systole 
(LVAWS) and diastole (LVAWD). Left ventricular end-systolic volume (LVESV) and 
diastolic volume (LVEDV), left ventricular ejection fraction (LVEF) were calculated by Vivid 
E9 from the LV volumes and diameters measured on M-mode examination of the left ventricle.  
5.3.1.1.2 Left ventricular diastolic function (Doppler measurement)  
Diastolic function was acquired based on the published report [410]. The Doppler spectra of 
blood inflow through mitral valves were recorded from the apical view (4-chamber). The 




mitral valve was identified using color-assisted pulse-wave Doppler. The sample volume 
cursor was then placed at the tip of the mitral valve to measure the peak velocities of the early 
ventricular filling (E) and late ventricular filling (A). The ratio of E and A (E/A ratio) velocities 
were used as an indicator to assess diastolic function. At the end of the procedure, mice were 
returned to their cages for recovery. The identity of each mouse was coded so that the analysis 
of data could effectively be blinded to the observer.  
5.3.1.2 Molecular analysis 
5.3.1.2.1 RNA isolation and real-time polymerase chain reaction (PCR)  
Total RNA was isolated from mouse heart samples using QIAzol reagent as described in 
“Chapter: 2.0”. Twenty nanograms of total RNA (derived from the tissue) was reverse 
transcribed using miRNA-320a specific reverse transcription primers (Life Technologies, NZ). 
Following reverse transcription, specific SYBR Green probes (BioRad, NZ)  were used to 
quantify the expression of miRNA-320a, which was normalized to internal control U6, as 
described in detail in “Chapter:2.0”.   
5.3.1.2.2 Preparation of tissue lysate from type-2 diabetic db/db mouse heart tissue and 
western blotting  
Tissues were homogenized in ice-cold RIPA-buffer. The protein quantification was performed 
using Bradford assay (BioRad) where the concentration was extrapolated against bovine serum 
albumin (BSA). Finally, western blotting was performed to study the expression of IGF-1, Bcl-2, 
and cleaved caspase-3 as described in “Chapter:2.0”. 
5.3.1.2.3 Cryosection of heart tissue 
The formalin-fixed heart tissue sample was first immersed in optimum cutting temperature 




placed on top of the sample stub and tightly secured onto the chuck. After that, the block was 
aligned with the knife-blade and sectioned until the desired tissue was exposed. Glass slides 
(Superfrost Plus microscope glass slide; LBS4951plus, LabServ) were used to retrieve the 
tissue sections on the cryostat stage and air-dried at room temperature prior to store at -80°C. 
5.3.1.2.4 Detection of apoptosis in the whole heart  
5.3.1.2.4.1 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
staining 
The heart tissue sections were incubated in 4% paraformaldehyde solution for 15 minutes at 
37°C. The tissue sections were washed twice using 1X PBS buffer for 5 minutes each time, 
followed by permeabilization by incubating the sections with 50 μl of Proteinase K solution 
for 40 minutes and washed away with 1x PBS buffer for 5 min. Next, the sections were fixed 
in 4% paraformaldehyde for 5 minutes at 37°C and washed twice with 1x PBS buffer for 5 
minutes each time, and rinsed with deionized water.  
The slides were then incubated with 100 μl of terminal deoxynucleotidyl transferase 
(dTd) reaction buffer for 10 minutes at 37°C. After removing the buffer, 50 μl of the dTd 
reaction mixture was added and incubated at 37°C for 60 minutes. Subsequently, the slides 
were washed with deionized water and 3% BSA, and 0.1% Triton X-100 in PBS for 5 minutes, 
followed by 1x PBS buffer.  
Click-iT Plus TUNEL reaction cocktail buffer was prepared according to (Table 5.1). 
The cocktail buffer (50 μl) was added to each slide. All slides were incubated at 37°C for 30 
minutes in a light-protected chamber. Following incubation, the cocktail buffer was removed, 






Table 5.1 Click-iT PLUS TUNEL reaction cocktails 
Reaction components Volume for 25 reactions 
Click-iT Plus TUNEL Supermix 1125 µL 
10x Click-iT Plus TUNEL Reaction buffer additive 125 µL 
Total volume 1250 µL 
 
The whole TUNEL-stained slides were further incubated with Cardiac troponin antibody 
overnight at 4°C and counterstained with secondary antibody Alexa Fluor 633 for an hour the 
following day (antibody dilution, represented in Table 5.2). Negative control staining was 
performed by omitting both primary and secondary antibodies.  
Table 5.2 Antibody information and dilution 
Primary antibody 
Antibody Dilution Species Manufacturer  
Cardiac troponin 
IgG1 





Goat anti-mouse IgG 
Alexa Fluor 633 
1:1000 Goat ThermoFisher 
Scientific 
 
5.3.1.2.4.2 Nuclear- 4′,6-diamidino-2-phenylindole (DAPI) staining  
After antibody staining, tissue sections were incubated in 3% BSA in 1x PBS for 5 minutes.  
The nuclei were counterstained with 0.5μg/ml of DAPI (1:1000 dilution) (Santa Cruz 
Biotechnology) for 3 minutes and washed with 1X PBS solution. Finally, the section was 





5.3.1.2.4.3 TUNEL analysis 
All slides were visualized under a 20x dry objective lens using Olympus BX51 Fluorescence 
Microscope. At least 3 random areas per section (N = 4-7 in each group) were counted. 
Cardiomyocyte apoptosis was expressed as a percentage of TUNEL positive cardiac troponin-
stained cardiomyocytes. Data were analyzed using Image J software 
(https://imagej.nih.gov/ij/). 
5.3.1.3 Statistical analysis 
All statistical analyses were performed using the software GraphPad Prism (version 7). All the 
data were expressed as mean ± standard error of the mean. Shapiro-Wilk test was used to check 
the normality before all the analysis. A one-way ANOVA or two-way ANOVA followed by a 
non-parametric Kruskal-Wallis test was used for all the analyses. A P-value <0.05 was 
predetermined as the level of significance for all statistical analyses. Non-significant=N.S 
5.4 Results 
5.4.1 The LNA-anti-miRNA-320a prevented diabetes-induced upregulation of miRNA-
320a 
The RT-PCR data from the animal heart sample demonstrated that the expression of miRNA-320a was 
significantly higher (P=0.0195) in diabetes with scrambled sequence treated group compared to 
nondiabetic with scrambled sequence treated group confirming the reproducibility of my data from 
Chapter: 3.0. Interestingly, diabetes with the LNA-anti-miRNA-320a sequence treated group 
demonstrated a significant downregulation (P=0.0410) in the expression of miRNA-320a compared to 





Fig. 5.2 Changes in the expression of miRNA-320a in Scrambled and LNA-anti-miRNA-
320a treated heart tissue. The bar with scatter plots showing quantitative RT-PCR analysis of 
mouse heart tissue sample in non-diabetic lean with scrambled treatment (ND-Scr; N=7), 
diabetic with scrambled treatment (D-Scr; N=4), and diabetic with LNA-anti-miRNA-320a 
treatment (D-LNA; N=7). Relative expression was based on the Ct of target miRNA vs. a Ct 
of a reference miRNA (2-ΔCt). U6 was used as an endogenous control. The experiments were 
repeated two individual times. Values are mean ± SEM. Shapiro-Wilk test was used to check 
the normality. All the data were analyzed by one-way ANOVA with Tukey’s multiple 
comparisons. *Significantly different from non-diabetic lean with scrambled treatment group 
(*P< 0.05) and diabetic with scrambled treatment group (#P<0.05).  
 
5.4.2 The LNA-anti-miRNA-320a administration improves the expression of apoptotic 
markers in type-2 diabetic db/db mouse heart 
After confirming the reduced expression of miRNA-320a with LNA-anti-miRNA treatment in 




evaluated by western blot analysis. As in Chapter: 3.0 section 3.4.2.1, the IGF-1 expression 
was significantly downregulated (P=0.0104) in type-2 diabetic db/db mouse heart compared to 
nondiabetic lean animals in which both the groups are treated with Scrambled sequence (Fig. 
5.3 A). On other hand, the diabetic animals treated with LNA-anti-miRNA-320a prevented this 
downregulation in IGF-1 (P=0.0423) compared to diabetic with Scrambled sequence treated 
group (Fig. 5.3 A) which is likely to improve other down-stream proteins involved in the 
apoptotic signaling cascade.  
 My next aim was to determine the expression of apoptotic markers in the diabetic 
mouse heart. To address this, downstream signaling proteins such as anti-apoptotic Bcl-2 and 
pro-apoptotic cleaved caspase-3 expression were measured. My results confirmed that 
treatment with LNA-anti-miRNA-320a significantly prevented the downregulation of anti-
apoptotic Bcl-2 (P=0.0.0410) (Fig. 5.3 B) while preventing the upregulation of pro-apoptotic 
cleaved caspase-3 (P=0.0476) (Fig. 5.3 C) in the diabetic animals compared to those treated 











Fig. 5.3 Modulation of miRNA-320a by LNA-anti-miRNA restored target protein and 
apoptotic markers in type2 diabetic db/db mouse heart. Representative western blot images 
and quantitative bar graphs with scatter plots showing relative expression of (A) IGF-1, (B) Bcl-2, 
and (C) cleaved caspase-3 proteins in non-diabetic lean with scrambled treatment (ND-Scr; 
N=7), diabetic with scrambled treatment (D-Scr; N=4), and diabetic with LNA-anti-miRNA-
320a treatment (D-LNA; N=7). Values are mean ± SEM. Shapiro-Wilk test was used to check 
the normality. All the data were analyzed by one-way ANOVA with Tukey’s multiple 
comparisons. *Significantly different from non-diabetic lean with scrambled treatment group 
(IGF-1 and Bcl-2; *P< 0.05 and cleaved caspase 3; **P< 0.01) and diabetic with scrambled 
treatment group (IGF-1, Bcl-2 and cleaved caspase 3; #P< 0.05). (The whole western blot and 
the corresponding Ponceau images were represented in the Appendix). 
 
5.4.3 The LNA-anti-miRNA-320a administration prevents apoptosis in type-2 diabetic 
db/db mouse heart 
Having demonstrated the improvement of apoptotic markers, my next aim was to determine if 




was performed in mouse cardiac tissue sections. Cardiac TUNEL-positive nuclei in diabetic 
mice heart with scrambled sequence treatment was significantly high compared to non-diabetic 
mice heart with scrambled sequence treatment (0.6193±0.05339% in ND-Scr vs 
1.909±0.1583% in D-Scr; P=0.0001), suggesting increased apoptotic cell death (Fig.5.4). On 
other hand, treatment with LNA-anti-miRNA-320a significantly reduced the TUNEL-positive 
nuclei in diabetic mice heart (1.909±0.1583% in diabetic with scrambled sequence group vs 
1.333±0.04138% in diabetic with LNA-anti-miRNA-320a group; P=0.0004), suggesting 

















(A) Non-diabetic- Scrambled (ND-Scr)       (B) Diabetic- Scrambled (D-Scr)
 
(C) Diabetic- LNA (D-LNA)                            (D) 
 
 
Fig. 5.4 Effect of LNA-anti-miRNA-320a on myocardial apoptosis. Representative 
immunohistochemical images under 40X objective lens showing whole heart TUNEL-positive 
nuclei in cardiac troponin-stained tissue. (A) Non-diabetic lean with scrambled treatment (ND-
Scr; N=7), (B) Diabetic with scrambled treatment (D-Scr; N=4), (C) diabetic with LNA-anti-
miRNA-320a treatment (D-LNA; N=7), (D) Quantitative bar graphs showing myocardial 
apoptosis. Values are mean ± SEM and expressed in percentage of TUNEL-positive stained 
nuclei in the myocardium. Shapiro-Wilk test was used to check the normality. All the data were 
analyzed by one-way ANOVA. *Significantly different from non-diabetic lean with scrambled 






5.4.4 The LNA-anti-miRNA-320a administration improved the cardiac function of type-
2 diabetic db/db mouse  
Having demonstrated the significant downregulation of miRNA-320a and improvement of 
apoptotic markers in type-2 diabetic db/db mouse following LNA-anti-miRNA-320a 
administration, the final question was to understand if the changes at the molecular level is 
reflected as the improvement in cardiac function.  
The echocardiography results demonstrated that the type-2 diabetic db/db mice with 
scrambled sequence treatment have significant systolic dysfunctions like ejection fraction (EF), 
fractional shortening (FS), and adverse remodeling such as, left ventricular internal diameter 
at systole (LVIDS), left ventricular internal diameter at diastole (LVIDD), left ventricular 
anterior wall at systole (LVAWS), left ventricular anterior wall at diastole (LVAWD), left 
ventricular posterior wall at systole (LVPWS), and left ventricular posterior wall at diastole 
(LVPWD) in all three-time points (baseline; 24 weeks, 28 weeks, and 32 weeks) except 
LVAWS at 28 weeks (values were represented in Table 5.1 and Fig. 5.5).  
Diastolic function was significantly altered in type-2 diabetic db/db mice with 
scrambled sequence treatment at 28 weeks, and 32 weeks compared to scrambled sequence 
treated lean mice. On other hand, after LNA-anti-miRNA-320a treatment the E/A was not 
significantly different in the type-2 diabetic db/db mice with LNA-anti-miRNA-320a treatment 
from the lean with scrambled sequence treated  mice, but nevertheless mildly elevated while scr-
treated type-2 diabetic db/db were significantly elevated (values were represented in Table 5.1 
and Fig. 5.5). Importantly, LNA-anti-miRNA-320a treatment significantly improved systolic 
function (EF and FS at 28 and 32 weeks). (LVAWS at 32 weeks, and both LVPWS and 
LVPWD at 28 weeks) (values were represented in Table 5.1 and Fig. 5.5). No improvement 





Table 5.1 The changes in systolic and diastolic function in ND-Scr, D-Scr, and D-LNA treated mice at baseline (24 weeks), 28 weeks, and 
32 weeks of age 
 Baseline; 24 weeks 28 weeks 32 weeks 
Characteristic ND-Scr D-Scr D-LNA ND-Scr D-Scr D-LNA ND-Scr D-Scr D-LNA 
EF (%) 88.72±1.77 60.07±3.38 
**** 
61.85±1.30  77.23±2.90 58.47±2.70**** 70.91±1.22# 78.70±2.70 59.35±1.09**** 71.21±1.1
5# 
FS (%) 47.34±2.75 27.77±0.84*
*** 
30.41±0.89 44.17±2.41 23.48±1.38**** 36.46±2.06## 44.70±2.34 27.15±0.70**** 37.29±1.4
5# 
LVIDS (mm) 1.59±0.05 2.62±0.11***
* 
2.52±0.07 1.75±0.06 2.62±0.11**** 2.27±0.05 1.65±0.06 2.51±0.12**** 2.37±0.05 
LVIDD (mm) 3.24±0.29 3.86±0.18** 3.91±0.40 2.86±0.35 3.39±0.333* 3.24±0.29 3.19±0.24 3.18±0.27* 3.34±0.21 
LVAWS (mm) 1.39±0.11 1.10±0.12** 1.20±0.16 1.30±0.11 1.09±0.02 1.17±0.15 1.51±0.07 1.05±0.20**** 1.32±0.10# 
LVAWD (mm) 0.93±0.03 0.67±0.03*** 0.75±0.03 0.95±0.04 0.76±0.05* 0.89±0.02 1.13±0.01 0.83±0.08** 0.87±0.02 
LVPWS (mm) 1.53±0.01 0.83±0.19***
* 
0.90±0.07 1.28±0.09 0.66±0.07**** 1.00±0.08#### 1.31±0.05 0.81±0.05**** 0.96±0.07 
LVPWD (mm) 1.16±0.02 0.75±0.08***
* 
0.81±0.04 0.89±0.09 0.59±0.06**** 0.81±0.05### 1.11±0.06 0.79±0.05**** 0.86±0.06 
E/A ratio 1.59±0.04 1.98±0.09 1.96±0.05 1.64±0.08 2.80±0.29**** 2.31±0.10 1.67±0.08 3.06±0.27**** 2.48±0.07 






Cardiac functional changes in ND-Scr, D-Scr, and D-LNA treated mice at baseline (24 
weeks), 28 weeks, and 32 weeks of age. Ejection fraction (EF), Fractional shortening (FS), 
Left ventricular internal diameter at systole (LVIDS), Left ventricular internal diameter at 
diastole (LVIDD), Left ventricular anterior wall at systole (LVAWS), Left ventricular anterior 
wall at diastole (LVAWD), Left ventricular posterior wall at systole (LVPWS), Left ventricular 
posterior wall at diastole (LVPWD), E/A ratio, and Deceleration time (Dec T). Values are mean 
± SEM and N=4 to 7. All the data were analyzed by two-way ANOVA followed by Tukey's 
multiple comparisons was performed. *Significantly different from non-diabetic lean with 
scrambled treatment animal (ND-Scr) (*P<0.05, **P<0.01, ***P<0.001, and ****P< 0.0001). 
#Significantly different from diabetic with scrambled treatment animal (D-Scr) (#P< 0.05, ##P< 



















Figure 5.5 Quantitative line graphs showing the changes in systolic and diastolic function 
in ND-Scr, D-Scr, and D-LNA treated mice at baseline (24 weeks), 28 weeks, and 32 weeks 
of age. (A) Ejection fraction (EF), (B) Fractional shortening (FS), (C) Left ventricular internal 
diameter at systole (LVIDS), (D) Left ventricular internal diameter at diastole (LVIDD), (E) 
Left ventricular anterior wall at systole (LVAWS), (F) Left ventricular anterior wall at diastole 
(LVAWD), (G) Left ventricular posterior wall at systole (LVPWS), (H) Left ventricular 
posterior wall at diastole (LVPWD), (I) E/A ratio, (J) Deceleration time (Dec T). Values are 
mean ± SEM and N=4 to 7. Shapiro-Wilk test was used to check the normality. All the data 
were analyzed by two-way ANOVA followed by Tukey's multiple comparisons was 
performed. *Significantly different from non-diabetic lean with scrambled treated animals 
(*P<0.05, **P<0.01, ***P<0.001, and ****P< 0.0001). #Significantly different from diabetic 
with scrambled treated animals (#P< 0.05, ##P< 0.01, ###P< 0.001, and ####P< 0.0001). Non-
significant = N.S. 
 
5.5 Discussion  
This chapter investigated the effect of the miRNA-320a knockdown by LNA-anti-miRNA in 
type-2 diabetic db/db mouse hearts. In the previous chapters, we demonstrated the association 
of cardiac-enriched miRNA-320a in the pathophysiology of diabetes-induced cardiac cell death 
(Chapter: 3.0) and the pro-survival effects of therapeutic modulation of miRNA-320a stem-
loop genomic sequence by CRISPR/Cas9 by preventing apoptotic cell death of high glucose 
cultured human ventricular cardiomyocytes (AC-16 cells) (Chapter: 4.0). Eventually, it was 
reasonable to evaluate the miRNA-320a knockdown in a pre-clinical model system. Therefore, 
in this chapter, we investigated the beneficial effects of in vivo LNA-anti-miRNA-320a 
treatment in type-2 diabetic db/db mouse hearts. Results showed that in vivo knockdown of 
miRNA-320a by LNA-anti-miRNA partially reversed the apoptotic cell death and improved 
the hemodynamic parameters, thereby attenuating the progression of DCM.  
5.5.1 In vivo knockdown of miRNA-320a prevents apoptosis in the diabetic mouse heart 
In relation to the previous chapters (Chapter:3.2 and 4.0), dysregulated miRNA-320a 
facilitated the progression of apoptosis [411]. Evidence suggests that muscle survival, 




the expression of IGF-1[320-323]. On other hand, as a cell survival factor, IGF-1 produces its 
action by enabling Bcl-2 which prevents the cleaving of caspase protein [239, 240, 303-306]. 
Of note, it has been previously demonstrated that downregulation of miRNA-320a improves 
cell survival by increasing the expression of pro-survival IGF-1 and Bcl-2, and declining anti-
apoptotic cleaved caspase-3 [120, 172, 325-331, 412]. In this chapter, we observed, the in vivo 
knockdown of miRNA-320a by LNA-anti-miRNA-320a demonstrated 50% improvement in 
the expression of IGF-1 protein leading to improvement of downstream anti-apoptotic Bcl-2 
and reduction of pro-apoptotic cleaved caspase-3 which less compared to the improvement of 
IGF-1 [120, 172, 239, 240, 303-306, 325-331, 412]. Moreover, this evidence was further 
supported by the apoptosis study performed in type-2 diabetic db/db mice where LNA-anti-
miRNA-320a administration shown less than 50% prevention apoptosis in the whole heart.  
This evidence strongly supported that modulation of one miRNA candidate (miRNA-320a) 
was not a complete approach to targeted miRNA therapy because of the involvement of several 
miRNAs in the pathophysiological progression of DCM.   
Therefore, the quantification of apoptosis in the whole heart along with the respective 
pathway analysis established that the in vivo modulation of miRNA-320a can be one of the 
factors to prevent apoptosis in the diabetic heart which was aligned with the previous pre-
clinical studies [144, 160, 172, 201, 274, 413, 414]. Taken together, my observation 
collectively provides an insight into the potential therapeutic role of miRNA-320a inhibition 
in the diabetic heart.  
5.5.2 Targeting the late responding miRNA-320a, is an added advantage in terms of 
therapy  
The growing body of evidence establishes and authenticates the role of pro-apoptotic-miRNAs 




hinder the progression of cardiac molecular and functional deterioration. Importantly, Wang et 
al showed that anti-miRNA-320a administration in Goto-Kakizaki rats prevents impaired 
angiogenesis [120]. On other hand, Song et al demonstrated that anti-miRNA-320a 
administration through lentiviral vector protect myocardial apoptosis in Wister rats during 
ischemia-reperfusion [172]. More recent findings from our laboratory demonstrated that the in 
vivo administration of  LNA-miRNA-126 (mimic) in type-2 diabetic db/db mice improves 
VEGF expression which facilitates the process of angiogenesis in type-2 diabetic db/db mouse 
heart [274]. Li, H et al demonstrated the expression pattern of miRNA-320a correlating cardiac 
functional deterioration in high-fat diet-induced diabetic type-2 diabetic db/db mice and 
streptozotocin-induced diabetes model where they observed overexpression of miRNA-320a, 
aggravated lipid accumulation in the heart leading to diastolic dysfunction [296]. Although Li, 
H et al established a relation between miRNA-320a expression and cardiac functional changes, 
but unable to correlate between miRNA-320a expression and onset of cardiac functional 
deterioration especially in diabetic conditions. All the in vivo studies mentioned in this chapter 
including the effect of miRNA-320a in impaired angiogenesis and ischemic-reperfusion [120, 
172] do not provide any insight into the onset of miRNA-320a upregulation in the diabetic 
heart [144, 160, 201, 413, 414]. In support of the previous chapter (Chapter:3.0), my 
observation revealed that miRNA-320a is a late responding miRNA (28 and 32 weeks) where 
the apoptosis and cardiac dysfunction was at its peak (Shruti Rawal PhD thesis) and [76, 108]. 
Hence, it is justified that miRNA-320a does not initiate apoptosis, rather it aggravates the 
progression of apoptosis. On other hand, it is established that diabetic cardiac complications 
are well involved with several miRNAs that express at the different phases of the disease 
progression. Hence, targeting only early responding miRNAs involved in post diabetic cardiac 
complications may not be a complete approach. Therefore, it is reasonable to put forward that, 




molecular and functional alteration in the diabetic heart. Conversely targeting late responding 
miRNAs like miRNA-320a along with early responding miRNA candidates (cocktail of 
external miRNAs; mimic/anti-miRNA), can be a more concrete approach in terms of therapy.     
5.5.3 In vivo knockdown of miRNA-320a partly restores cardiac function in the diabetic 
mouse  
The principal findings of this chapter represent that the in vivo modulation of miRNA-320a has 
an impact on the improvement of cardiac function supported by very few previous studies [120, 
172]. Previously, in  a similar study by Li, H et al demonstrated the AAV mediated modulation 
of miRNA-320a in diabetic in vivo model system leading to partial improvement of cardiac 
dysfunction [296], whereas this study has shown substantial cardiac dysfunction (both systolic 
and diastolic) in type-2 diabetic db/db mice compared to age-matched non-diabetic lean mice 
from 24 weeks (baseline) to 32 weeks. However, a study from Katare’s laboratory 
demonstrated significant cardiac dysfunction starts from 20 weeks of age and persists till 32 
weeks in type-2 diabetic db/db mice [131]. In support of this, baseline hemodynamic 
parameters (24 weeks) in this study demonstrated the existence of cardiac dysfunction in 
diabetic animals. 
The cardiac performance has been evaluated through diastolic and systolic function, 
where the mitral inflow gives rise to early LV filling wave (E wave) and late atrial filling wave 
(A wave). In normal physiological conditions, the ratio of “E” wave and “A” wave (E/A ratio) 
> 1. However, during abnormal cardiac conditions (impaired relaxation) the ratio alters 
(E/A<1) [415]. While interpreting the results at the baseline time points (24 weeks) before  
LNA-anti-miRNA-320a injection, we observed a nonsignificant difference in E/A ratio 
between nondiabetic lean and diabetic animals, possibly due to the pseudonormal filling pattern 




increase in the pressure of left atria (LA) superimposed on a relaxation abnormality [131, 132, 
416]. On other hand, DecT is the interval from the peak “E” wave to its projected baseline 
which usually decreases during the pseudonormal filling pattern [131, 132, 416]. This 
parameter is extremely crucial from a clinical perspective as this could be diagnosed as “false 
normal” myocardium. In this study, we observed a significantly higher E/A ratio in diabetic 
animals compared to the non-diabetic animals at 28 and 32 weeks, which represents a further 
deterioration of cardiac relaxation. On other hand, after consecutive injections of LNA-anti-
miRNA-320a, no significant improvement in the E/A ratio at 28 and 32 weeks, demonstrating 
modulation of miRNA-320a does not have any effect on improving diastolic dysfunction. 
In general, the diastolic function is related to the passive elastic properties of the LV. 
Zile et al demonstrated that patients having heart failure with preserved ejection fraction had 
irregular LV relaxation and augmented resting LV stiffness with an alteration in the diastolic 
pressure-volume [417]. However, Kawaguchi et al showed that the resting ventricular stiffness 
is not always increased in patients with heart failure with preserved ejection fraction [418]. 
More precisely, an increase in myocardial mass and collagen content has a major contribution 
in increasing LV passive diastolic stiffness [417, 419]. Moreover, diastolic dysfunction is 
accompanied by fibrosis that arises in conjunction with an increase in profibrotic cytokines 
[420]. In another study, Muller et al noticed that diastolic dysfunction is associated with 
patients having myocardial fibrosis with elevated collagen deposition [421]. Eventually, two 
studies from Katare’s laboratory shown that ventricular relaxation is highly associated with 
cardiac fibrosis [131, 132]. Moreover, concerning the previous section (section 5.5.2), fibrosis 
in type-2 diabetic db/db animals starts from 20 weeks of age, and persists till 32 weeks [131, 
132], whereas, miRNA-320a overexpress at 28 weeks to 32 weeks when fibrosis was at its 
peak. Additionally, the effect of miRNA-320a in fibrosis and collagen content has not been 




dysfunction after miRNA-320a knockdown, is due to the presence of fibrosis and higher 
collagen deposition on the myocardium.  
 On other hand, the results from systolic events designate a progressive ventricular 
dilation in diabetic mice when compared to age-matched non-diabetic mice. Of note, restrictive 
filling pattern, ejection fraction, left ventricular wall thinness, and enlargement of the left 
ventricular chamber are the typical hallmarks of DCM and suggest that the diabetic heart may 
have undergone adverse remodeling under a chronic diabetic environment [422]. Moreover, it 
is a well-known fact that heart failure with preserved ejection fraction considers being a 
combination of diastolic and systolic abnormalities [419, 423]. In relation to this, Teringova et 
al demonstrated a direct correlation between cell death (apoptosis) and ejection fraction in 
patients with myocardial infarction [424]. In another study, Gelpi et al demonstrated that the 
prevention of apoptosis can significantly increase left ventricular fractional shortening in 
Sprague-Dawley rat model system [425]. Eventually, Lew et al also revealed the correlation 
between improvement of cell death and cardiac systolic function  [274]. 
During the evaluation of systolic function in type-2 diabetic db/db mice, we observed 
a significant improvement of ejection fraction and fractional shortening at 28 weeks and 32 
weeks after LNA-anti-miRNA-320a injection (Table 5.1 and Fig.5.5).  Therefore, my findings 
are consistent with the previous findings from Katare and other laboratories [274, 419, 422-
425] through which, it has been established that the in vivo modulation of miRNA-320a can 
partially improve cardiac functional deterioration in type-2 diabetic db/db mice. Finally, the 
pre-clinical study provides an insight into the potential therapeutic role of miRNA-320a in the 
prevention or treatment of DCM.  




Effectively targeting miRNA candidates is still a major challenge for in vivo model system [1]. 
The intrinsic properties of miRNAs including hydrophilic nature, negative charge, and high 
molecular weight reduce their permeability through biological membranes [1]. Therefore, a 
delivery system plays an important role in miRNA modulation in vivo, in order to facilitate the 
cellular uptake of exogenous miRNA-oligonucleotides to their target sites by protecting it from 
early nuclease degradation, which may hinder the target specificity [426]. Ideally, the delivery 
system should possess low cytotoxicity and high target specificity. Despite the effort to develop 
suitable RNA delivery systems for therapeutic use, it is often reported that a delivery system 
which worked efficiently in vitro, failed in vivo due to toxicity, poor pharmacokinetic profiles, 
nonspecific uptake, or immune responses [335], thereby implying that the success of 
therapeutic miRNAs is highly dependent on the availability of a safe and efficient delivery 
system.  
 In the in vivo study, the LNA-anti-miRNA-320a and scrambled sequence has been 
injected systemically as a bolus injection through the intraperitoneal route. Therefore, it is 
obvious that the LNA-anti-miRNA-320a produced its action not only in myocardial cells but 
also in other organs. Hence, there may be a chance that the systemic administration of LNA-
anti-miRNA-320a hampered the normal physiology by modulating miRNA-320a in other 
organs. Moreover, the systemic administration of naked LNA-anti-miRNA-320a reduces its 
pharmacokinetic profile. Perhaps, the non-selectivity oriented problem can be resolved by 
either viral vector or by enveloping nano-particles, fabricated with the specific cell surface 
acting monoclonal antibody [427].  
Especially adeno-associated virus (AAV) is a non-enveloped virus [428] which is the 
smallest known viral vector ideal for the delivery of miRNA [429]. Since recombinant AAVs 
can target several tissues, it is crucial to improving tissue specificity (muscle specific including 




sequences for tissue-specific miRNAs [430]. Several studies demonstrated successful cardiac-
specific delivery of miRNAs by AAV vector in type-2 diabetic db/db and other mice model 
systems [209, 431-433]. However, besides all the advantages, the safety issue is a massive 
obstacle for the viral vector delivery system. Hence, the nano-particles, fabricated with the 
specific cell surface acting monoclonal antibody-mediated delivery system are gaining interest 
at a rapid pace [434-439].  Therefore, target-specific nanocarriers will become an attractive 
alternative in delivering exogenous miRNAs in the future due to their better target specificity, 
safety profile and lower production cost. 
5.6 Consideration/Limitations of the study  
 Previous evidence suggested that diastolic dysfunction is associated with fibrosis and 
collagen deposition. As miRNA-320a knockdown does not produce any improvement in 
diastolic function, therefore it is reasonable to accomplish that the diastolic function was 
not improving because of the existence of fibrosis and collagen deposition. Moreover, it is 
necessary to evaluate the effect of miRNA-320a in fibrosis and collagen deposition which 
were not been able to perform due to the insufficiency of time and samples. Therefore, to 
achieve the best possible result, targeting both early and late responding miRNAs could be 
a complete approach in terms of therapy. 
 Increase in number of animals may provide much concrete data.  
 Modulation of miRNA-320a appears to be one of the target for therapeutic development. 
 In just over two decades since their first discovery in humans, miRNAs have already 
provided important insight into the biology of several cardiovascular diseases [1]. Their 
emergent potential as biomarkers in clinical diagnostics as well as modulators for the 
treatment of a variety of diseases is truly exciting [42]. The potential for these molecules 
to be used as therapeutic targets for diseases such as DCM is a widely promising research 




studies are required to elucidate the exact methods by which miRNAs can modulate 
translation and initiate mRNA degradation. Similarly, the exact sources, location, and role 
of miRNAs need to be better defined. Eventually, the miRNA-based therapies are 
proceeding at a swift rate, with successful completion of phase 1 and phase 2 clinical trials 
of Santaris Pharma’s LNA-modified anti-miRNA, targeting miRNA-122 for the treatment 
of hepatitis C virus infection [440]. In the future, this may pave the way for large-scale 
mechanism-orientated miRNA-based therapeutic trials in cardiovascular medicine. 
Additionally, technological advances are required to enable rapid, reliable, and 
reproducible results for the absolute quantification of miRNAs to facilitate transition into 
clinical practice. Finally, while there remain a number of challenges to overcome, clinicians 
should be aware of the potential arrival of miRNA-based therapeutics into the domain of 
clinical medicine. 
5.7 Conclusion  
The findings from this chapter demonstrate that the upregulation of miRNA-320a in type-2 
diabetic db/db mice facilitates the process of apoptosis leading to aggravation of cardiac 
functional deterioration (both systolic and diastolic). Furthermore, in vivo knockdown of 
miRNA-320a by LNA-anti-miRNA may partially prevents apoptosis and cardiac functional 
deterioration. Therefore, this pre-clinical study provided an insight into the potential 


























6.1 Overview of key findings 
Diabetic cardiomyopathy (DCM) is defined as a chronic complication in individuals with 
diabetes and is characterized by ventricular dilation and hypertrophy, diastolic, and systolic 
dysfunction eventually resulting in heart failure [30-33]. Regardless of substantial progression 
in glycaemic control, the prevalence of DCM is increasing exponentially throughout the globe. 
Consequently, the fundamental mechanisms leading to DCM are still elusive. Recent studies 
identified the involvement of miRNAs playing a key role in the etiology of DCM [1, 42, 101].  
Over two decades since their first discovery in humans, miRNAs have already provided 
important insight into the biology of several cardiovascular diseases. Their emergent potential 
as biomarkers as well as a therapeutic tool for the treatment of a variety of diseases are really 
promising [1, 42, 101]. The potential for the miRNA candidates to be used as therapeutic tools 
for diseases such as DCM is widely promising but remains an open question to be answered. 
MiRNA modulation mediated animal data in cardiovascular science is currently under 
investigation in several laboratories worldwide. This will provide more insight into their 
therapeutic potential translational research. Therefore, the main aim of this thesis was to 
investigate whether the modulation of cardio-enriched pro-apoptotic miRNA-320a can prevent 
or treat cardiac dysfunction in the diabetic heart. The findings from this thesis not only suggest 
that the modulation of miRNA-320a can partially improve cardiac dysfunction in terms of 
preventing apoptosis in diabetic condition but also serve as a foundation for future studies 
aimed at improving the method of miRNA modulation, identification of the off-target effect, 
and cell-specific delivery in diabetic patients.  
In Chapter:3.0, I determined the expression pattern of miRNA-320a in the diabetic 
heart. To investigate the expression of miRNA-320a in human heart samples (right atrial 
appendage tissue; RAA), a comparative study was performed between non-diabetic with no 




heart disease. we further evaluated the time-dependent expression of miRNA-320a in non-
diabetic lean and age-matched type-2 diabetic db/db mouse heart tissue sample and high 
glucose-cultured human ventricular cardiomyocytes (AC-16 cells). In the next phase, the target 
protein IGF-1 expression was validated in all three different samples. Eventually, the apoptotic 
signaling pathway was analyzed by evaluating anti-apoptotic Bcl-2 and cleaved caspase-3 
protein expression. Finally, cell survival in human ventricular cardiomyocytes (AC-16 cells) 
was validated by caspase assay. 
The findings from this chapter (Chapter:3.0) revealed that irrespective of ischemic 
heart disease, diabetes is one of the crucial factors which aggravate the expression of miRNA-
320a in the heart (Fig. 3.1). The assessment of miRNA-320a expression in non-diabetic lean 
and age-matched type-2 diabetic db/db mouse heart tissue sample also supported that diabetes 
aggravates the expression of miRNA-320a in the heart (Fig. 3.3). Along with human and animal 
samples, the comparative study between normal and high glucose-cultured human ventricular 
cardiomyocytes (AC-16 cells) also confirmed increased expression of miRNA-320a with high 
glucose treatment (Fig. 3.5). This was associated with downregulation of the target protein IGF-
1 and corresponding downstream anti-apoptotic Bcl-2 protein and upregulation of pro-
apoptotic cleaved caspase-3 in all the samples collected from three different sources. Finally, 
higher caspase activity in high glucose-culture human ventricular cardiomyocytes (AC-16 
cells) indicated the decline in cell survival which was aligned with miRNA-320a 
overexpression (Fig. 3.2 A, B & C; Fig. 3.4 A, B & C and Fig. 3.6 A, B, C & D). These findings 
are important and reveal that the diabetes-induced overexpression of miRNA plays a crucial 
role in apoptotic cell death in the heart and miRNA-320a is one more addition to this group [1, 




Interestingly, the study with the human heart sample confirmed the marked 
upregulation of miRNA-320a in diabetic condition but does not provide any insight into the 
cause or consequence of cardiac dysfunction with changes in miRNA-320a expression. 
Therefore, the time-dependent expression of miRNA-320a in type-2 diabetic db/db mice 
revealed that the miRNA-320a is a late responding miRNA (28 and 32 weeks) when cardiac 
dysfunction was at its peak [131, 132]. This finding was important to accomplish that miRNA-
320a does not affect the onset of cardiac dysfunction. Moreover, my expression study with 
normal and high glucose-cultured cells also showed a late response of miRNA-320a expression 
(96 and 120 hours) aligning with the animal study. Additionally, a previous study from Katare’s 
laboratory demonstrated significant overexpression of cleaved caspase-3 starting from 16 
weeks and persisting until 32 weeks in type-2 diabetic db/db mice (Shruti Rawal PhD thesis) 
and [76] which suggests that the process of apoptosis starts well before the onset of miRNA-
320a overexpression. Although I did not measure the cleaved caspase-3 expression from early 
stages in type-2 diabetic db/db mice, hence, it is reasonable to accomplish that the process of 
apoptosis likely to be aggravated by the upregulation of miRNA-320a, and the upregulation of 
apoptosis may facilitate the cardiac functional deterioration in type-2 diabetic db/db mice.   
The expression study of miRNA-320a in the diabetic heart as well as in high glucose-
cultured human cardiomyocytes leading to the next research question; Can knockdown of 
miRNA-320a, prevent apoptosis in high glucose-exposed human ventricular cardiomyocytes? 
After the expression of miRNA-320a was confirmed, in Chapter:4.0 the deterrence in cell 
death was evaluated between normal and high glucose-cultured human ventricular 
cardiomyocytes (AC-16 cells) after the knockdown of miRNA-320a genomic DNA by 
CRISPR/Cas9. To target the pri-miRNA-320a genomic sequence, four different gRNAs were 
designed by using Benchling design tool (URL: Benchling.com), and obtained from Integrated 




plasmid and the gRNA construct was confirmed with Sanger sequencing (Fig.4.7). The 
efficacy of the four gRNAs to knockdown miRNA-320a was evaluated by RT-PCR (Fig.4.5) 
and the ideal gRNA cloned with the plasmid was selected for further experiments. The normal 
and high glucose-cultured cells were transfected with empty plasmid DNA (negative control) 
and gRNA-CRISPR/Cass9-miRNA-320a plasmid DNA before the onset of miRNA-320a 
elevation. Subsequently, the expression of miRNA-320a, target protein IGF-1 expression, the 
downstream anti-apoptotic Bcl-2, and pro-apoptotic cleaved caspase-3 protein and caspase 
activity were evaluated.  
The findings from this chapter (Chapter:4.0) demonstrated the downregulation of 
miRNA-320a in high glucose-cultured cells transfected with gRNA-CRISPR/Cass9-miRNA-
320a plasmid DNA compared to high glucose-cultured cells transfected with empty plasmid 
DNA (Fig.4.6). This study further exhibited improvement of pro-survival target protein IGF-1 
followed by elevation of anti-apoptotic Bcl-2 protein and reduction of pro-apoptotic cleaved 
caspase-3 protein in high glucose-cultured cells transfected with gRNA-CRISPR/Cass9-
miRNA-320a plasmid DNA compared to high glucose-cultured cells transfected with empty 
plasmid DNA. Finally, a declined in caspase activity accomplished that knockdown of miRNA-
320a genomic DNA produces the beneficial actions through reduction in pro-apoptotic 
signaling in high glucose-cultured human ventricular cardiomyocytes (AC-16 cells) (Fig. 4.7,  
and Fig. 4.8 A, B & C) [1, 41, 110, 120, 132, 133, 138, 139, 172, 239, 240, 303-306, 325-331]. 
Therefore, these findings from Chapter:4.0 not only support that modulation of miRNA-320a 
(miRNA-320a genomic DNA knockdown) improves cell survival in high glucose-exposure, 
but also collectively provides an insight into the potential therapeutic role of miRNA-320a 
inhibition in improving apoptosis mediated cardiac complication in the diabetic heart.  
With the promising results from Chapter 4.0, in the last phase of my project, we 




administration of LNA-anti-miRNA-oligonucleotides can improve cardiac performances 
(Chapter:5.0). Animal models of type-2 diabetes are important tools that not only reliably 
resemble the phenotypic manifestations of diabetic humans but also progressively display 
cardiac complications. Therefore, type-2 diabetic db/db with age-matched lean mice were used 
in the in vivo experiments. The type-2 diabetic db/db mouse model is considered as one of the 
reliable models for investigating the progression of diabetic heart disease, because, leptin-
resistance alters the maintenance of energy intake and homeostasis which is a well-established 
characteristic of diabetes patients as well as type-2 diabetic db/db mouse [242, 243]. Moreover, 
the leptin receptor deficiency spontaneously facilitates hyperglycemia, hyperinsulinemia, 
polyuria, polydipsia, and obesity in type-2 diabetic db/db mouse which mimics the clinical 
phenotype of type-2 diabetes [242, 244-249]. Additionally, studies from Katare’s laboratory 
demonstrated the cardiac functional deterioration (systolic and diastolic) in type-2 diabetic 
db/db mouse which resembles the clinical phenotype of DCM [131, 134]. Based on the 
previous findings (Chapter:3.0), the onset of miRNA-320a overexpression was 28 weeks in 
type-2 diabetic db/db mice. Therefore, LNA-anti-miRNA-oligonucleotides and scrambled 
sequence oligonucleotides were systemically injected for four consecutive times (with one-
week interval) in the type-2 diabetic db/db and age-matched nondiabetic lean mice (Fig. 5.1) 
from 24 weeks to 28 weeks. Baseline echocardiography was performed before the dosing 
started. After 4 weeks of dosing cardiac performances were measured and repeated at the end 
of the experiments (28 weeks and 32 weeks). The miRNA-320a expression followed by target 
protein and apoptotic markers were evaluated in the heart tissue samples collected at the end 
of the experiments. Finally, the whole heart apoptosis was measured in heart tissue samples.  
The findings of Chapter:5.0 demonstrated a significant reduction in miRNA-320a in 
type-2 diabetic db/db mice injected with LNA-anti-miRNA-oligonucleotides compared to 




associated with alteration of the target protein (IGF-1 upregulated) and apoptotic markers (Bcl-
2 upregulated and cleaved caspase-3 downregulated) expression. The alteration in apoptotic 
markers prevented apoptosis in the whole heart. Moreover, while determining the cardiac 
performances, we observed all the diastolic and systolic events were considerably deteriorated 
in diabetic mice with scrambled oligonucleotide treatment compared to non-diabetic lean mice 
with scrambled oligonucleotide treatment at all the time points (baseline; 24 weeks, 28 weeks, 
and 32 weeks) (Table 5.1 and Fig. 5.5) which was consistent with the previous findings from 
Katere’s laboratory [131, 134]. Furthermore, as systolic events, ejection fraction (EF), and 
fractional shortening (FS) were improved in  LNA-anti-miRNA-320a oligonucleotide treated 
diabetic mice compared to the diabetic with scrambled oligonucleotides [274, 419, 423-425]. 
Additionally, no significant improvement was observed in diastolic events after treatment with 
LNA-anti-miRNA-320a oligonucleotides in diabetic mice compared to the diabetic with 
scrambled oligonucleotides treated mice. It was speculated that a higher amount of collagen 
deposition and fibrosis increased the stiffness of the myocardium which may be the reason for 
impaired relaxation, although myocardial collagen content and fibrosis were not assessed in 
this study [131, 132, 417-421]. Therefore, these findings from Chapter:5.0 support that in vivo 
modulation of miRNA-320a improves cell survival in type-2 diabetic db/db mouse heart and 
partially improves cardiac functional deterioration. Finally, this pre-clinical study provided an 
insight into the potential therapeutic role of miRNA-320a inhibition in improving apoptosis 
mediated cardiac complication in the diabetic heart.  
6.2 Future directions 
 Although this study advances the knowledge of miRNA-320a’s expression on diabetic 
hearts, this is only based on the phenotypic study. Future studies are required to identify 




stress. Moreover, it is reasonable to look forward to other factors involved in the 
alteration of this miRNA along with diabetes.  
 As mentioned in my thesis several miRNAs are involved in the progression of DCM. 
Therefore, to identify the key miRNAs involved in this disease progression can be done 
by a high throughput nanostring technology. The modulation of miRNA-320a was 
unable to improve diastolic dysfunction and I speculated that it may be due to fibrosis 
and collagen deposition which can be facilitated by other early responding miRNAs. 
Subsequently, a protein microarray should also be performed to identify the most 
regulated protein candidates to match them with the selected miRNA panels. 
Eventually, the high throughput data could help to improve the precision and specificity 
for identifying the main targets involved in diabetic heart disease. 
 To validate the functional efficacy of miRNA, a miRNA-320a knockout (stable cell 
line) cell line should be generated which will provide a solid basis for loss or gain of 
function of this miRNA.  
 Similarly, as in vitro knockout cell lines, a miRNA-320a knockout mouse model can 
also provide an insight into the functional role of the miRNA in a mouse model where 
the effect of this miRNA modulation can be crucially identified.  
 Understanding of disease propagation pathway of miRNA-320a will help to develop 
clinical therapeutic strategies to prevent DCM in the future.    
6.3 Conclusion  
The findings from this thesis demonstrated that diabetes is one of the determinants of miRNA-
320a upregulation in the heart, which plays a pro-apoptotic role eventually leading to cardiac 
function deterioration. Of note, this study also revealed that miRNA-320a does not have any 
role in initiating cardiac functional deterioration, possibly aggravation of apoptosis worsens 




miRNA-320a can prevent apoptosis which confirmed in vivo type 2 diabetic db/db mice which 
confirmed partial prevention of apoptosis in the whole diabetic heart and partial improvements 
in cardiac functions. Finally, this study provides a foundation for future studies that aimed to 




































Appendix 1.1 List of volunteers recruited in the study 


















96 51 M 12.03.13 No No 7.2 47 No data available 
112 72 M 18.04.13 No No 6.5 38.8 No data available 
114 55 M 08.05.13 No Yes 6.0 35.3 Metoprolol, and Atorvastatin 
145 77 M 03.09.13 No Yes - - Amlodipine, Metoprolol, and Simvastatin 
156 75 M 24.10.13 No Yes - - Cilazapril, Metoprolol, and Simvastatin 
167 66 M 08.11.13 No Yes 5.5 35 Metoprolol, and Atorvastatin 
118 68 M 23.05.13 No Yes - - Metoprolol, and Atorvastatin 
189 70 M 27.02.14 No No 5.4 39 Atorvastatin 
193 52 M 20.03.14 No Yes 5.4 34 Metoprolol, and Atorvastatin 
196 60 M 14.03.14 No Yes 5.5 35 Metoprolol 
202 76 M 09.04.14 No Yes 6.4 38.1 Amlodipine, Metoprolol, and Atorvastatin 





























197 75 M 01.04.14 13 Type-2 Yes 8.5 52.6 Bisoprolol, Atorvastatin, Metformin, and 
Glipizide  
335 61 M 28.05.15 10 Type-2 Yes 12 49 Amlodipine, Cilazapril, Metformin, 
Hydrochlorothiazide, and Glipizide 
340 76 M 04.06.15 11 Type-2 Yes 10 53 Cilazapril, Nadolol, Simvastatin, and 
Glipizide  
438 56 M 03.05.16 8 Type-2 Yes 13.1 57 Metoprolol, Glipizide, and Atorvastatin 
439 72 M 17.06.16 13 Type-2 Yes 6.4 61 Cilazapril, Metoprolol, Glipizide,and 
Atorvastatin 
521 71 M 19.06.17 Unknown Type-2 Yes 14 54 Cilazapril, Metoprolol, Glipizide, and 
Atorvastatin 
543 55 M 23.08.17 9 Type-1 Yes 9.3 56 Amlodipine, Bisoprolol, Insulin, and 
Atorvastatin 
630 68 M 10.04.18 14 Type-2 Yes 8.6 68 Quinapril, Carvedilol, Glipizide, 
Atorvastatin, and Aspirin 
632 72  M 12.04.18 Unknown Type-2 Yes 13.8 65 Cilazapril, Metoprolol, Metformin, 
Aspirin, and Atorvastatin 
633 61 M 04.04.18 9  Type-2 Yes 7 50 Quinapril, Carvedolol, Metformin, 
Atorvastatin, and Aspirin 
642 67 M 08.05.18 12 Type-2 Yes 11.2 53 Metformin, Glipizide, Aspirin, 
Simvastatin, and Bisoprolol 
715 57 M 11.10.18 10 Type-2 Yes 13 50 Amlodipine, Cilazapril, Metoprolol, 




Appendix 2.1 Changes in the target protein and apoptotic markers in the human heart 
(The whole western blot and the corresponding Ponceau images) 
(A) IGF-1 expression in human heart 
           
(B) Bcl-2 expression in human heart 
 
(C) Cleaved caspase-3 expression in human heart 
 
 
Fig. S2.1 Target protein and apoptotic marker’s expression in the human heart. 
Representative western blotting image showing relative expression of (A) IGF-1, (B) Bcl-2, and 




heart disease patients and diabetic-ischemic heart disease patients. Total protein (ponceau) was 
used as a reference control for western blot analysis.  
 
Appendix 2.2 Time-dependent expression of the target protein and downstream apoptotic 






















Fig. S2.2 Target protein and apoptotic marker’s expression in mouse heart. Representative 




caspase-3 protein in mouse heart tissue samples. Total protein (ponceau) was used as a reference 
control for western blot analysis.  
Appendix 2.3 Time-dependent expression of IGF-1 and downstream apoptotic markers in 
human ventricular cardiomyocytes (AC-16 cells). (The whole western blot and the 














Fig. S2.3 Target protein and apoptotic marker’s expression in AC-16 cells. Representative 
western blotting image showing relative expression of (A) IGF-1, (B) Bcl-2, and (C) cleaved 
caspase-3 protein in AC-16 cells. Total protein (ponceau) was used as a reference control for 










(A) Reference sequence: CACCGTCCCGGAGTCGGGAAAAGCT 
(B) Reference sequence: CACCGTCCCGACTCCGGGAAGAACC 
(C) Reference sequence: CACCGAACCGGGAAGAGAAGGCGGA 
(D) Reference sequence: CACCGACCCAGCTTTTCCCGACTCC 
 
Fig. S3.1 Sanger Sequencing Results Confirming each Correct gRNA sequence after 
Maxiprep Plasmid Purification. The highlighted area in this figure is each confirmed gRNA 
sequence that was cloned into the plasmid. (A) Cloned with gRNA-1. (B) Cloned with gRNA-
2. (C) Cloned with gRNA-3. (D) Cloned with gRNA-4. Each of the sequences highlighted was 
correctly aligned to the original sequence with complete homology (zero mismatches). The 
original cloned sequence is shown below each respective sequencing result for reference. 














Appendix 3.2 Knockdown of miRNA-320a expression by gRNA-2-CRISPR/Cas9-





















Fig. S3.2 Target protein and apoptotic marker’s expression in AC-16 cells after miRNA-
320a knockdown by gRNA-2-CRISPR/Cas9-miRNA-320a. Representative western blotting 
image showing relative expression of (A) IGF-1, (B) Bcl-2, and (C) cleaved caspase-3 protein in 


















Appendix 4.1 The LNA-anti-miRNA-320a administration improves the expression of 










Fig. S4.1 Modulation of miRNA-320a by LNA-anti-miRNA restored target protein and 
apoptotic markers in diabetic mouse heart. Representative western blot images showing 
relative expression of (A) IGF-1, (B) Bcl-2, and (C) cleaved caspase-3 proteins in non-diabetic 
lean with scrambled treatment, diabetic with scrambled treatment, and diabetic with LNA-anti-
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